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ABSTRACT 
REGULATION AND ACTION OF SKP2 AND RHOA IN CELL AND TUMOR 
MODELS: INVESTIGATION INTO THE MOLECULAR MECHANISMS 
RESPONSIBLE FOR THE AGGRESSIVE PHENOTYPE OF TRIPLE-
NEGATIVE BREAST CANCER 
 
FEBRUARY 2013 
 
KATERINA D. FAGAN-SOLIS, B.S., STATE UNIVERSITY OF NEW YORK AT 
ALBANY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Kathleen F. Arcaro 
 
 
Breast cancer tops the list of new cancer cases and is predicted to be the second 
leading cause of cancer deaths in women in 2012.  The primary objective of the present 
study was to provide insights into the molecular mechanisms underlying the aggressive 
growth and metastasis of triple-negative and basal-like breast cancers.  To study 
increased growth and invasive behavior in triple-negative and basal-like breast cancers 
we utilize both an interesting and relevant cell culture model and examination of human 
tissue.   
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast 
cancer cell line.  TMX2-28 cells are triple-negative in that they lack expression of the 
estrogen receptor alpha (ERα), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2).  They also have acquired a mixed basal/luminal cytokeratin 
profile, suggestive of a more basal-like phenotype. TMX2-28 cells are highly 
proliferative and invasive. 
ix 
In addition to our cell culture model, we also examine human tissue.  Thirty 
frozen breast carcinoma samples were evaluated for mRNA expression.  Additionally, I 
analyzed protein expression, using immunohistochemistry (IHC), of 50 benign reduction 
mammoplasty and 188 breast tumors (formalin-fixed paraffin embedded).  Of the 188 
breast tumors, 93 were ERα-positive and 95 were ERα-negative.  Of the 95 ERα-negative 
samples, 24 were further classified as non-triple negative (either PR or HER2 positive), 
49 were classified as triple-negative, and 22 were not further classified due to 
unavailability of HER2 status and were used only in analyses of ERα-negative tumors.  
Thirty-seven of the 188 tumor samples were ductal carcinoma in situ, 138 were invasive 
ductal carcinomas, and 13 were classified as other.  Lastly, 23 of the 188 tumors were 
grade 1, 48 were grade 2, 105 were grade 3, and 12 did not have grade data available.   
S-phase kinase-associated protein 2 (SKP2) plays an important role in cell cycle 
regulation by targeting p27 for degradation.  The cyclin-dependent kinase (CDK) 
inhibitor p27 regulates G1/S transition by binding cyclin/CDK complexes and abrogating 
its activity.  By targeting p27 for degradation, SKP2 frees the complexes needed to 
progress into the S phase of the cell cycle.  Evaluation of SKP2 expression in TMX2-28 
revealed significantly higher levels than in other breast cancer cell lines.  Despite the high 
levels of SKP2 expression, p27 protein was not reduced.  However, levels of the Serine 
10 phosphorylated form of p27 (pSer10p27), which has been associated with increased 
proliferation rates, was found to be increased.  Furthermore, suppression of SKP2 
completely eliminated the pSer10p27 and slowed cycle progression confirming the role 
of SKP2 in the aggressive growth of TMX2-28 cells.  
x 
Assessment of mRNA from 30 frozen human breast cancers demonstrated that 
SKP2 is more highly expressed in ERα-negative and basal-like breast cancers.  
Immunohistochemical analysis of 188 breast cancers and 50 benign reduction 
mammoplasty tissues confirmed that SKP2 is more highly expressed in ERα-negative 
breast cancers and for the first time demonstrated that triple-negative breast cancers are 
more likely to overexpress SKP2 than are non-triple-negative, but still ERα-negative, 
tumors.  In contrast to some previous reports, we did not observe an inverse relationship 
between SKP2 and p27 expression. Only 11% of tumors expressed high SKP2 and low 
p27, while 32% of tumors had high SKP2 and high p27.  Although no significant 
relationship between SKP2 and p27 expression was observed in human breast cancers, a 
significant positive relationship was discovered between SKP2 and pSer10p27.  
Furthermore, high levels of SKP2 and pSer10p27 were observed significantly more often 
in ERα-negative and triple negative breast tumors than in ERα-positive breast cancers.  
Based on these results and those of the cell culture experiments showing complete 
elimination of pSer10p27 after suppression of SKP2 it appears that levels of pSer10p27 
may be a better indicator of SKP2-dependent p27 degradation than are levels of p27.  
Therefore, that inhibiting SKP2 in triple-negative breast cancers expressing high levels of 
both SKP2 and pSer10p27 regardless of p27 levels may be a valid therapeutic approach.   
A foremost threat to patients is tumor invasion and metastasis, with the greatest 
risk to patients diagnosed with triple-negative and basal-like breast cancers.  Two distinct 
morphological/functional mechanisms are known for single cell migration in tissues: 
mesenchymal and amoeboid invasion.  Mesenchymal movement involves the use of 
proteases that cause cellular lysis in tissues, thereby creating a path through which cells 
xi 
can invade.  Amoeboid movement is protease-independent; cells find paths through the 
ECM by pushing and squeezing through regions of adequate size.  Despite their invasive 
phenotype, TMX2-28 retains morphology similar to non-aggressive MCF-7 cells, 
suggesting that their invasion may be proteolytic-independent.   
We determined that TMX2-28 lack MMP-1 mRNA, and MMP-2/MMP-9 protein 
expression; each of which is important in protease-dependent invasion.  Furthermore, 
TMX2-28 cells have low expression of other genes key to protease-dependent invasion 
including Slug, Zeb 1, Zeb 2, Vimentin, Fibronectin and N-cadherin.  RhoA is a member 
of the Rho superfamily of GTPases that acts as a molecular switch to control signal 
transduction and is critical to the amoeboid invasion mechanism.  TMX2-28 cells have 
high expression of protease-independent invasion genes such as RhoA, ROCK 1, ROCK 
2, and E-cadherin.  Finally, treating TMX2-28 cells with a RhoA pathway inhibitor or an 
shRNA targeting RhoA significantly reduces their invasiveness.  These data suggest that 
TMX2-28 cells use a RhoA-dependent, proteolytic-independent invasion mechanism.  
Collectively, the data presented here demonstrate the roles of SKP2 and RhoA in triple-
negative and basal-like breast cancers, making both genes, as well as their pathways, 
desirable therapeutic targets.  
xii 
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CHAPTER 1 
INTRODUCTION 
Breast Biology and Breast Cancer Statistics 
The breast is composed of glands, named lobules, which are responsible for milk 
production, and ducts that connect the lobules to the nipple (Figure 1.1).  The remainder 
of the breast is made up of fatty, connective, and lymphatic tissue (1).  Cancer is a disease 
characterized by uncontrolled growth and spreading of abnormal cells.  Breast cancer 
originates in the breast in either lobular or ductal cells (2, 3).  Two types of breast cancer 
exist; in situ cancers are confined within ducts or lobules while invasive or infiltrating 
breast cancers began in lobules or ducts but has succeeded in migrating beyond the site of 
origin (2, 3). 
Breast cancer is estimated to top the list of new cancer cases and to be the second 
leading cause of cancer deaths in women in 2012.  An estimated 227,000 women will be 
diagnosed with breast cancer this year and approximately 40,000 will die as a result of 
their breast cancer (Figure 1.2) (4).  In recent years, incidence rates of breast cancer have 
been steadily increasing among all races (Figure 1.3 Top).  Incidence rates are higher in 
non-Hispanic white women compared to African Americans in most age groups.  
However African American women have higher incidence rates before the age of forty 
and are more likely to die of breast cancer at every age. (Figure 1.3 Bottom) (5). 
 
The Discovery of Breast Cancer Subtypes 
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The development of gene expression profiling in 2000 using cDNA microarray 
technology has led to the identification of five breast tumor subtypes with distinct 
molecular signatures and each correlated with different clinical outcomes (Figure 1.4) (6-
10). Luminal A and luminal B subtypes are defined by expression of estrogen receptor α 
(ERα) and luminal cell cytokeratins (CK) 8 and 18.  The luminal A subtype typically has 
greater ERα expression and has a favorable outcome while the luminal B subtype 
expresses less ERα and has intermediate outcome.  The ERBB2+ subtype is characterized 
by over expression of human epidermal growth factor receptor 2 (HER2) and has poor 
overall outcome.  The normal-like tumor subtype is ERα-negative and has high 
expression of some basal epithelium markers including CK 5 and 17.  Lastly, the basal or 
basal-like tumors are ERα negative and have high expression of basal cell markers 
including CK 5 and 17.   Basal-like tumors are highly aggressive and generally have poor 
patient outcome (7, 11). 
A new subtype of breast cancer, termed the triple-negative subtype, was brought 
to the forefront of research in 2005. Triple-negative breast cancers were defined as 
tumors that lack expression of ERα, Progesterone Receptor (PR), and HER2 (12).  While 
the majority of triple-negative tumors also express basal cell markers, and the majority of 
basal-like cancers are also triple-negative (13-15), it is noteworthy to mention that 
clinical, microarray, and immunohistochemical data show that these tumor types are not 
entirely the same and thus cannot be lumped together into one subtype (16).  Patients 
with triple-negative breast cancer face poor prognosis, as their tumors will not respond to 
anti-estrogen nor anti-HER2 therapies (17, 18).  Rather than conventional cytotoxic 
therapies, designing individualized treatment for specific subgroups of disease is 
3 
necessary and requires targeting genes or pathways actively engaged in the 
pathophysiology of the breast cancer subtype. 
The Hallmarks of Cancer 
In  2000, Douglas Hanahan and Robert Weinberg proposed that six biological 
capabilities are acquired during the development of human cancer (Figure 1.5).  These 
hallmarks of cancer are distinctive and complimentary and enable cancer cells to grow 
and metastasize (19).   Importantly, they provide cancer researchers with a foundation in 
which to understand the diverse biology of cancer.  The six hallmarks consist of:  1. 
Sustaining proliferative signaling.  2. Evading growth suppressors.  3.  Activating 
invasion and metastasis.  4.  Enabling replicative immortality.  5.  Inducing angiogenesis.  
6.  Resisting cell death.  Since this this landmark publication, a number of other cell 
processes have emerged as potential hallmarks including reprograming of energy 
metabolism, and evading immune destruction (20).  The research described in this 
dissertation involves sustaining proliferation signaling through dysregulation of the cell 
cycle and activating invasion and metastasis.   
The Cell Cycle and SKP2 
The cell cycle comprises a series of tightly controlled events that drive the 
replication of DNA and cell division.  Cyclins, cyclin dependent kinases (CDK) and 
CDK inhibitors regulate cell cycle progression by controlling the transitions between cell 
cycle phases.  Formation of specific cyclin/CDK complexes is required for phase 
transitioning as these complexes target substrates involved in the transition process (21-
23).  CDK inhibitors are negative regulators of the cell cycle.  They act through binding 
4 
to CDKs and blocking the formation of cyclin/CDK complexes, thus preventing the 
progression of the cell cycle.  Dysregulation of the cell cycle results in uncontrolled cell 
proliferation in particular the G1/S transition.  Abnormal regulation of the proteins 
involved in these processes is more than likely to be pivotally involved in cancer 
development and progression (19, 24). 
S-phase kinase-associated protein 2 (SKP2) is an F-box protein and is component 
of the SKP1-Cullin1-F-box (SCF)/E3-ligase complex (25).  The F-box proteins of SCF 
complexes are variable and function as receptors for specific target proteins and promote 
their degradation (26).  SKP2 is the specific factor of the SCF
SKP2
/E3 ligase (Figure 1.6 
A) and is involved in cell cycle progression through degradation of p27 (25, 27).  In 
normal cells, SKP2 targets a number of proteins including the negative cell cycle 
regulator p27 for ubiquitin-mediated degradation (28). During the transition from G1 to S 
phase, p27 undergoes phosphorylation modifications at three major sites, Serine 10 
(Ser10), Threonine 187 (Thr187) and Threonine 198 (Thr198) (29).  Phosphorylation at 
Ser10, catalyzed by KIS and MIRK kinases, stabilizes p27 in quiescent cells; however, 
this phosphorylation event has been shown to promote cell proliferation (29-32).  Thr198 
phosphorylation is catalyzed by ROCK 1 kinase, only when Ser10 is already 
phosphorylated, and results in the inactivation of both free and CDK bound p27 (33, 34).  
Lastly, phosphorylation of Thr187 is catalyzed by SKP2 and promotes the ubiquitin 
ligase-mediated degradation of p27 (Figure 1.7) (21, 28, 35-39).  p27 is a cyclin 
dependent kinase (CDK) inhibitor that regulates the G1/S transition by binding 
cyclin/CDK complexes, specifically Cyclin E/CDK2 and Cyclin A/CDK2 complexes, 
and abrogating their actions, thus promoting progression into the S phase of the cell cycle 
5 
(Figure 1.6 B) (21, 35, 36).  Because SKP2 is responsible for the degradation of p27, SKP2 
is thought to function as an oncoprotein and high protein levels have been associated with 
triple-negative and basal-like tumors (16, 40).   
Invasion, Metastasis and RhoA 
Metastasis is dependent upon cancer cells being able to invade surrounding 
extracellular matrix (ECM) and adapt to different microenvironments within the primary 
tumor, the ECM, blood and/or lymphatic systems, and finally, to establish a new niche in 
a distant tissue (41-43).   The proteins that control cell-cell and ECM interactions are 
thought to play a role in tumor cell invasion and metastasis by controlling cell 
morphology, motility, and interactions with the tumor microenvironment (41, 44).  Thus, 
such proteins provide attractive therapeutic targets.   
Two distinct morphological/functional mechanisms are known for single cell 
migration in tissues: fibroblast-type mesenchymal invasion, and leucocyte-type amoeboid 
invasion.  Mesenchymal movement is characterized by an elongated cellular shape, and 
involves the use of proteases that cause cellular lysis in tissues, thereby creating a path 
through which cells can invade (44-48).  In this kind of motility, cell speed is relatively 
slow (0.1-1 µm/min) and is dependent on actin polarization and lamellipodium formation 
for directionality of cell movement (49, 50).  Amoeboid migrating cells have a rounded 
morphology and their movement is protease–independent (Figure 1.8).  Instead, cells find 
paths through the ECM by pushing and squeezing through regions of adequate size (43, 
44, 47, 48, 51, 52).  In this kind of motility, cells exploit the propulsory forces resulting 
from acto-myosin cytoskeleton contractility, which results in very high migratory speeds 
(up to 4 µm/min).  Amoeboid movement occurs independently of cell polarization but 
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requires RhoA-ROCK signaling to promote the rapid remodeling of the cell cortex (45, 
51, 53, 54). 
Migration of cancer cells is dependent on Ras Homolog Gene Family, Member A 
(RhoA) signaling (43, 44, 47, 51, 52).  RhoA is a member of the Rho superfamily of 
GTPases that acts as a molecular switch to control signal transduction (Figure 1.9 A) 
(55). It carries out its actions through activation of its two targets: Rho-associated, coiled-
coil containing protein kinase (ROCK) 1 and ROCK 2, which in turn regulate different 
facets of actin dynamics including stress fiber assembly, cell contraction, actin-filament 
stabilization, and focal adhesion organization (Figure 1.9 B) (56-59).   
The role of RhoA and its effector ROCK in mesenchymal motility is complex; 
their activity needs to be reduced to extend protrusion at the front of the cell but they 
promote the retraction of the lagging end (50, 60).  However, the overall effect of 
inhibiting RhoA/ROCK in mesenchymal cells is often minimal (51).  Conversely, RhoA 
activity is critical to the amoeboid invasion mechanism (53, 61-63).  Up-regulation of 
RhoA mRNA and protein is well documented for a variety of human cancers and has 
been positively correlated with cancer metastasis (64-66). 
A Triple-Negative Breast Cancer Cell Line Model 
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast 
cancer cell line.  TMX2-28 cells have lost expression of the estrogen receptor (ERα) and 
have acquired a mixed basal/luminal cytokeratin profile, suggestive of a more basal-like 
phenotype (67-69).
 
 Morphologically, TMX2-28 cells retained an epithelial cell shape 
similar to MCF-7.  Behaviorally, TMX2-28 cells are highly proliferative (Figure 1.10 A) 
and invasive (Figure 1.10 B) (67, 68). It is these characteristics that make TMX2-28 cells 
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an interesting and relevant model for studying increased growth and invasive behavior in 
triple-negative and basal-like breast cancers.  Studies of TMX2-28 cell cultures have 
guided our investigation of proteins expressed in human breast cancer. 
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Figure 1.1 Anatomical structure of the human breast (1). 
 (http://www.cancer.gov/cancertopics/screening/understanding-breast-changes/allpages#2) 
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Figure 1.2 Leading new cancer cases and deaths; 2012 estimates.  Breast cancer is 
estimated to top the list of leading new cancer cases and to be the second leading cause of 
cancer deaths in women in 2012.  An estimated 227,000 women will be diagnosed with 
breast cancer this year and approximately 40,000 will die as a result of their breast cancer 
(4, 5). 
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Figure 1.3 Breast cancer incidence and mortality rates. (Top) Age-specific female breast 
cancer incidence (2004 – 2008) and mortality (2003 – 2007) rates.  Incidence rates of 
breast cancer have been steadily increasing among all races.  (Bottom) Trends in female 
breast cancer incidence by race and ethnicity, US, 1975 – 2008.  Rates are higher in non-
Hispanic white women compared to African Americans in most age groups.  African 
American women have higher incidence rates before the age of forty and higher death 
rates at all ages (5). 
 (American Cancer Society, Inc., Surveillance Research 2012) 
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Figure 1.4 Identification of five breast tumor subtypes with distinct molecular signatures. 
Expression of ERα and luminal cell CKs 8 and 18 define luminal A and luminal B 
subtypes.  The luminal A subtype typically has greater ERα expression and has a 
favorable outcome while the luminal B subtype expresses less ERα expression and has 
intermediate outcome.  The ERBB2+ subtype is characterized by over expression of 
HER2 and has poor overall outcome.  The normal-like tumor subtype is ERα-negative 
and has high expression of some basal epithelium markers including CK 5 and 17.  
Lastly, the basal or basal-like tumors are ER negative status and have high expression of 
basal cell markers including CK 5 and 17.   Basal-like tumors are highly aggressive and 
generally have poor patient outcome (9). 
 
(Sorlie et. al. 2003) 
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Figure 1.5 The Hallmarks of Cancer (19). 
   
 
 
 
 
 
 
 
 
 
 
(Hanahan & Weinberg 2000) 
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Figure 1.6 SKP2 protein structure and mechanism. (A) SKP2 is a component of the 
SCF
SKP2
 complex and promotes progression into the S-phase of the cell cycle by 
regulating p27.  (B) In proliferating cells, SKP2 targets p27 for ubiquitin-mediated 
degradation.  By targeting p27 for degradation, SKP2 promotes progression into the S-
phase of the cell cycle.  p27 abrogates the actions of cyclin/CDK complexes thereby 
preventing the G1-S transition and inhibiting the cell cycle (70, 71).   
 
(Modified from Duensing et. al. 2009; Magori et. al. 2011) 
A 
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Figure 1.7 Model of p27 phosphorylation.   During the transition from G1 to S phase, p27 
undergoes phosphorylation modifications at three major sites, Serine 10 (Ser10), 
Threonine 187 (Thr187) and Threonine 198 (Thr198) (29).  Phosphorylation at Ser10, 
catalyzed by KIS and MIRK kinases, stabilizes p27 in quiescent cells; however, this 
phosphorylation event has been shown to promote cell proliferation (29-32).  Thr198 
phosphorylation is catalyzed by ROCK 1 kinase, only when Ser10 is already 
phosphorylated, and results in the inactivation of both free and CDK bound p27 (33, 34).  
Lastly, phosphorylation of Thr187 is catalyzed by SKP2 and promotes the ubiquitin 
ligase-mediated degradation of p27 (21, 28, 35-39). 
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Figure 1.8 Morphological/functional mechanisms for single cell migration in tissues, 
fibroblast-type mesenchymal invasion and leucocyte-type amoeboid invasion (72). 
 (Condeelis & Segall 2003) 
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Figure 1.9 RhoA protein structure and mechanism.  (A) Protein structure of RhoA 
kinase. (B) Rho acts as a molecular switch to control signal transduction in cells.  Its 
main targets are the Rocks (1 & 2), which regulate difference facets of actin dynamics 
(73, 74).  
A 
B 
(Riento et. al. 2003; Voth et. al. 2005) 
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Figure 1.10 TMX2-28 cells are (A) highly proliferative and (B) invasive (67, 68). 
 (Gozgit et. al. 2006; 2007) 
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CHAPTER 2 
S-PHASE KINASE-ASSOCIATED PROTEIN 2 (SKP2) OVEREXPRESSION IS 
ASSOCIATED WITH INCREASED SERINE 10-PHOSPHORYLATED p27 
(pSer10p27) IN TRIPLE-NEGATIVE BREAST CANCERS 
Introduction 
Breast cancer is the most common female malignancy, and the second leading 
cause of cancer related death in the U.S. (75).  Breast cancer patients with disease of 
similar stage and grade often respond differently to therapy resulting in disparate clinical 
outcomes.  The development of gene expression profiling, using cDNA microarray 
technology, has led to the identification of several subgroups of breast cancers with 
distinct molecular signatures (7, 11).  Historically, only estrogen receptor α (ERα), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have 
been widely accepted as predictive factors and are used to dictate a patient’s therapeutic 
regime (76). 
Approximately 70% of breast cancers express ERα and are termed ERα-positive 
(77).  For these patients, targeted endocrine therapy with anti-estrogens is available and 
their tumors are often responsive.  The remaining 30% of breast cancers do not express 
ERα and are classified as ERα-negative (77).  ERα-negative breast cancers are more 
aggressive, and have been further classified by molecular profiling into two biologically 
different subtypes, triple-negative and basal-like subtypes (7, 11).  Triple-negative tumors 
lack ERα, PR, and HER2 expression while basal-like tumors are typically triple-negative 
but are also associated with positive basal cytokeratin (CK) 5, 14, and/or 17 expression 
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patterns (7, 16, 78-80).  Basal or basal-like tumors are also ERα-negative but have high 
expression of basal cell markers including CK 5 and 17.   Triple-negative and basal-like 
tumors are highly aggressive and generally have poor patient outcome as patients with 
these subtypes have tumors that will not be responsive to anti-estrogen or anti-HER2 
therapies (7, 11, 17, 18).  Rather than treating patients with conventional cytotoxic 
therapies, designing individualized treatment for specific subgroups of disease is 
necessary and requires targeting genes or pathways actively engaged in the 
pathophysiology of breast cancer.  
Dysregulation of the cell cycle results in uncontrolled cell proliferation.  In 
particular, the G1/S transition, and aberrant regulation of the proteins involved in this 
process are pivotally involved in cancer development and progression (19, 24).  S-phase 
kinase-associated protein 2 (SKP2) plays an important role in cell cycle regulation, and 
was originally identified as part of a SCF ubiquitin-protein ligase complex though its 
interaction with Cyclin A during S phase of the cell cycle (35).  SCF complexes have 
three core components, SKP1, Cullin/cdc53, Rbx1/Roc, and an F-box containing protein 
that confers its name (Figure 1.6).  SKP2 serves as the F-box component of the SCF
SKP2
 
complex and governs its specificity (81).  p27 is a cyclin dependent kinase (CDK) 
inhibitor that regulates the G1/S transition by binding cyclin/CDK complexes, specifically 
Cyclin E/CDK2 and Cyclin A/CDK2 complexes, and abrogating their actions. In normal 
cells, SKP2 targets a number of proteins including p27 for ubiquitin-mediated 
degradation, thus promoting progression into the S phase of the cell cycle (21, 28, 35, 
36).  During the transition from G1 to S phase, p27 undergoes phosphorylation 
modifications at three major sites, Serine 10 (Ser10), Threonine 187 (Thr187) and 
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Threonine 198 (Thr198) (29).  Phosphorylation at Ser10 (pSer10p27) stabilizes p27 in 
quiescent cells, however pSer10p27 has been shown to promote cell proliferation (29-
32).  Thr198 phosphorylation (pThr198p27) is catalyzed by ROCK 1 kinase, only when 
Ser10 is already phosphorylated, and results in the inactivation of both free and CDK 
bound p27 (33, 34).  Lastly, phosphorylation of Thr187 (pThr187p27) is catalyzed by 
SKP2 and promotes the ubiquitin ligase-mediated degradation of p27 (21, 28, 35-39). 
SKP2 has oncogenic potential and its overexpression has been found in several 
cancers, including thyroid, oral epithelial, colorectal, lymphomas, non-small cell lung 
carcinoma, melanoma, and Kaposi’s sarcomas (40, 82-89). Emerging evidence has 
demonstrated that SKP2 overexpression significantly promotes the transition from G1 to 
S phase of the cell cycle, resulting in accelerated proliferation, making this process 
critically involved in the pathogenesis of breast cancer (89-93).  Overexpression of SKP2 
has been associated with poor prognosis on its own (94) and in combination with high 
Cyclin E expression (92) as well as other unfavorable prognostic factors including 
increased tumor grade, lack of expression of ERα and PR, and HER2 overexpression (95, 
96).  High SKP2 expression has been shown to be a hallmark of triple-negative, basal-
like tumors (16).  Additionally, SKP2 expression was found to have an inverse 
relationship to p27 expression levels (94, 95, 97-99).  However, to date eight published 
studies have examined the relation between SKP2 and p27 expression in breast cancer 
and reported mixed results.  Of the two largest studies, one did not observe an inverse 
relationship between SKP2 and p27 (92, 100), while other found the relationship to have 
little prognostic value (96).  
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Given the inconsistency in the literature regarding the relationship between SKP2, 
p27 and prognosis, the extent to which overexpression of SKP2 results in increased 
phosphorylation of p27 and cell proliferation in breast cancer is uncertain.  Therefore, we 
directly examined SKP2, p27, and Ser10-phosphorylated p27 (pSer10p27) in human 
breast cancers.  We also examined the expression of the related pathway cell cycle genes, 
CDK2 and Cyclin E, as well as Cyclin D1.  Additionally, we examined SKP2 and related 
proteins in MCF-7-derived TMX2-28 cells that are triple-negative and have a mixed 
basal/luminal CK profile (68, 69).  Suppression of SKP2 in these cells provided an 
opportunity to examine the function of SKP2 in the development of triple-negative, 
basal-like breast cancers.  
Materials and Methods 
Cell Culture:  TMX2-28 and MCF-7 cells were maintained in T-75 culture flasks 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with cosmic calf serum 
(5%), insulin (10 µg/ml), non-essential amino acids (100X), penicillin-streptomycin 
(10,000 µg/ml), and L-glutamine (200 mM) at 37°C and 5% CO2.  TMX2-28-NC, 
TMX2-28-S2, and TMX2-28-MC cells were maintained as above with the addition of 2.5 
µg/ml Puromycin to the culture medium. MDA-MB-231 cells were maintained in L-15 
medium supplemented with 10% FBS at 37°C and 0% CO2.  SKBR-3 cells were 
maintained in McCoy’s 5A medium supplemented with 10% fetal bovine serum (FBS) at 
37°C and 5% CO2.  All cells were passaged when near 80% confluence.   
 
RNA and Protein Isolation:  Total RNA (n=3 biological samples) was isolated 
with Tri-Reagent (Molecular Research Center, Cincinnati, OH) according to 
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manufacturer’s suggestions and protocols as previously described (67, 68, 101).  RNA 
was treated with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA 
contamination; RNA quality was assessed by 260/280 nm spectrophotometer readings 
(Nanodrop 8000; Thermo Scientific, Wilmington, DE).  Protein- containing cell lysates 
were isolated from cell cultures (n=3 biological samples) with pre-chilled SDS lysis 
buffer (1% SDS, 0.06 M Tris-HCL, and 10% glycerol) according to our standard 
laboratory protocols (67, 68, 101).  Extracts were used for Western immunoblotting.   
 
Western Immunoblotting:  Protein lysates were mixed with NuPage sample 
buffer and reducing agent (Invitrogen, Carlsbad, CA), heated at 70°C for 10 min, 
separated on Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and then transferred to 
an Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) according 
to manufacturer’s protocols.  Membranes were incubated in blocking buffer (5% nonfat 
dry milk/Tris buffered saline and 0.1% Tween 20) for 1 hour at room temperature with 
gentle shaking.  Membranes were then incubated with primary antibodies, [SKP2 (1:200; 
sc-7164), Cyclin D1 (1:200; sc-753), Cyclin E (1:200; sc-198), p27 (1:200; sc-528) 
(polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA); CDK2 (1:500; ab6538; 
polyclonal) and pSer10p27 (1:10,000; ab62364; monoclonal) (Abcam, Cambridge, MA)], 
overnight at 4°C, followed by incubation with the secondary antibody, anti-rabbit IgG 
linked to horseradish peroxidase (1:1000; 7074S; Cell Signaling Technology, Danvers, 
MA), for 1 hour at room temperature.  Chemiluminescent signals were detected with 
SuperSignal West Pico Kit (Peirce, Rockford, IL), and imaged using the G.BOX Chemi 
HR-16 (Syngene, Fredrick, MD).  Membranes were stripped using Restore stripping 
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buffer (Thermo Scientific, Rockford, IL) and reprobed for gleceraldehyde-3-phosphate 
(GAPDH; 1:10,000; 5174; Cell Signaling Technology, Danvers, MA).   
 
Quantitative Real-Time Reverse Transcriptase PCR (qRT-PCR):  RNA samples  
(n=3 biological samples) were reverse transcribed and amplified using the One Step RT-
PCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN).  
Total RNA (75 ng) was incubated with Qiagen RT-PCR master mix including primers 
(25µM each) and SYBR Green I nucleic acid stain (2X; Invitrogen, Carlsbad, CA, 
product number S7563) in pre-cooled capillaries (Roche, Indianapolis, IN) and was 
reversed transcribed (50°C for 30 min).  Following reverse transcription, samples were 
heated to 95°C for 15 min to activate the HotStar Taq DNA polymerase and to 
simultaneously inactivate the reverse transcriptase.  The generation of amplified products 
was monitored over 45 PCR cycles by fluorescence of intercalating SYBR Green.  Each 
cycle consisted of the following steps: 1. Denaturation at 95°C for 15 sec.  2. Annealing 
at 60°C for 15 sec.  3. Extension at 72°C for 30 sec.  Relative mRNA levels were 
normalized to hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality 
and concentration.  Gene specific primers that span an exon-exon junction, designed 
using Primer3 software (http://frodo.wi.mit.edu/), and purchased from Integrated DNA 
Technologies, Inc. (Coralville, IA), were used for ERα, PR, HER2, SKP2, p27, CDK2, 
Cyclin E, Cyclin D1, and HPRT (Table 2.1). 
 
RNA Interference:  pGIPz lentiviral shRNAmir (Open Biosystems, Lafayette, 
CO) targeted against SKP2 (Source ID: V2LHS_199552) or a negative control (random 
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sequence with no significant homology to any endogenous human, mouse or rat gene) 
pGIPz lentiviral shRNAmir were transfected into TMX2-28 cells using Superfect 
Transfection Reagent (Qiagen, Valencia, CA) per manufacturer’s instructions.  Forty-
eight hours post transfection; cells were treated with selection medium (DMEM 
supplemented with 2.5 µg/ml Puromycin).  Five days following initial selection, cells 
transfected with the negative control shRNAmir were seeded at low density into 100 mm 
culture dishes and cultured until small colonies formed (<50 cells).  Cloning cylinders 
(BellCo Glass, Inc. Vineland, NJ) were used to isolate colonies resulting from a single 
clone to create the TMX2-28-NC (Negative Control) cell line.  Cells transfected with the 
shRNAmir targeting SKP2 were split into two populations.  One population of cells was 
kept and termed TMX2-28-MC (Mass Culture), and the other population was seeded at 
low density into 100 mm culture dishes and cultured until small colonies formed (<50 
cells).  Cloning cylinders (BellCo Glass, Inc. Vineland, NJ) were used to isolate colonies 
resulting from a single clone to create the TMX2-28-S2 (SKP2 knockdown) cell line. 
 
Cell Cycle Analysis: Adherent cells cultures were harvested by trypsinization, 
resuspended in phosphate buffered saline (PBS), and fixed with 95% ethanol (ETOH) at 
4°C overnight.  Fixed cells were resuspended in staining solution (PBS, 2 mM MgCl2, 10 
µg/ml RNase A, 100 µg/ml propidium iodide) and incubated at 37°C for 20 minutes.   
Single cell populations (1x10
6
 cells/ml) were analyzed using FACSDiva 4.1 and cell 
cycle analysis was performed using BD FACSDiva software (Becton-Dickinson 
Bioscience, Franklin Lakes, NJ). 
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Human Tissue:  Institutional Review Board approval was obtained from Baystate 
Medical Center and the University of Massachusetts at Amherst.  Samples were 
identified numerically to maintain patient anonymity.  For the mRNA analysis of SKP2 
and cytokeratins, 30 frozen breast tumor samples were retrieved from Baystate Medical 
Center, Department of Surgical Pathology as previously described (67, 68, 101). For the 
immunohistochemistry of SKP2 and related proteins, 159 tumor and 40 reduction 
mammoplasty (RM) tissues were stained. These tissues were obtained as follows: six 
sections were cut from each of five tissue microarrays (TMAs) containing a total of 101 
tumor and 40 RM cases represented in triplicate as previously described (101), and six 
slides from each of 58 formalin-fixed paraffin-embedded (FFPE) breast tumors were 
purchased from University of Massachusetts Medical School Cancer Tissue Bank, 
Worcester, MA.  An additional 29 tumor cases and 10 RM blocks were stained and 
scored for SKP2 only as previously described (102).  The combined tumor cases = 188 
and RM = 50.  Clinical pathology reports accompanied all cases providing data on age, 
tissue type, histological grade, and ERα, PR, and HER2 status when available.  Table 2.2 
provides an over view of the clinical and pathological characteristics of the reduction 
mammoplasty and breast carcinoma patients.   
 
Immunohistochemistry (IHC):  Immunohistochemical study was performed 
using the Dakocytomation LSAB2 System-HRP kit (Dako, Carpinteria, CA) as 
previously described (101).  Primary antibodies for the IHC were the same as those used 
for the Western immunoblotting, with IHC-specific dilutions as follows: SKP2 (1:25), 
Cyclin D1 (1:200), Cyclin E (1:200), p27 (1:200) (polyclonal; Santa Cruz Biotechnology, 
26 
Santa Cruz, CA); CDK2 (1:1000; polyclonal) and p27 (phosphor S10; 1:50; monoclonal; 
Abcam, Cambridge, MA), with secondary antibody anti-rabbit from Dako (Dako polymer 
K4003; Dako, Carpinteria, CA).  Slides were stained with diaminobenzidine (DAB) 
chromogen for 10 minutes. The slides were then counterstained for 15 seconds in 
Mayer’s hematoxylin, transferred to glacial acetic acid water for 15 seconds, and then to 
ammonia water to blue. Finally, slides were dehydrated in ETOH and xylene before 
manual coverslipping.   
The performance of each antibody was optimized through the use of negative (no 
primary antibody) and positive (tonsil, skeletal muscle, or breast cancer tissues with 
known protein positivity) controls and by testing a series of dilutions bracketing the 
manufacturer’s suggested dilutions.  Antigen retrieval methods (Sodium citrate, pH, 
EDTA) were also optimized.  Western immunoblotting was performed to confirm protein 
specificity based on protein size.  
 
Review of IHC Sample Staining and Pathology:  Scoring was conducted by one 
anatomic pathologist (CNO) without knowledge of the hormone receptor status of 
samples.  TMAs and tissue slides were scored for immunoreactivity of all six proteins, 
assigning values of negative, weak, moderate, or strong for the intensity of staining.  
Tissues in which immunoreactivity was scored as weak, moderate or strong were further 
evaluated for the distribution of the staining and received descriptors of focal or diffuse 
for high and low percentage of cells stained respectively. While the number of cells 
showing immunoreactivity was not counted, tissue in which it appeared that greater than 
50% of the cells were stained was scored as diffuse.  Tissue in which it appeared that less 
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than 50% of the cells were stained was scored as focal, and in general these tissues had 
less than 10% of the cells stained.  Tissues scored as negative were not evaluated for 
focal versus diffuse distribution. Scoring occurred over twelve sessions during which a 
single observer (KDF-S) recorded all evaluations.  Periodically, previously evaluated 
slides were included in the blinded scoring session resulting in a total of ten different 
tumors being independently scored three times (three tumors for SKP2, two for p27, two 
for pSer10p27 and one each for Cyclin E, CDK2 and Cyclin D1).  Of these thirty repeat 
scores, there was only one discrepancy: a tumor was scored once as moderate/diffuse and 
twice as strong/diffuse for p27.  
 
 Statistical Analyses:  Cell cycle and mRNA expression data were analyzed and 
graphed with GraphPad Prism Version 3.02 (GraphPad Software, Inc., San Diego, CA).  
For ANOVA and post hoc two-tailed comparisons, significance was set at p<0.05.  A 
Bonferonni correction was used to adjust the p-value whenever multiple t-tests were 
conducted.   
 For analysis of the immunohistochemistry results the intensity scores of negative, 
weak, moderate and strong were converted to two metrics: positive (including weak, 
moderate and strong) versus negative (including negative only) and high (including 
moderate and strong) versus low (including negative and weak).  For each case in the 
TMAs, the highest score given to any of the three punches was used for analysis.  For the 
slides, scores were based on evaluation of all tumor or RM tissue.  Analysis also was 
conducted on the descriptors of diffuse and focal, as well as the original scores of 
negative, weak, moderate and strong, providing a total of four metrics that were analyzed. 
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Relationships between protein levels and hormone status, tumor grade, and tumor type 
were assessed with two-tailed Fisher Exact tests and p-values are presented.  For tumor 
type and grade the original evaluations of negative, weak, moderate and strong were used 
in the analysis. Relationships between protein levels and age were assessed with 
regression analysis on the original evaluations of negative, weak, moderate and strong.  
STATA 11.2 (Statacorp LP, College Station, TX) was used for analysis of IHC data. 
Results 
Characterization of TMX2-28 receptor status 
ERα, PR, and HER2 expression are the most important prognostic factors for 
breast cancer, dictating a patient’s therapeutic regime.  Prior studies have shown that 
TMX2-28 cells lack expression of ERα and have many characteristics of basal-like breast 
tumors (Chapter 1) however the status of PR and HER2 expression was not examined 
(67, 69).  To determine the triple-negative receptor status of TMX2-28 cells, ERα, PR, 
and HER2 expression was analyzed by qRT-PCR and IHC.  When compared to its 
ERα/PR positive parent cell line, MCF-7, triple-negative cell line MDA-MB-231, and the 
ERα/PR negative, HER2 overexpressing cell line SKBR-3, it is clear that TMX2-28 cells 
not only lack expression of ERα, but also lack expression of PR and HER2 (Figure 2.1), 
making them a triple-negative breast cancer cell line. 
SKP2 is overexpressed in the triple-negative breast cancer cell line, TMX2-28 
 High levels of SKP2 protein in breast cancers have been associated with poor 
prognosis, ERα- and HER2-negative status, and basal cell markers (92, 94, 99).  To 
determine whether the triple-negative, Tamoxifen-selected TMX2-28 cells have 
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increased levels of SKP2 we compared mRNA and protein levels among three breast 
cancer cell lines, TMX2-28, MCF-7, and MDA-MB-231.  The mRNA and Western 
immunoblot analyses demonstrated that SKP2 expression was significantly higher in 
TMX2-28 cells (Figure 2.2 A).  SKP2 mRNA levels in TMX2-28 cells were roughly six 
times greater than in the parent cell line MCF-7 and the aggressive MDA-MB-231 cell 
line.  These data suggest TMX2-28 may be a good model for studying the aggressive 
nature of a subset of triple-negative breast cancers that have high SKP2 and basal-like 
phenotypes.    
Overexpression of SKP2 regulates expression of its pathway genes in TMX2-28 
SKP2 controls cell cycle progression through regulation of p27.  SKP2 targets 
p27 for degradation, which allows the formation of CDK2/Cyclin E complexes and 
entrance of the cell into the S phase of the cell cycle (16-18).  We have shown that 
TMX2-28 cells overexpress SKP2, next we sought to determine the expression of other 
genes involved in this pathway.  The mRNA and protein expression of the SKP2 pathway 
genes, p27, pSer10p27 (protein only), CDK2, and Cyclin E, as well as the expression of 
Cyclin D1, a cell cycle gene not involved in the SKP2 pathway, was determined using 
qRT-PCR and Western immunoblotting. Since TMX2-28 cells have higher expression of 
SKP2 than do MCF-7, we expected TMX2-28 to have lower levels of p27 protein, due to 
increased phosphorylation.  Contrary to our prediction, TMX2-28 cells had significantly 
higher p27 mRNA and protein levels than did either MCF-7 or MDA-MB-231 (p<0.05; 
Figure 2.3 A).  As expected, however, protein levels of pSer10p27, the form of p27 
tagged for degradation, was present at substantially higher levels in TMX2-28 than in 
other cell lines (Figure 2.3 A).  The targets of p27 inhibition, Cyclin E and CDK2 were 
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also overexpressed in TMX2-28 as compared to MCF-7 cells (p<0.05 & p<0.01 
respectively; Figure 2.3 B & C), while the levels of the non-SKP2 pathway gene, Cyclin 
D1, were similar among all cell lines (p>0.05; Figure 2.3 D).  
To determine whether the overexpression of SKP2 alters the expression of genes 
in the p27 S phase transition, we assessed the effects of suppressing SKP2 expression in 
TMX2-28 cells.  For this study, TMX2-28 cells were stably transfected with either a 
negative control shRNA or an shRNA targeted against SKP2.  The resulting lines were 
termed TMX2-28-NC (negative control), TMX2-28-S2 (single clone SKP2 knockdown), 
and TMX2-28-MC (mass culture SKP2 knockdown).  As shown in Figure 2.2 B, we were 
able to reduce SKP2 gene expression by approximately 83% in both knockdown lines; 
suppression was confirmed by Western immunoblotting. Expression of p27, pSer10p27, 
CDK2, Cyclin E, and Cyclin D1 was determined in the three cell lines.  Knockdown of 
SKP2 resulted in a significant (p<0.001) increase of p27 gene expression that was 
reflected in an increase in protein expression (Figure 2.3 A).  In agreement with this 
finding, pSer10p27 protein levels decreased in TMX2-28-S2 cells compared to the 
negative control.  Although not significant, there was a slight increase in Cyclin E gene 
expression and protein levels confirmed this (Figure 2.3 B).   SKP2 knockdown in 
TMX2-28 cells also resulted in a significant increase in CDK2 gene and protein 
expression and as expected, gene and protein expression of Cyclin D1 remained 
consistent (p>0.05; Figure 2.3).  TMX2-28-MC cells mirrored TMX2-28-S2 cells in their 
expression profiles. 
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Knockdown of SKP2 alters cell cycle in TMX2-28  
To further investigate the role played by SKP2 overexpression in the control of 
cell cycle in breast cancer, TMX2-28-NC, TMX2-28-S2, and TMX2-28-MC cells were 
subjected to fixation, staining with propidium iodide, and subsequent cell cycle analysis.  
Suppression of SKP2 in both the clonally selected and mass culture cell lines resulted in a 
noticeable shift of the cell cycle towards G0/G1 (Figure 2.4).  We found a significant 
increase in the percentage of cells in the G0/G1 phase and a significant decrease in the 
percentage of cells in the S phase of the cell cycle.  We did not, however, see a 
significant change in the percentage of cells in the G2/M phase of the cell cycle.  The 
results from this experiment point to a prominent role of SKP2 in the proliferative 
potential of TMX2-28 cells.  
  SKP2 gene expression is higher in basal-like human breast cancers 
 We examined SKP2 mRNA expression in 30 frozen breast carcinoma samples by 
qRT-PCR to determine the extent to which expression patterns detected in the triple-
negative, basal-like TMX2-28 cells reflect those of breast cancer.  Eighteen ERα-positive 
and twelve ERα-negative breast cancers were assessed for mRNA expression of SKP2 
and basal cytokeratins 5 and 17 (Figure 2.5).  Tumors expressing CK5 and/or 17 were 
classified as basal cytokeratin expressing.  ERα-negative tumors that also expressed CK 5 
and/or 17 were classified as basal-like tumors.  Data revealed that there was a marginally 
significant trend towards higher SKP2 expression in ERα-negative tumors (n=12) over 
ERα-positive (n=18; p=0.067).  When tumors were classified by expression of basal 
cytokeratins, tumors expressing CK 5 and/or 17 (n=11) also expressed significantly 
higher SKP2 mRNA levels than tumors that did not express basal cytokeratins (n=19; 
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p=0.038).  Additionally, significantly higher SKP2 expression was found in tumors 
classified as basal-like (ERα-negative and expressing basal cytokeratins) (n=6) than non-
basal-like (n=24; p=0.043).  These results correspond well with the SKP2 overexpression 
in our TMX2-28 cell model. 
SKP2 and phosphorylated p27 are overexpressed in triple-negative breast cancers 
 SKP2, p27, pSer10p27, CDK2, Cyclin E, and Cyclin D1 expression was 
examined immunohistrochemically using tissue microarrays and tissue slides.  We 
evaluated protein nuclear staining characteristics of benign RM epithelial cells and of 
tumor epithelial cells.  Figure 2.6 provides examples of breast cancer cases that received 
scores of negative, weak, moderate, or strong based on staining intensity. 
Table 2.3 provides a summary of the protein expression in human breast tissue.  
Scores of negative, weak, moderate, and strong were converted to two metrics: positive 
versus negative and high versus low (described in detail in the methods section).  Tissues 
with immunoreactivity were further evaluated for distribution of staining and received 
scores of diffuse or focal, representing high and low percentage of cells stained 
respectively.  Immunohistochemical analysis of 238 breast tissue specimens revealed that 
SKP2 protein is predominantly expressed in breast cancer (59%; 111 out of 188) as 
compared to RM tissue (8%; 4 out of 50; p<0.001).  Of the tumors evaluated for 
distribution of SKP2 immunoreactivity, 21% (21 out of 98) were scored as diffuse.    
 Breast cancer cases were classified by ERα status and ERα-negative tumors were 
further stratified by triple-negative status.  Note that for 22 ERα-negative tumors, HER2 
status was unavailable and therefore these cases were excluded from triple-negative 
analyses.  SKP2 was expressed significantly more often in ERα-negative tumors than in 
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ERα-positive tumors: 84% of ERα-negative tumors were positive for SKP2 while only 
33% of ERα-positive tumors were positive for SKP2 (p<0.001).  Similar results were 
obtained when immunoreactivity was analyzed by high/low: 63% of ERα-negative 
tumors had high SKP2 expression while only 16% of ERα-positive tumors had high 
SKP2 (p< 0.001).  Additionally, of the tumors scored for staining distribution, 28% of 
ERα-negative tumors had diffuse staining whereas only 6% of ERα-positive tumors were 
scored diffuse (Table 2.3). 
Among ERα-negative tumors, triple-negative tumors were more likely to be 
positive for SKP2 than were non-triple-negative tumors: 98% versus 75%, respectively  
(p=0.002), and the staining intensity was more frequently scored as high in triple-
negative tumors than it was in non-triple negative tumors (80% versus 58%, respectively; 
p=0.056).  Furthermore, triple-negative tumors were significantly more likely to be 
scored as having a high percent of cells with immunoreactivity for SKP2: 40% of triple-
negative tumors were scored as having diffuse SKP2 expression, while 0% of non-triple 
negative were scored as having diffuse SKP2 expression (p=0.003).  
 SKP2 expression has been inversely correlated with p27 levels in subsets of breast 
cancer with poor prognosis (94, 95, 97-99).  Therefore, since we observed higher levels 
of SKP2 in ERα-negative and triple-negative tumors, we expected these groups of tumors 
to have low p27 immunoreactivity.   In contrast to our expectation, p27 expression was 
not lower in ERα-negative or triple-negative tumors; indeed there was no significant 
relationship between any of the p27 scoring metrics and hormone receptor status.  The 
lack of relationship between p27 and hormone receptor status was not due to low p27 
expression, as tumors were scored positive (92%), high (69%) and diffuse (61%) for p27 
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immunoreactivity.  In contrast to SKP2, p27 expression was common in RM tissue but 
still at significantly lower levels than in cancer when analyzed as both positive/negative 
and high/low (p=0.040 and p<0.001, respectively; Table 2.3).  
 SKP2 promotes the ubiquitin-mediated proteolysis of p27 through 
phosphorylation, which targets it for degradation via the proteasome pathway (28), yet no 
study has examined levels of phosphorylated p27 in breast cancer.  Analysis in 192 breast 
tissue specimens showed that pSer10p27 protein is more frequently expressed in breast 
cancer (50%) as opposed to RM tissue (24%; p= 0.006).  Of the 80 tumors scored 
positive for pSer10p27, 34% had diffuse staining.    
 Given the high levels of SKP2 in ERα-negative and triple-negative tumors, we 
predicted that pSer10p27 would also be high in these tumors.  As predicted, pSer10p27 
expression was significantly greater in ERα-negative than in ERα-positive tumors when 
assessed by either positive/negative or high/low immunoreactivity (Table 2.3: p<0.001 
for both comparisons).  However, staining distribution (diffuse versus focal) did not 
differ with ERα status.  When categorized by triple-negative status, there were no 
significant differences in pSer10p27 expression or staining distribution. 
 All three of the remaining cell cycle genes, Cyclin E, CDK2 and Cyclin D1, were 
expressed primarily in cancer as opposed to RM tissue (Table 2.3).  Despite the higher 
levels in cancer, when evaluated as high/low, most tumors, regardless of hormone status, 
were scored as low for Cyclin E.  Likewise the majority of tumors were scored low for 
CDK2.  In contrast, Cyclin D1 was scored as positive and high more frequently in ERα- 
positive cancers, and was more likely to be scored as low in triple-negative cancers.  
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Expression of SKP2 and phosphorylated p27 are highly correlated  
 Relationships between SKP2 and other proteins are presented in Table 2.4 in 
which the total number of tumors staining positive or negative, and high or low for SKP2 
are presented, along with the percentage and number of those tumors that were scored 
positive (left side of table) or high (right side of the table) for each of the cell cycle genes.  
Analysis of 159 tumors in which data were available for both SKP2 and p27 revealed no 
significant relationship between the two proteins, either when the analysis was conducted 
on positive/negative or high/low scores.  In contrast, phosphorylated p27 levels were 
positively associated with SKP2 expression.  Comparing the relationship between SKP2 
and pSer10p27 for high/low staining shows that of the 98 SKP2-positive tumors, 66 
(67%) were also positive for pSer10p27.  In contrast, of the 61 SKP2-negative tumors, 
only 14 (23%) were positive for pSer10p27.  Another way of expressing the relationship 
between SKP2 and pSer10p27 is to consider that of the 80 tumors positive for 
pSer10p27, 66 or 83% were positive for SKP2.  The positive relationship between SKP2 
and pSer10p27 was highly significant (p<0.001; n=159) as was the relationship when 
data were analyzed using high/low scores (p< 0.001; n=159).   Furthermore, ERα-
negative and triple negative tumors were more likely to be scored high for both SKP2 and 
pSer10p27 than were ER-positive cancers (data not shown; Fisher’s Exact < 0.001 for 
both comparisons). 
 Higher levels of SKP2 were associated with increased Cyclin E expression, for 
both metrics analyzed (p=0.035 and p=0.04).  CDK2 on the other hand, was more likely 
to be scored high in tumors that were scored low for SKP2 (p=0.031).  There was no 
relationship between SKP2 and Cyclin D1 expression.  Examples of the 
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immunoreactivity observed for SKP2 and related proteins are shown in Figures 2.7 
through 2.10; cases are provided of both when SKP2 expression was high and low.   
 Previous research suggests that high levels of SKP2 and Cyclin E together with 
low levels of p27 may occur more frequently in triple negative tumors and may be a 
biomarker for poor prognosis (92). While we did not find a relationship between p27 and 
SKP2, it remains feasible that the combined expression pattern could be an indicator of 
prognosis.  Despite small sample sizes, we found that the pattern of high SKP2 and 
Cyclin E with low p27 was significantly more common in triple negative tumors than in 
ERα-negative tumors that were not triple negative (data not shown; Fisher’s Exact = 
0.008).  
SKP2 is more highly expressed in ERα-negative and triple-negative tumors from 
younger women while pSer10p27, Cyclin D1, p27, and CDK2 are more highly 
expressed in tumors from older women  
The relationship between strong protein expression and age are presented in Table 
2.5.  SKP2 expression in tumors was inversely correlated with age (p=0.005; n=159).  
When tumors were categorized by ERα status, SKP2 expression was inversely correlated 
with age in ERα-negative tumors only (p= 0.014; n=75).  Further stratification of ERα-
negative tumors revealed that SKP2 immunoreactivity was more frequently scored as 
strong in younger women with triple-negative tumors (p=0.029; n=49), but not in 
younger women with non-triple negative tumors (p=0.84; n=18).  While expression of 
SKP2 was generally stronger in younger women, age explained little of the variability in 
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SKP2 expression, either when the analysis was conducted on all tumors (R
2
=0.05), ERα-
negative tumors (R
2
=0.08), or triple-negative tumors (R
2
=0.1). 
In contrast to SKP2, immunoreactivity of p27, pSer10p27, CDK2 and Cyclin D1 
was positively correlated with age. Analyses on the total tumor set revealed a trend for 
stronger staining in older women for pSer10p27 (p=0.003; n=159) and Cyclin D1 
(p=0.012; n=158), this trend was also significant in ERα-negative tumors (pSer10p27: 
p=0.004; n=75 and Cyclin D1: p=0.006; n=84), and for Cyclin D1 in triple-negative 
(p=0.017; n=49).  Strong immunoreactivity of p27 was positively correlated with age 
among non-triple negative tumors only (p=0.018l; n=18), while the association between 
strong CDK2 immunoreactivity and age was significant among ERα-negative tumors 
only (p=0.032; n=71).  There was no significant relationship between Cyclin E 
expression and age.  
SKP2 is more highly expressed in invasive and high grade tumors 
 The relationship between tumor type or grade and protein immunoreactivity is 
presented in Table 2.6 and Table 2.7 respectively.  Invasive ductal carcinomas (IDC) 
were more likely to have strong SKP2 staining then were ductal carcinomas in situ 
(DCIS; p=0.018; n=188).  Furthermore, strong SKP2 expression was more frequently 
associated with grade three tumors than with lower grade tumors (p=0.010; n=188).  The 
only other association between cell cycle protein expression and tumor type or grade was 
for CDK2, which was more likely to be strongly expressed in DCIS than in IDC tumors 
(p<0.001; n=159). 
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Discussion 
Patients with triple-negative and basal-like tumors face poor prognosis, as their 
tumors are not responsive to anti-estrogen or anti-HER2 therapies (17, 18).  The 
progression of these hormone receptor negative breast cancers may be significantly 
impacted by dysregulation of cell cycle regulatory proteins.  SKP2 is a component of the 
E3 ligase SCF
SKP2
 complex, and functions as a receptor to specific target proteins 
initiating their degradation and promoting cell cycle progression (25, 27, 103).  High 
expression of SKP2 has been associated with aggressive cancers including the basal-like 
breast cancer subtype (16, 94-96).  While several researchers have suggested that SKP2 is 
a suitable therapeutic target for breast cancer, the subset of breast cancers that will 
respond to treatment with inhibitors of SKP2 has not been clearly identified. 
The primary objective of the present study was to provide insight into the 
oncogenic role of SKP2 in triple-negative and basal-like breast cancers.  To accomplish 
this, we first validated the triple-negative status of the ERα-negative, basal-like breast 
cancer cell line, TMX2-28.  Next we learned that, unlike the parent MCF-7 cell line, or 
the triple-negative, aggressive MDA-MB-231 cell line, TMX2-28 express high levels of 
SKP2, befitting of a triple-negative and basal-like breast tumor model.  Based on the 
well-known role of SKP2 in p27 degradation we expected TMX2-28 cells to have low 
levels of p27 protein.  However, both mRNA and protein levels of p27 were significantly 
higher in TMX2-28 cells than in either of the cell lines with low SKP2 expression.  This 
finding led us to ask whether SKP2 was targeting p27 for degradation in TMX2-28 cell 
cultures.  We found significantly higher levels of pSer10p27 in TMX2-28 as compared to 
other cell lines.  Furthermore, suppression of SKP2 in TMX2-28 cells using RNAi 
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techniques resulted in significantly decreased levels of pSer10p27, increased levels of 
p27, and importantly, a slowing of cell cycle progression as evidenced by an increase in 
the percentage of cells in the G1/G0 and a decrease in the percentage of cells in S phase of 
the cell cycle.   
To our knowledge, TMX2-28 is the only breast cancer cell line that is triple-
negative and naturally expresses high levels of SKP2, a hallmark of basal-like phenotype 
(16).  In a study of four breast cancer cell lines transfected with SKP2, Sonoda and 
colleagues (99) reported a ‘marked’ decrease in p27 protein. However, from the Western 
blots shown in the publication, the decrease in p27 protein appears to be quite modest. 
The continued, albeit lower, expression of p27 protein in the presence of high SKP2 
expression is in agreement with our findings from TMX2-28 cells indicating that levels 
of p27 protein may not be the best biomarker of SKP2-dependent degradation of p27.  On 
the other hand, the results may simply highlight the need for more accurate quantification 
of p27 protein levels; a problem we will encounter again with the IHC data.  However, as 
we showed in Figure 2.2A, while suppression of SKP2 results in a detectable increase in 
p27 protein, it also results in the complete elimination of pSer10p27, clearly 
demonstrating the value of assessing pSer10p27 levels.  
TMX2-28 cells were derived from MCF-7 cells treated with Tamoxifen.  To some 
extent, this selection process mimicked the progression that occurs in many women, for 
whom after prolonged treatment with Tamoxifen their tumors become resistant to the 
drug and they develop ERα-negative breast cancer.  Signoretti and colleagues (94) 
reported that MCF-7 cells arrested in G1 by combined Tamoxifen treatment and estrogen 
deprivation showed increased expression of SKP2, and suggested that deregulated SKP2 
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may play a role in the development of resistance to anti-estrogens. The extent to which 
overexpression of SKP2 in TMX2-28 cells was critical to the development of Tamoxifen 
resistance or is a consequence of loss of ERα is unknown.  However, in human tissue 
SKP2 overexpression has been associated, although not consistently, with ERα-negative 
breast cancers.  In the present study, using real time qRT-PCR and tissue from 30 frozen 
breast cancers, we found SKP2 mRNA more frequently overexpressed in ERα-negative, 
basal-cytokeratin-expressing, and basal-like breast cancers.  Since SKP2’s role in 
regulating p27 expression occurs post translation, we next examined protein expression in 
formalin-fixed breast tissue. 
Based on the published literature, the relationship between SKP2 and p27 protein 
expression in breast cancer subtypes and its relevance to prognosis is unclear.  In 2002 
Signoretti and colleagues (94) examined cDNA microarrays of 89 breast cancers and 
discovered that high levels of SKP2 were more frequent in ER-negative (11 of 18) as 
compared to ER-positive tumors (16 of 71), and that a small subset of cancers (five) with 
the highest levels of SKP2 were ER-, PR- and HER2-negative.  They then used IHC to 
examine a new set of 84 breast cancers for expression of SKP2, p27, Ki67, and ER 
proteins (but not HER2).  Again, higher levels of SKP2 were observed in ER-negative 
tumors (12 of 18) as compared to ER-positive tumors (7 of 47).  Among the 19 tumors 
that had high levels of SKP2 expression, p27 was significantly more likely to be low (18 
of 19).  Both high SKP2 and low p27 expression were associated with poor survival, but 
a univariate analysis including expression of both proteins found no independent 
prognostic value of SKP2 expression, and no improved prognostic ability of the 
combination.  Still, the authors concluded that SKP2 has oncogenic potential that it is 
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overexpressed in a subset of ER- and HER2-negative breast tumors, that inhibition of 
SKP2 is a valid therapeutic goal, and that more studies are needed.  
Since the publication by Signoretti et. al., seven additional studies examining the 
expression of SKP2 and p27 in breast cancer have been published.  In 2005, two studies 
of 82 (97) and 50 (98) breast cancers found expression of SKP2 to be significantly higher 
in ER-negative tumors, and to be inversely correlated with p27 expression.  A year later 
Traub and colleagues (100) reported that 34% of the 338 breast cancers they examined 
had high SKP2 and low p27 and this combined ‘risk factor’ was significantly associated 
with a poorer outcome as compared to tumors with all other combinations of SKP2 and 
p27 expression patterns.  However, contrary to the first three studies, they found no 
association between SKP2 expression and ER status.  Furthermore, they found SKP2 
levels to be higher in HER2-positive breast cancers.  In another study published the same 
year, Sonoda and coworkers (99) examined SKP2 mRNA levels in 167 breast cancers, of 
which they selected 137 for IHC analysis of both SKP2 and p27.  Based on the IHC 
analysis they reported SKP2 expression to be inversely correlated with p27, and based on 
the mRNA analysis they reported SKP2 to be associated with poorer survival and to be 
an independent indicator of prognosis. They also were the first to report higher SKP2 
expression in tumors of younger women.  In the three studies published in 2008, one 
study reported no relationship between SKP2 and p27 expression among 438 breast 
cancers (92), another study reported an inverse relationship between SKP2 and p27 
among 40 breast cancers (95), while the third and largest study of 1598 breast cancers 
reported a significant inverse relationship: among the 313 breast cancers positive for 
SKP2 a greater percentage (66 %) had low levels of p27 (96).  Interestingly, the authors 
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of the largest study found no predictive or prognostic value of the inverse relationship 
and did not recommend routine assessment of SKP2 and p27 for node-negative early 
breast cancer.  
In our analysis of 159 tumors for which we had IHC results for both SKP2 and 
p27, we found no relationship between the expression levels of SKP2 and p27.  Eleven 
percent of tumors expressed high SKP2 and low p27, while 32% of tumors had high 
SKP2 and high p27.  Furthermore, there was no relationship between p27 and ERα or 
triple-negative status, even though our sample included 95 ERα-negative and 49 triple-
negative breast cancers (the largest sample of triple-negative and third largest sample of 
ERα-negative breast cancers among published results).  Given the range of previous 
results discussed above, our findings are in agreement with some aspects of some 
previous reports, but not others. For example, we are the first to confirm the findings of 
Sonoda and colleagues showing that younger women tend to have higher expression of 
SKP2 (99).    
Our most important finding, however, was not about the relationship between 
SKP2 and p27 expression.  In contrast to our findings on p27, we found expression of 
SKP2 to be significantly positively correlated with pSer10p27 in human breast cancers.  
Furthermore, the combination of high levels of SKP2 and high pSer10p27 were observed 
significantly more often in ERα-negative and triple negative breast tumors than in ERα-
positive breast cancers.  We learned from the cell culture data that suppressing SKP2 in 
our triple-negative breast cancer model TMX2-28 reduced the phosphorylation of p27 at 
Ser10 and slowed the cell cycle, while the level of p27 was high both before and after 
SKP2 knockdown.  Therefore, inhibiting SKP2 in triple-negative and basal-like breast 
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cancers that express high levels of both SKP2 and pSer10p27, regardless of p27 levels, 
may be an appropriate therapeutic approach.   
It appears from the cell culture and IHC studies that levels pSer10p27 may be a 
better indicator of SKP2-dependent p27 degradation than are levels of p27.  But why are 
pSer10p27 levels more closely associated with SKP2 expression than are p27 levels?  We 
considered whether inconsistencies in relationship between SKP2 and p27 in the 
published literature could be due to differences and difficulties in scoring 
immunoreactivity (See Appendix A).  In all of the eight studies that examined p27 and 
SKP2 expression in breast cancer, “low p27” was defined as less than 50% of the cells 
showing anti-p27-immunoreactivity (92, 94-100).  However, the cutoffs used to define 
SKP2 expression varied among these same eight studies.  Depending upon the study, 
SKP2 expression was considered “high” or “positive” if greater than 5% (100), 10% (92, 
94-96, 98) or 50% (97, 99) of cells showed immunoreactivity to the SKP2 antibody.  
Considerable variability was observed in number of tumors expressing SKP2 and p27.  
The percentage of tumors that were scored low for p27 ranged from 20 (95) to 64 (100), 
while the percentage of tumors scored high for SKP2 ranged from 20 (96) to 65 (97).  
Surprisingly, one of the papers with the highest cut-off for defining SKP2 
immunoreactive cells (>50%) reported the greatest percentage of tumors with high SKP2 
(97).  In none of these studies was intensity of the immunoreactivity considered even 
though intensity of staining is part of the validated “Allred score” for evaluating hormone 
receptor status in breast cancer (104) and intensity is routinely used in analysis of protein 
expression in pathological tissue (67, 68, 101, 105).   
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In the present study, immunoreactivity of all six proteins was scored for both 
intensity (negative, weak, moderate, strong) and distribution (diffuse and focal), 
providing a total of four metrics for analysis (described in detail in the methods).  Our 
metric of diffuse and focal corresponds roughly with greater and less than 50% of cells 
showing immunoreactivity; therefore it useful to compare results from this metric with 
published reports.  Limiting our results to diffuse and focal we still find no significant 
relationship between SKP2 and p27 and a highly positive relationship between SKP2 and 
the pSer10p27.  It is unlikely that inconsistencies in scoring alone account for the closer 
association between SKP2 and pSer10p27 or the differences in results among the 
published studies. 
Other factors, such as low levels but hyperactive SKP2, have been proposed to 
explain the inconsistent relationship between SKP2 and p27 and prognosis. Additionally 
p27 inactivation could occur through cytoplasmic sequestration, which is known to occur 
in other tumors (106-108) and which would result in low nuclear p27 staining that was 
independent of SKP2 expression.  Alternatively p27 expression in breast cancer may be 
partially regulated by currently unknown mechanisms. Decreased expression of p27 is 
associated with poor clinical outcome in breast cancer (109-111).  Decreased expression 
of p27 could be due to increased SKP2 and in those cases targeting SKP2 would be 
appropriate.  However, decreased levels of p27 in tumor tissue may be unrelated to SKP2 
expression, in which case inhibitors of SKP2 would likely have little effect on tumor 
proliferation.  Results from the TMX2-28 cell model demonstrate that SKP2-mediated 
cell cycle entry is occurring in the presence of continued high levels of p27 and that 
inhibition of SKP2 eliminates pSer10p27 and slows cell cycle while only modestly 
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reducing p27.  These results suggest that the combined high levels of SKP2 and 
pSer10p27 may be a good indicator of whether inhibiting SKP2 will result in slowing cell 
cycle and proliferation.  
The relationship between SKP2 and pSer10p27 is a strong, but not perfect 
correlation.  SKP2 does not directly affect the phosphorylation of p27 at Ser10, thus, as 
with the relationship between SKP2 and p27 the limited correlation could be due to other 
factors that affect Ser10 phosphorylation, including but not limited to expression of 
KIS/MIRK.  However the strong relationship between SKP2 and pSer10p27 does suggest 
that SKP2 is indirectly regulating this phosphorylation event.   
The results from the present IHC analysis identified a subset of tumors with poor 
prognosis and no available therapy, triple-negative tumors, which could respond to 
inhibitors of SKP2.  Agents that can specifically decrease SKP2 expression or activity 
will provide a significant therapeutic impact and new, targeted therapeutic options for 
patients who otherwise solely depend on the radiation and chemotherapy available to 
them.  Two studies have shown that the mTOR inhibitor rapamycin can also abrogate 
SKP2’s actions by increasing degradation of SKP2 protein and interfering with its 
transcription (112, 113).  Additionally, one small molecule, Compound A, has been 
shown to overcome chemotherapeutic resistance, specifically to dexamethasone, 
doxorubicin and melphalan (114, 115).  Compound A also inhibits cell growth via cell 
cycle arrest in multiple myeloma cells by blocking recruitment of SKP2 to SCF 
complexes (114).  Another small molecule, SMIP0004 has been shown to decrease SKP2 
expression in prostate cancer cells (115).  Recently, a number of natural inhibitors of 
SKP2 expression have been studied in breast cancer cell cultures.  These compounds 
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include curcumin, lycopene, pentagalloylglucose, quercetin, epigallocatechin-3-gallate 
(EGCG), and gallic acid (116-118).  However, further preclinical and clinical studies are 
needed to verify the efficacy of these compounds.  
 The results of the present study provide additional and important information 
about patients with triple-negative and basal-like breast cancers, and provide insight into 
the importance of alterations in the cell cycle regulatory gene SKP2 on tumor 
progression.  Our findings suggest that SKP2 overexpression could modulate the 
malignant phenotype of triple-negative and basal-like breast cancers, through regulation 
of p27 phosphorylation.  The precise molecular characterization of p27, direct and 
indirect phosphorylation by SKP2 will be relevant to delineate the properties of these 
breast cancer subtypes and identify patients with triple-negative and/or basal-like tumors 
driven by SKP2 pathway dysregulation.  These patients could possibly improve their 
prognostic outcomes if treated with a targeted molecular therapy aiming to reduce 
increased SKP2 levels by either small molecules and/or natural inhibitors.   
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Table 2.1 
Primers used to detect relative mRNA expression of genes 
Gene RefSeq 
Number 
Forward Sequence 
(5'-3') 
Reverse Sequence 
(5'-3') 
SKP2 NM_005983  
CATTTCAGCCCT
TTTCGTGT 
GGGCAAATTCA
GAGAATCCA 
p27 NM_004064 
TGCAACCGACGA
TTCTTCTA 
TTCCATGAAGT
CAGCGATATGT 
CDK2 NM_001798 
TTGTCAAGCTGC
TGGATGTC 
TGATGAGGGGA
AGAGGAATG 
Cyclin E NM_001238  
CCTGTACTGAGC
TGGGCAAA 
CAAGCTCACCT
CCATTAACCA 
Cyclin D1 NM_053056  
TGTGCCACAGAT
GTGAAGTT 
CGGGTCACACT
TGATCACTC 
HPRT NM_000194 
ACCCCACGAAGT
GTTGGATA 
AAGCAGATGGC
CACAGAACT 
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Table 2.2 
Clinical and pathological characteristics of patients 
Characteristic Median (Range) N (%) 
Age (in years)   
   Reduction Mammoplasty 25.5 (15-55) 40 (80)
* 
   All Tumors  55 (25-89) 188 (100) 
        ERα+ 55 (25-89) 93 (49) 
        ERα- 54 (29-87) 95 (51) 
             NTN
† 
58 (32-85) 24 (25)  
             TN 53 (29-87) 49 (52) 
             N/A
‡ 
59.5 (38-86) 22 (23) 
Histology    
   DCIS  37 (20) 
   IDC  138 (73) 
   Other  13 (7) 
Tumor Grade   
   G1  23 (12) 
   G2  48 (26) 
   G3  105 (56) 
   N/A  12 (6) 
*Age was not available for 10 reduction mammoplasty tissues; 
†ERα-negative but either PR or HER2 positive; ‡ERα-negative 
tumors that did not have HER2 status available 
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Table 2.3 
Expression of SKP2, p27, pSer10p27, Cyclin E, CDK2 and Cyclin D1 in breast tumors and 
reduction mammoplasty (RM) 
  Positive 
%( N) 
P-
value 
High 
% (N) 
P-value 
Diffuse
a
 
% (N) 
P-
value 
SKP2 
Tissue 
Type 
RM 
8 
(4 of 50) 
<0.001 
0 
(0 of 46)
c
 
<0.001 
b
 
- 
 
Cancer 
59 
(111 of 188) 
40 
(75 of 188) 
21 
(21of 98)
b
 
Hormone 
Receptor 
Status 
  ERα+ 
33 
(31of 93) 
<0.001 
16 
(15 of 93) 
<0.001 
6 
(2 of 31) 
0.016 
  ERα- 
84 
(80 of 95) 
63 
(60 of 95) 
28 
(19 of 67)
b
 
    NTN
d
 
75 
(18 of 24) 
0.002 
58 
(14 of 24) 
0.056 
0 
(0 of 14)
b
 
0.003 
    TN
e
 
98 
(48 of 49) 
80 
(39 of 49) 
40 
(19 of 48) 
p27 
Tissue 
Type 
RM 
79 
(23 of 29) 
0.040 
21 
(6 of 290 
<0.001 
4 
(1 of 23) 
<0.001 
Cancer 
92 
(146 0f 159) 
69 
(109 of 159) 
61 
(95 of 146) 
Hormone 
Receptor 
Status 
  ERα+ 
93 
(78 of 84) 
0.615 
69 
(58 of 84) 
0.887 
71 
(55 of 78) 
0.165 
  ERα- 
91 
(68 of 75) 
68 
(51 of 75) 
59 
(40 of 68) 
    NTN
d
 
100 
(18 of 18) 
0.120 
67 
(12 of 18) 
0.917 
56 
(10 of 18) 
1.0 
    TN
e
 
88 
(43 of 49) 
65 
(32 of 49) 
58 
(25 of 43) 
pSer10p27 
Tissue 
Type 
RM 
24 
(8 of 33) 
0.006 
12 
(4 of 33) 
0.015 
12 
(1 of 8) 
0.427 
Cancer 
50 
(80 of 159) 
33 
(53 of 159) 
34 
(27 of 80) 
Hormone 
Receptor 
Status 
  ERα+ 
36 
(30 of 84) 
<0.001 
15 
(13 of 84) 
<0.001 
33 
(10 of 30) 
1.0 
  ERα- 
67 
(50 of 75) 
53 
(40 of 75) 
34 
(17 of 50) 
    NTN
d
 
56 
(10 of 18) 
0.372 
56 
(10 of 18) 
0.856 
30 
(3 of 10) 
0.711 
    TN
e
 
67 
(33 of 49) 
53 
(26 of 49) 
36 
(12 of 33) 
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CDK2 
Tissue 
Type 
RM 
0 
(0 of 28) 
<0.001 
0 
(0 of 28) 
0.032 
- 
- 
Cancer 
38 
(58 of 153) 
14 
(22 of 153) 
55 
(32 of 58) 
Hormone 
Receptor 
Status 
  ERα+ 
46 
(38 of 82) 
0.021 
22 
(18 of 82) 
0.004 
71 
(27 of 38) 
0.002 
  ERα- 
28 
(20 of 71) 
6 
(4 of 71) 
25 
(5 of 20) 
    NTN
d
 
59 
(10 of 17) 
0.208 
0 
(0 of 17) 
0.291 
14 
(1 of 7) 
0.603 
    TN
e
 
25 
(12 of 48) 
6 
(3 of 48) 
33 
(4 of 12) 
Cyclin E 
Tissue 
Type 
RM 
16 
(5 of 33) 
0.001 
9 
(3 of 33) 
0.186 
100 
(5 of 0) 
0.151 
Cancer 
49 
(77 of 154) 
19 
(30 of 157) 
58 
(45 of 77) 
Hormone 
Receptor 
Status 
  ERα+ 
46 
(39 of 84) 
0.482 
12 
(10 of 84) 
0.014 
72 
(28 of 39) 
0.021 
  ERα- 
52 
(38 of 73) 
27 
(20 of 73) 
45 
(17 of 38) 
    NTN
d
 
41 
(7 of 17) 
0.579 
24 
(4 of 17) 
0.688 
40 
(4 of 10) 
0.723 
    TN
e
 
51 
(25 of 49) 
29 
(14 of 49) 
48 
(12 of 25) 
Cyclin D1 
Tissue 
Type 
RM 
0 
(0 of 40) 
<0.001 
0 
(0 of 40) 
<0.001 
- 
- 
Cancer 
80 
(127 of 158) 
61 
(97 of 158) 
30 
(38 of 127) 
Hormone 
Receptor 
Status 
  ERα+ 
92 
(77 of 84) 
<0.001 
70 
(59 of 84) 
0.015 
40 
(31 of 77) 
0.002 
  ERα- 
68 
(50 of 74) 
51 
(38 of 74) 
14 
(7 of 50) 
    NTN
d
 
82 
(14 of 17) 
0.084 
71 
(12 of 17) 
0.024 
14 
(2 of 14) 
1.0 
    TN
e
 
59 
(29 of 49) 
39 
(19 of 49) 
14 
(4 of 29) 
a
Diffuse and Focal staining was evaluated only for tissues that scored positive  
b
Thirteen tumors and 4 RM tissues with SKP2 reactivity were not evaluated for distribution of 
staining, therefore the numbers for diffuse and focal are reduced 
c
Four RM tissues were scored as positive/negative only, therefore the numbers for high/low are 
reduced 
 
d
NTN: Non-triple-negative, tumors that were negative for ERα, but positive for PR and/or HER2 
receptors 
e
TN: Triple-negative, tumors that were negative for ERα, PR and HER2 receptors 
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Table 2.4 
Relationship between SKP2 expression in breast cancer and cell cycle genes 
 SKP2 Expression 
% (N) 
 
SKP2 Expression 
% (N)  
 
Positive Negative 
P-
Value 
 High  Low 
P-
Value 
Cell Cycle  
Gene 
   Cell Cycle  
Gene 
   
p27  
Positive 
94 
(92 of 98) 
89 
(54 of 61) 
0.231 
p27  
Positive 
74  
(51 of 69) 
64  
(58 of 90) 
0.202 
pSer10p27  
Positive 
67  
(66 of 98) 
23 
(14 of 61) 
<0.001 
pSer10p27  
Positive 
55  
(38 of 69) 
17  
(15 of 90) 
<0.001 
CDK2  
Positive 
35 
(33 of 94) 
42  
(25 of 59) 
0.367 
CDK2  
Positive 
 7  
(5 of 67) 
20  
(17 of 86) 
0.031 
Cyclin E 
Positive 
56  
(54 of 97) 
40  
(23 of 57) 
0.035 
Cyclin E 
Positive 
26  
(18 of 68) 
13  
(12 of 89) 
0.040 
Cyclin D1 
Positive 
78 
(76 of 97) 
84  
(51 of 61) 
0.418 
Cyclin D1 
Positive 
65  
(44 of 68) 
59 
(53 of 90) 
0.457 
p-values reflect results of χ2 testing the relationship between expression of SKP2 and one other 
cell cycle gene 
Note: The percentages (and numbers) provided are based on the positive and high expression 
of specific cell cycle genes in tumors when SKP2 was evaluated as positive/negative and as 
high/low. 
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 Table 2.5  
Relationship between strong protein expression and age 
 Relationship N (P-value) 
SKP2   
   Total tumors  Inverse 159 (0.005) 
      ERα+   84 (0.261) 
      ERα-  Inverse  75 (0.014) 
         NTN  18 (0.835) 
         TN Inverse 49 (0.029) 
p27   
   Total tumors   159 (0.530) 
      ERα+   84 (0.929) 
      ERα-   75 (0.440) 
         NTN Positive 18 (0.018) 
         TN  49 (0.219) 
pSer10p27   
   Total tumors  Positive 159 (0.003) 
      ERα+   84 (0.237) 
      ERα-  Positive 75 (0.004) 
         NTN Positive 18 (0.021) 
         TN Positive 49 (0.020) 
CDK2   
   Total tumors  Positive 153 (0.212) 
      ERα+   82 (0.759) 
      ERα-  Positive 71 (0.032) 
         NTN                    * 
         TN  48 (0.103) 
Cyclin E   
   Total tumors   157 (0.640) 
      ERα+                     * 
      ERα-   73 (0.612) 
         NTN                    * 
         TN  49 (0.471) 
Cyclin D1   
   Total tumors  Positive 158 (0.012) 
      ERα+   84 (0.389) 
      ERα-  Positive 74 (0.006) 
         NTN  17 (0.726) 
         TN Positive 49 (0.017) 
* Relationship could not be established due to zero tumors 
with strong positive staining. 
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 Table 2.6 
Relationship between strong protein expression and tumor type 
Cell Cycle 
Gene 
DCIS 
% (N) 
IDC 
% (N) 
P-value 
SKP2 3 (1 of 37) 19 (26 of 138) <0.001 
p27 38 (14 of 37) 33 (36 of 109) 0.955 
pSer10p27 11 (4 of 37) 17 (19 of 109) 0.467 
CDK2 27 (9 of 33) 1 (1 of 107) <0.001 
Cyclin E 0 (0 of 36) 1 (1 of 108) 0.106 
Cyclin D1 27 (10 of 37) 30 (32 of 108) 0.009 
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Table 2.7 
Relationship between strong protein expression and tumor grade 
Cell Cycle 
Gene 
Grade 1 
% (N) 
Grade 2 
% (N) 
Grade 3 
% (N) 
P-value 
SKP2 0 (0 of 23) 10 (5 of 48) 26 (27 of 105) 0.004 
p27 3 (6 of 20) 28 (11 of 40) 37 (32 of 87) 0.690 
pSer10p27 10 (2 of 20) 8 (3 of 40) 21 (18 of 87) 0.177 
CDK2 5 (1 of 19) 10 (4 of 40) 5 (4 of 85) 0.454 
Cyclin E 0 (0 of 20) 3 (1 of 40) 1 (1 of 86) 0.702 
Cyclin D1 25 (5 of 20) 38 (15 of 40) 26 (23 of 87) 0.298 
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(Figure 2.1) 
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56 
 
(Figure 2.1) 
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TMX-2-28 MCF-7 
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(Figure 2.1) 
 
 
 
C 
MDA-MB-231 SKBR-3 
TMX-2-28 MCF-7 
58 
Figure 2.1 TMX2-28 is a triple-negative derivative of the MCF-7 breast cancer cell line.  
Upper panel: Relative mRNA expression of (A) ERα, (B) PR, and (C) HER2 were 
determined by real time qRT-PCR and normalized to HPRT.  Differences among cell 
lines were analyzed with one-way ANOVA and post hoc t-tests with Bonferroni 
correction; *p<0.05, ***p<0.001; Panel A & B: MCF-7 differed significantly from all 
other cell lines Panel C: SKBR-3 differed significantly from all other cell lines.  Lower 
panel: ERα, PR, and HER2 protein expression was determined by 
immunohistochemistry. 
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(Figure 2.2) 
B 
SKP2 
GAPDH 
A 
SKP2 
GAPDH 
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Figure 2.2 SKP2 is overexpressed in TMX2-28 cells.  (A) Relative SKP2 mRNA 
expression in TMX2-28, MCF-7, and MDA-MB-231 cells was determined by real time 
qRT-PCR.  SKP2 protein expression was determined by Western immunoblotting 
(GAPDH as loading control).   (B) TMX2-28 cells were stably transfected with either a 
negative control pGIPZ shRNAmir (TMX2-28-NC), or a pGIPZ shRNAmir targeted 
against SKP2 (TMX2-28-S2, TMX2-28-MC).  Relative SKP2 mRNA and protein 
expression was determined as in panel A.  Differences in mRNA levels among cell lines 
were analyzed using one-way ANOVA and post hoc t-tests with a Bonferroni correction 
(*p<0.05; **p<0.01); Panel A: TMX2-28 differed significantly from other cell lines; 
Panel B: TMX2-28 and TMX2-28-NC differed significantly from other groups but not 
from each other.   
 
 
 
 
 
 
 
 
 
61 
 
 
 
(Figure 2.3) 
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Figure 2.3 Expression of SKP2 pathway genes in TMX2-28 cells.  Relative mRNA 
expression of (A) p27, (B) Cyclin E, (C) CDK2, and (D) Cyclin D1 were determined by 
real time qRT-PCR and normalized to HPRT.  Protein expression of (A) p27, (B) Cyclin 
E, (C) CDK2, and (D) Cyclin D1 were determined by Western immunoblotting (GAPDH 
as loading control).  Differences in mRNA levels among cell lines were analyzed using 
one-way ANOVA and post hoc t-tests with a Bonferroni correction for comparisons 
between TMX2-28 cells and MCF-7 cells
 †
p<0.005; for comparisons between TMX2-28 
cells and MDA-MB-231 cells 
‡
p<0.05; for comparisons between TMX2-28-NC and 
TMX2-28-S2 or TMX2-28-MC cells **p<0.01, ***p<0.001.  
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Figure 2.4 SKP2 knockdown decreased the percentage of cells in the S-phase of the cell 
cycle.  TMX2-28-NC, TMX2-28-S2, and TMX2-28-MC cells were fixed and stained 
with propidium iodide.  Cell cycle analysis was assessed by flow cytometry (*p<0.05; 
**p<0.01). 
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Figure 2.5 SKP2 is overexpressed in ERα-negative, basal-like breast tumors.  Relative 
SKP2 mRNA expression was determined in 30 frozen breast carcinoma samples using 
real time qRT-PCR normalized to HPRT.  Numbers 1-18 indicates ERα-positive tumors, 
while ERα-negative tumors were assigned numbers 19-30.  ERα-positive tumors that had 
CK 5 and/or CK17 positivity were classified as basal-cytokeratin-expressing tumors and 
are represented by striped bars.  ERα-negative tumors that also had expression of CK 5 
and/or 17 were termed basal-like and are represented by black bars. 
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Figure 2.6 Scoring system used to evaluate cell cycle proteins in human tissue.  Intensity 
of immunoreactivity of epithelial cells was used to assign scores of negative, weak, 
moderate, and strong staining.  Images are from tumor samples with insets show 
increasing intensity of protein staining.  Scale bar = 100 µm. 
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(Figure 2.7) 
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67 
Figure 2.7 Expression of SKP2 in breast cancer tumors is highly correlated with 
pSer10p27 (Case 1).  Breast tumors TMAs and tissue slides were prepared, stained, and 
scored as described in the Methods.  Representative images of tumor tissue show the 
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and 
Cyclin D1 when SKP2 expression is high.  Scale bar =100 µm. 
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(Figure 2.8) 
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Figure 2.8 Expression of SKP2 in breast cancer tumors is highly correlated with 
pSer10p27 (Case 2).  Breast tumors TMAs and tissue slides were prepared, stained, and 
scored as described in the Methods.  Representative images of tumor tissue show the 
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and 
Cyclin D1 when SKP2 expression is high.  Scale bar =100 µm. 
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(Figure 2.9) 
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71 
Figure 2.9 Expression of SKP2 in breast cancer tumors is highly correlated with 
pSer10p27 (Case 3).  Breast tumors TMAs and tissue slides were prepared, stained, and 
scored as described in the Methods.  Representative images of tumor tissue show the 
relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin E, and 
Cyclin D1 when SKP2 expression low.  Scale bar =100 µm. 
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(Figure 2.10) 
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Figure 2.10 Expression of SKP2 in breast cancer tumors is highly correlated with 
pSer10p27 (Case 4).  Breast tumors and RM TMAs and tissue slides were prepared, 
stained, and scored as described in the Methods.  Representative images of tumor tissue 
show the relationships between the expression of SKP2, p27, pSer10p27, CDK2, Cyclin 
E, and Cyclin D1 when SKP2 expression low.  Scale bar =100 µm. 
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CHAPTER 3 
THE RAS HOMOLOG GENE FAMILY, MEMBER A (RHOA) PATHWAY 
MEDIATES PROTEASE-INDEPENDENT INVASIVE BEHAVIOR IN A 
TRIPLE-NEGATIVE BREAST CANCER CELL LINE 
Introduction 
Metastasis is dependent upon cancer cells being able to invade surrounding extra 
cellular matrix (ECM) and adapt to different microenvironments within the primary 
tumor, the ECM, blood and/or lymphatic systems, and finally, to establish a new niche in 
a distant tissue (41-43).   The proteins that control cell-cell and ECM interactions are 
thought to play a role in tumor cell invasion and metastasis by controlling cell 
morphology, motility, and interactions with the tumor microenvironment (41, 44).  Thus, 
such proteins provide attractive therapeutic targets.   
Two distinct morphological/functional mechanisms are known for single cell 
migration in tissues: fibroblast-type mesenchymal invasion, and leucocyte-type amoeboid 
invasion.  Mesenchymal movement is characterized by an elongated cellular shape, and 
involves the use of proteases that cause cellular lysis in tissues, thereby creating a path 
through which cells can invade (44-47). Amoeboid migrating cells have a rounded 
morphology and their movement is protease–independent.  Instead, cells find paths 
through the ECM by pushing and squeezing through regions of adequate size (43, 44, 47, 
51, 52). 
 Matrix Metalloproteinases (MMPs) are a family of endopeptidases capable of 
degrading ECM components.  MMPs are synthesized and secreted as zinc dependent 
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proenzymes that require activation prior to becoming proteolytically active (119).  It is 
known that MMP-1, MMP-2, and MMP-9 are responsible for degrading fibrillar collagen 
as well as collagen type IV, the primary components of the connective tissue matrix and 
basement membranes respectively (120-122).
 
 A number of studies have shown that there 
is an association between high MMP-2 and MMP-9 expression and the invasiveness of 
tumors when compared to normal breast epithelium. Cells undergoing epithelial to 
mesenchymal transition (EMT) in particular have high expression of MMP-2 and MMP-9 
(123-128).  
 Migration of cancer cells is dependent on Ras Homolog Gene Family, Member A 
(RhoA) signaling (43, 44, 47, 51, 52).  RhoA is a member of the Rho superfamily of 
GTPases that acts as a molecular switch to control signal transduction (55). It carries out 
its actions through activation of its two targets: Rho-associated, coiled-coil containing 
protein kinase (ROCK) 1 and ROCK 2, which in turn regulate different facets of actin 
dynamics including stress fiber assembly, cell contraction, actin-filament stabilization, 
and focal adhesion organization (56-59). Up-regulation of RhoA mRNA and protein is 
well documented for a variety of human cancers and has been positively correlated with 
cancer metastasis (64-66). 
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast 
cancer cell line.  TMX2-28 cells are triple-negative (Figure 2.1) and have acquired a 
mixed basal/luminal cytokeratin profile, suggestive of a more basal-like phenotype (67-
69).
 
 Morphologically, TMX2-28 cells retained an epithelial cell shape similar to MCF-7.  
Behaviorally, TMX2-28 cells are highly invasive, as assessed through the ability to 
invade though Matrigel, when compared to MCF-7 and MDA-MB-231 breast cancer 
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cells (67). These phenotypic characteristics suggest that these cells may exhibit an 
amoeboid mode of invasion. However, the importance of matrix metalloproteinases 
(MMPs) in invasion was not experimentally excluded nor was evidence of amoeboid 
invasion by these cells demonstrated.   
A cDNA microarray comparing gene expression of TMX2-28 cells to their parent 
cell line, MCF-7, indicated that the Rho family member, RhoE is downregulated in 
TMX2-28 (Table 3.1).  RhoE was the first member of the Rho kinase family to be 
identified (129).  Unlike the other family members, RhoE does not act as a classic 
GTPase switch, as it does not hydrolyze GTP (129-131).  RhoE functions by binding to 
and inhibiting the RhoA effector ROCK 1 (but not ROCK 2).  This interaction also 
results in the phosphorylation of RhoE by ROCK 1, which increases RhoE’s stability and 
activity (73, 132).  In addition, RhoE binds to p190RhoGAP and increases its activity 
toward RhoA, thus promoting the formation of inactive GDP-bound RhoA (133).  This 
data led to the question, since TMX2-28 cells downregulate the expression of RhoA 
inhibitor RhoE, do TMX2-28 upregulated RhoA, and if so, is the upregulation of RhoA 
resulting in the increased invasiveness of these cells? In the present study we seek to 
further define the molecular aspects underlying their invasive mechanism.   
Materials and Methods 
Cell Culture:  TMX2-28, MCF-7, and HeLa cells were maintained in T-75 culture 
flasks at 37°C and 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with calf serum (5%), insulin (10 µg/ml), non-essential amino acids 
(100X), penicillin-streptomycin (10,000 µg/ml), and L-glutamine (200 mM). MDA-MB-
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231 cells were maintained in Leibovitz-15 (L-15) medium supplemented with 10% FBS 
at 37°C and 0% CO2.  All cells were passaged when near 80% confluence.   
 
RNA and Protein Isolation:  Total RNA (n=3 biological samples) was isolated 
with Tri-Reagent (Molecular Research Center, Cincinnati, OH) according to 
manufacturer’s suggestions and protocols as previously described (67, 68, 101).
 
 RNA 
was then treated with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA 
contamination.  The quality of the RNA was assessed by 260/280 nm spectrophotometer 
readings (Nanodrop 8000; Thermo Scientific, Wilmington, DE).  Protein- containing cell 
lysates were isolated from cell cultures (n=3 biological samples) with pre-chilled SDS 
lysis buffer (1% SDS, 0.06 M Tris-HCL, and 10% glycerol) according to our standard 
laboratory protocols (67, 68, 101).  Extracts were used for Western immunoblotting.   
 
Western Immunoblotting:  Protein lysates were mixed with NuPage sample 
buffer and reducing agent (Invitrogen, Carlsbad, CA), heated at 70°C for 10 min, 
separated on a Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA) and then transferred 
to an Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) 
according to manufacturer’s protocols.  Membranes were incubated in blocking buffer 
(5% nonfat dry milk/Tris buffered saline and 0.1% Tween 20) for 1 hour at room 
temperature with gentle shaking.  Membranes were then incubated with anti-RhoA rabbit 
monoclonal antibody (Cell Signaling Technology, Danvers, MA) diluted 1:1000 
overnight at 4°C, followed by incubation with the secondary antibody, anti-rabbit IgG 
linked to horseradish peroxidase; diluted 1:1000 (Cell Signaling Technology, Danvers, 
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MA), for 1 hour at room temperature.  Chemiluminescent signals were detected with 
SuperSignal West Pico Kit and protocol (Peirce, Rockford, IL), and imaged using the 
G.BOX Chemi HR-16 (Syngene, Fredrick, MD).  Membranes were stripped using 
Restore stripping buffer (Thermo Scientific, Rockford, IL) and reprobed for 
gleceraldehyde-3-phosphate (Cell Signaling Technology, Danvers, MA; 1:10,000).   
 
Quantitative Real Time Reverse Transcriptase PCR (qRT-PCR):  RNA samples  
(n=3 biological samples) were reverse transcribed and amplified using the One Step RT-
PCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN).  
Total RNA (75 ng) was incubated with Qiagen RT-PCR master mix including primers 
(25µM each) and SYBR Green I nucleic acid stain (2X; Invitrogen, Carlsbad, CA, 
product number S7563) in pre-cooled capillaries (Roche, Indianapolis, IN) and was 
reversed transcribed (50°C for 30 min).  Following reverse transcription, samples were 
heated to 95°C for 15 min to activate the HotStar Taq DNA polymerase and to 
simultaneously inactivate the reverse transcriptase.  The generation of amplified products 
was monitored over 45 PCR cycles by fluorescence of intercalating SYBR Green.  Each 
cycle consisted of the following steps: 1. Denaturation at 95°C for 15 sec.  2. Annealing 
at 60°C for 15 sec.  3. Extension at 72°C for 30 sec.  Relative mRNA levels were 
normalized to hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality 
and concentration.  Gene specific primers, designed using Primer3 software 
(http://frodo.wi.mit.edu/), and purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA), were used for MMP-1, MMP-2, MMP-9, SLUG, ZEB 1, ZEB 2, 
Vimentin, Fibronectin, N-Cadherin, RhoA, ROCK 1, ROCK 2, and HPRT (Table 3.2).   
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Matrigel Invasion Assay:  BD BioCoat Matrigel Invasion Chambers and 8.0 µm 
pore size PET track-etched membranes (Becton Dickinson, Franklin Lakes, NJ) were 
used according to the manufacturer’s protocol.  Cells (5 x 10
4
 cells total; n=3 biological 
samples) were plated in the top chamber containing a basal medium (DMEM).  A 
medium rich in nutrients (DMEM supplemented with 10% FBS) was used in the bottom 
chamber as a chemoattractant.  Twenty-two to twenty-four hours later, cells were fixed 
and stained using 10% formalin and crystal violet respectively.  Cell numbers were 
determined from microphotographs taken over four (non-overlapping) areas of the 
membrane.   
 
Zymography:  Gelatin zymography was performed using precast polyacrylamide 
gels containing 10% gelatin (Bio-Rad, Hercules, CA).  Collected serum free, conditioned 
medium (n=3 biological samples) was mixed in equal volumes with sample buffer (0.5 M 
Tris-HCL, glycerol, 10% SDS, 0.1% Bromophenol blue).  To prepare serum free 
conditioned medium, cells were seeded into 24-well tissue culture plates at a 
concentration of 1x10
5
 cells/well in normal culture medium.  Twenty-four hours post 
seeding, cells were washed three times with phosphate-buffered saline followed by 
incubation in serum free medium.  Serum free conditioned medium was collected 48 
hours later and stored at -20°C until use.  Twenty to fifty microliters of mixed sample 
was loaded into the gel and electrophoresed at 100 V for 90 min.  Following 
electrophoresis, gels were rinsed with 1X renaturing buffer (2.5% Triton X-100) for 30 
min with gentle agitation.  Gels were then transferred to 1X developing buffer (50 mM 
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Tris base, 200 mM NaCL, 5 mM CaCl2, 0.02% Brij 35) for 30 min at room temperature 
with gentle agitation to equilibrate the gel.  Gels were then incubated overnight at 37°C 
with gentle agitation in fresh 1X developing buffer.  Gels were then stained for 1 hour 
with 0.5% Coomassie Blue, de-stained twice for 30 min each with de-staining solution 
[Methanol: Acetic Acid: Water (50:10:40)], and rehydrated in H2O for 10 min.   
 
Inhibitor and siRNA Treatments:  For inhibitor assays, cells (n=3 biological 
samples) were treated with the Rho Kinase pathway inhibitor H-1152 (Calbiochem, 
Billerica, MA) at 0, 20, and 100 µM concentrations for 24 hours (134, 135).  
Concentrations were determined by dose response testing (See Appendix B).  Following 
treatment, either RNA was isolated as mentioned above, or cells were seeded into 
invasion chambers in the respective concentrations of inhibitor.   
For siRNA assays, RhoA specific and negative control (random sequence without 
homology to any human gene) siRNAs (RhoA-siRNA and NC-siRNA respectively) were 
designed using Ambion’s (Austin, TX) siRNA Template Design Tool (RhoA sense: 
CCUUAUAGUUACUGUGUAATT; antisense: UUACACAGUAACUAUAAAGGTA; 
negative control sense: UUAUCGCCAAAUUCUUUUAUCGGACAGAG; antisense: 
UUGAUAAAAGAAUUUGGCGAUGGACAGAG). DNA oligonucleotides were 
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and siRNA generated 
using Silencer® siRNA Construction Kit (Ambion, Austin, TX) per manufactures’ 
protocols.  TMX2-28, MCF-7 (non-invasive control) and HeLa (RhoA dependent 
invasion control) cells were seeded into 100 mm dishes at a concentration of 10
6 
cells/dish and allowed to attach overnight (n=3 biological samples).  On the day of 
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transfection, HiPerFect transfection agent (Qiagen, Valencia, CA) and 25 mg/well of a 
RhoA specific or a negative control siRNA was diluted into Opti-MEM (Invitorgen, 
Carlsbad, CA) and added to cells.  Following incubation under normal growth conditions 
for 48 hours, cells were harvested for both RNA and Protein isolation or invasion assays.   
  
Statistical Analyses:  Data were analyzed and graphed with GraphPad Prism 
Version 3.02 (GraphPad Software, Inc., San Diego, CA).  For ANOVA and post hoc 
comparisons, significance was set at p<0.05. 
Results 
TMX2-28 cells do not express MMP-1 mRNA or active MMP-2 or MMP-9 protein 
In breast cancer, MMPs have been shown to be important players in mesenchymal 
invasion, specifically MMP-1, -2, and -9 (120-122, 136). To determine the possible 
involvement of MMPs in the invasion mechanism of TMX2-28 cells, MMP-1, -2, and -9 
mRNA expression was analyzed by qRT-PCR.  As shown in Figure 3.1 A-C, TMX2-28 
cells have significantly lower MMP-1 mRNA expression (no detectable level) when 
compared to the mesenchymal MDA-MB-231 cells.  However, there was no significant 
difference in mRNA expression of MMP-2 or MMP-9 among the cell lines.  MMPs are 
synthesized and secreted as zinc dependent pro-enzymes that require activation (119).  To 
assess activity of MMP-2 and -9, conditioned media from all cell lines were run on a 
zymography gel.  It was determined that although TMX2-28 cells have mRNA 
expression, they do not express active MMP-2 or MMP-9 enzymes (Figure 3.1 D).  These 
results indicate that TMX2-28 cells do not rely on MMP activity to degrade the ECM. 
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TMX2-28 cells have little to no expression of six common EMT genes 
Epithelial-mesenchymal transition (EMT) is a well-recognized process facilitating 
migration and invasion of cancer cells during metastasis (137).  An increase in expression 
of a number of genes including SLUG, ZEB1, ZEB2, Fibronectin, Vimentin, and N-
Cadherin is characteristic of this process (138-143).  The mRNA levels of these genes 
were assessed by qRT-PCR to determine whether TMX2-28 cells have increased 
expression.  Gene expression of SLUG, ZEB1, ZEB2, Fibronectin and Vimentin, was 
found to be low in TMX2-28 cell cultures (Table 3.3), similar to that in the non-invasive 
parent cell line, MCF-7. The expression of all six genes was significantly higher in the 
invasive, mesenchymal-like MDA-MB-231 cell line than in either the non-invasive 
MCF-7 or the invasive TMX2-28 cells.   While expression of N-Cadherin in TMX2-28 
was slightly above that in MCF-7 cells, it was still significantly less than in MDA-MB-
231 cells.  Together with results on MMP expression, these data suggest that TMX2-28 
cells do not utilize the protease-dependent, mesenchymal invasion mechanism.   
RhoA pathway genes are overexpressed in TMX2-28 cells 
Next, we questioned whether TMX2-28 cells exploit the Rho kinase pathway, 
specifically RhoA pathway signaling. RhoA mRNA was overexpressed in TMX2-28 
cells at both the mRNA and protein levels (Figure 3.2 A) when compared to levels in 
MCF-7 and MDA-MB-231 cells.  Additionally, the major downstream targets of RhoA, 
ROCK 1 and ROCK 2, were also found to be overexpressed in these cells (Figure 3.2 B 
and C).  These data suggest that TMX2-28 cells may take advantage of RhoA dependent, 
protease-independent invasion process. 
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Blocking RhoA pathway activity decreased migratory and invasive behaviors  
We next designed experiments to determine whether blocking the activity of 
RhoA resulted in impairment of migratory and invasive behavior.  For these studies, 
TMX2-28 cells were treated with the ROCK inhibitor H-1152 to block RhoA pathway 
signaling.  HeLa (RhoA dependent invasion control), and MCF-7 (non-invasive control) 
cells were also used as positive and negative controls respectively.  As expected, 
blocking RhoA activity in the RhoA dependent HeLa cells resulted in significant 
abrogation (~66%) of invasive behavior.  When RhoA activity was blocked in TMX2-28 
cells, there was significant inhibition of migration and invasion (Figure 3.3). Migration 
was reduced by ~90% and ~94% when cells were treated with 20 and 100 µM of the 
inhibitor respectively.  In contrast, the reduction of invasion was dose-dependent, ~62% 
inhibition after treatment with 20 µM and ~92% inhibition after treatment with 100 µM.    
To further investigate the effect of blocking RhoA signaling on migration and 
invasion, siRNA specifically targeting RhoA was used to knockdown expression in 
TMX2-28, MCF-7 and HeLa cells (Figure 3.4 A).  Knockdown of RhoA in these cells 
resulted in a significant decrease in both migratory (50%) and invasive (52%) behavior 
(Figure 3.4 B), confirming the phenotypic changes observed when RhoA pathway 
signaling was blocked using H-1152 (Figure 3.3).  This effect was specific and was not 
seen when cells were transfected with the negative control siRNA.  Together these data 
show that RhoA plays an important role in the ability of TMX2-28 cells to be highly 
invasive and migratory while maintaining an epithelial morphology. 
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Discussion 
Cancer cells can use alternative mechanisms of motility for invasion (45, 47).  
Two distinct mechanisms have been identified, the more widely utilized, protease-
dependent, mesenchymal, and the less utilized, protease-independent, amoeboid 
movements (44-47).
 
 In breast cancer, MMPs have been tied to mesenchymal cell 
movement (128), however blocking MMP activity was unsuccessful in preventing growth 
and metastasis of late stage cancers in clinical trials (46, 144). Additionally, a study by 
Wolf and colleagues showed that when triple-negative, mesenchymal, MDA-MB-231 
breast cancer cells were challenged with MMP inhibitors, these cells adapted a round, 
epithelial-like morphology and continued to be invasive (47).  These studies suggest that 
breast cancer cells have the ability to utilize an amoeboid invasion mechanism.  Thus, 
determining the mechanisms behind this mode of invasion is critical for the development 
of therapies to block the metastatic process.   
The primary objective of the present study was to better define the molecular 
aspects underlying invasion, in TMX2-28 cells as a model of triple-negative, basal-like 
breast cancer.  We previously reported that the Tamoxifen-selected derivative of MCF-7 
cells, TMX2-28, are ERα negative and highly invasive (67-69); comparable to MDA-
MB-231 cells, an established breast cancer cell line known for being highly invasive and 
exploiting the proteolytic-dependent, mesenchymal mode of invasion. The rounded, 
epithelial-like cell morphology of TMX2-28 cells suggests an amoeboid mode of cellular 
invasion, however, this was not investigated.  
 The Tamoxifen-selected, MCF-7 derived TMX2-28 cells were used as a model to 
study migration and invasion in triple-negative, basal-like breast cancer.  Previous studies 
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of gene expression and IHC identified TMX2-28 cells as triple-negative (Chapter 2) and 
having a mixed basal/luminal CK expression profile (Chapter 4) (68).  In the present 
paper, our initial inquiry focused on experimentally excluding proteolytic pathways in 
TMX2-28 invasion.  We determined that TMX2-28 cells do not express MMP-1 mRNA 
or active MMP-2 or -9 protein, nor do they have expression of genes known to increase 
in expression during EMT.  Interestingly, a cDNA microarray comparing gene expression 
of TMX2-28 cells to their parent cell line, MCF-7, indicated that a number of proteases, 
MMPs, and adhesion molecules are downregulated in TMX2-28 (Table 3.1) (67, 68).  
These data together with the lack of MMP-1, -2, or -9 or EMT gene expression indicate 
that proteases are not critical to TMX2-28’s invasion mechanism and thus they do not 
utilize a mesenchymal migration mechanism.    
The next logical research direction we took was to determine which pathway 
TMX2-28 cells use to migrate.  cDNA microarray analysis indicated the TMX2-28 cells 
downregulate the RhoE, which acts as an inhibitor of RhoA (133).  It is known that RhoA 
signaling is important for many types of migration, and up-regulation of RhoA in cancer 
has been associated with cancer metastasis (45, 46, 64-66).  It was found that TMX2-28 
cells overexpress RhoA mRNA and protein.  Additionally, they overexpress mRNA from 
RhoA’s two main targets ROCK 1 and 2.  This provides three potential targets for 
therapy development against metastasis.  Furthermore, inhibition of RhoA pathway 
activity through the use of either the ROCK inhibitor H-1152, or a RhoA specific siRNA 
resulted in decreased migratory and invasive behavior.  
Based on these observations, we can conclude that TMX2-28 cells do not use 
protease dependent mesenchymal movements as their primary invasion mechanism. Their 
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rounded morphology, use of RhoA, and lack of mesenchymal phenotype, supports our 
hypothesis that TMX2-28 use amoeboid movement.  Furthermore, the cDNA microarray 
mentioned previously, also revealed that TMX2-28 cells expressed mRNA for a number 
of genes known to regulate cell membrane morphology and control cytoskeletal 
organization (Table 3.1).  These included mitogen inducible gene 2 (MIG2).  MIG2 is a 
component of cell-ECM adhesion sites that control cell shape and spreading.  MIG2 
promotes cellular dynamics though the recruitment of Migfilin and its interactions with 
Filamin and actin (67, 145, 146).  A study by Gozgit et. al. showed that MIG2 is 
overexpressed in TMX2-28 cells as well as in breast cancer tissues (67).  Knockdown of 
MIG2 also resulted in reduced invasive behavior.  RhoA signaling is known to be 
involved in focal adhesion formation along with MIG2 (145, 147, 148).  From this 
knowledge one could suggest that RhoA and MIG2 may work collectively to facilitate 
amoeboid invasion.  Further investigation into how these two proteins may interact is 
necessary for complete understanding of this mechanism. 
An understanding of the mechanisms behind cell migration and tumor metastasis 
is critical given that metastasis accounts for the majority of breast cancer deaths.  
Collectively, the results of our study suggest that TMX2-28 cells exploit a RhoA 
dependent, proteolytic-independent invasion mechanism. Targeting the RhoA pathway in 
triple-negative, basal-like breast cancer cells that have a proteolytic-independent invasion 
mechanism may provide therapeutic strategies for the treatment of cancer patients with 
increased risk of metastasis. 
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Table 3.1 
Genes associated with cytoskeleton organization, protease secretion, adhesion, and 
membrane morphology differentially regulated in TMX2-28 as compared with 
MCF-7 
Gene Name 
Gene Symbol Accession 
Number 
 
ADAM metallopeptidase with 
thrombospondin type 1 motif 
ADAMTS19 NM_133638.1 
D
O
W
N
R
E
G
U
L
A
T
E
D
 
Matrix metallopeptidase-like 1 
(Matrix metallopeptidase 25) 
MMPL1 
(MMP25) 
NM_004142.1 
Protease, Serine, 23 SPUVE 
(PRSS23) 
NM_007173.1 
TIMP metallopeptidase inhibitor 1 TIMP1 NM_003254.1 
TIMP metallopeptidase inhibitor 2 TIMP2 NM_003255.2 
Neuronal cell adhesion molecule NRCAM NM_005010.1 
Fibronectin leucine rich  
transmembrane protein 3 
FLRT3 NM_013281.1 
Fibroblast growth factor 13 FGF13 NM_004114.1 
Selectin L  SELL NM_000655.2 
Ras homolog gene family, member E RHOE NM_001254738.1 
EGF-containing fibulin-like 
extracellular matrix protein 1 
EFEMP1 NM_004105.2 
Carcinoembryonic antigen-related  
cell adhesion molecule 5 
CEACAM5 NM_004363.1 
Cathespin D CTSD NM_001909.4 
Cathepsin F CTSF NM_003793.3 
Cathepsin S CTSS NM_001199739.1 
Integrin β8 ITGB8 NM_002214.2 
Integrin α6 ITGA6 NM_000210.1 
Laminin, gamma 1 LAMC1 NM_002293.3 U
P
R
E
G
U
L
A
T
E
D
 
Laminin, beta 1 LAMB1 NM_002291.1 
Vitronectin  VTN NM_000638.1 
Serpin peptidase inhibitor, clade E  
member 1 
SERPINE1 NM_000602.3 
Mitogen inducible gene 2 MIG2 NM_006832 
http://www.nature.com/bjc/journal/v97/n6/suppinfo/6603926s1.html?url=/bjc/journal/v9
7/n6/full/6603926a.html; (68) 
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Table 3.2 
Primers used to detect relative mRNA expression of genes 
Gene RefSeq Number Forward Sequence 
(5'-3') 
Reverse Sequence 
(5'-3') 
ERα NM_000125 
ATGATCAACTGGG
CGAAGAG 
GATCTCCACCATG
CCCTCTA 
PR NM_000926.4 
GGAAGGGCTACGA
AGTCAAA 
TAACTTGCATGAT
CTTGTCAAACA 
HER2 M11730  
CCCCAGCCTGAAT
ATGTGAA 
CTCTGGGTTCTCTG
CCGTAG 
MMP-1 NM_002421 
CGACTCTAGAAAC
ACAAGAGCAAGA 
AAGGTTAGCTTAC
TGTCACACGCTT 
MMP-2 NM_004530 
GTGCTGAAGGACA
CACTAAAGAAGA 
TTGCCATCCTTCTC
AAAGTTGTAGG 
MMP-9 NM_004994 
CACTGTCCACCCC
TCAGAGC 
GCCACTTGTCGGC
GATAAGG 
SLUG NM_003068.4 
CATGCCTGTCATA
CCACAAC 
GGTGTCAGATGGA
GGAGGG 
ZEB 1 NM_001128128.2 
GGGAGGAGCAGTG
AAAGAGA 
TTTCTTGCCCTTCC
TTTCTG 
ZEB 2 NM_014795.3 
AAGCCAGGGACAG
ATCAGC 
CCACACTCTGTGC
ATTTGAACT 
Vimentin NM_003380.3 
AAAGTGTGGCTGC
CAAGAAC 
AGCCTCAGAGAGG
TCAGCAA 
Fibronectin NM_212482.1 
GAACTATGATGCC
GACCAGAA 
GGTTGTGCAGATT
TCCTCGT 
N-Cadherin NM_001792.3 
CACTGCTCAGGAC
CCAGAT 
TAGCCGAGGATGG
TCC 
RhoA NM_001664 
GATGGAAAGCAGG
TAGAGTTGG 
TCAGTATAACATC
GGTATCTGGGTA 
ROCK 1 NM_005406 
AATGCTTGTAGGT
GATACACCTTTT 
CTGTCAGTAAGGA
AGGCACAAA 
ROCK 2 NM_004850 
GAAGTGCAGTTGG
TTCGTCA 
GCTATTGGCAAAG
GCCATAA 
HPRT NM_000194 
ACCCCACGAAGTG
TTGGATA 
AAGCAGATGGCCA
CAGAACT 
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Table 3.3 
Relative mRNA expression of epithelial to mesenchymal genes in cell lines 
Target TMX2-28 MCF-7 MDA-MB-231 
SLUG 0.0039 ± 8.8 x10
-4 ** 
0.0060 ± 0.002 1.8748 ± 0.464 
ZEB1 0.0336 ± 0.008 
** 
0.0098 ± 0.003 0.5865 ± 0.158 
ZEB2 0.0009 ± 3.7 x 10
-4 *** 
0.0013 ± 6.1 x 10
-4 
0.2202 ± 0.041 
Fibronectin 0.0090 ± 0.004
§* 
1.1013 ± 0.364 0.7001 ± 0.042 
Vimentin 0.0005 ± 3.7 x 10
-5 **
 0.0005 ± 1.2 x 10
-4 
0.5461 ± 0.139 
N-Cadherin 0.6086 ± 0.282 
** 
0.1414 ± 0.066 1.4790 ± 0.172 
Data were analyzed using one-way ANOVAs and t-tests with Bonferroni 
corrections; for comparisons between TMX2-28 cells and MCF-7 cells 
§
p<0.005; for comparisons between TMX2-28 cells and MDA-MB-231 cells 
*p<0.05, **p<0.01, ***p<0.001  
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Figure 3.1 TMX2-28 cells do not secrete active MMP-1, -2, and -9.  Total RNA was 
isolated from TMX2-28, MCF-7, and MDA-MB-231 cells at 80% confluence.  Relative 
mRNA expression of MMP-1 (A), MMP-2 (B), and MMP-9 (C) were determined by 
qRT-PCR and normalized to the housekeeping gene HPRT.  Differences among cell lines 
were analyzed with one-way ANOVA and post hoc t-tests with a Bonferroni correction; 
*p<0.05.  (D) Conditioned media was collected from confluent cell cultures grown in 
serum-free medium for 48 hours and used for MMP-2 and -9 activity assessment. 
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Figure 3.2 Expression of RhoA, ROCK 1, and ROCK 2 are upregulated in TMX2-28 
cells.  Relative mRNA expression of (A) RhoA,  (B) ROCK 1, and (C) ROCK 2 were 
determined by qRT-PCR and normalized to the housekeeping gene HPRT.  Differences 
among cell lines were analyzed with one-way ANOVA and post hoc t-tests with a 
Bonferroni correction; **p<0.01.  Protein lysates (~20 µg) were probed for RhoA 
expression by Western immunoblotting (GAPDH used as loading control). 
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Figure 3.3 Blocking RhoA kinase pathway activity with the ROCK inhibitor H-1152 
reduces migratory and invasive behavior.  TMX2-28, HeLa (positive control) and MCF-7 
(negative control) were treated with H-1152 at 0, 20, and 100 µM concentrations for 24 
hours.  Cells were then seeded into invasion chambers with basal media containing the 
respective concentration of inhibitor and incubated for 22-24 hours.  Cells were then 
fixed, stained and counted.  Differences among cell lines were analyzed with one-way 
ANOVA and post hoc t-tests with a Bonferroni correction; *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 3.4 RhoA knockdown in TMX2-28 
cells results in inhibition of migration and 
invasion.  TMX2-28 and HeLa cells were transiently transfected with either a negative 
control siRNA (NC-siRNA) or a RhoA specific siRNA (RhoA-siRNA; MCF-7 cells were 
not transfected).  Forty-eight hours post transfection cells were collected for either 
RNA/protein isolation or invasion assay.  (A) Relative mRNA expression of RhoA was 
determined by qRT-PCR and normalized to HPRT.  Protein lysates (~20 µg) were probed 
for RhoA expression by Western blotting (GAPDH as loading control).  (B) Cells were 
seeded into invasion chambers, incubated for 22-24 hours, fixed, stained and counted.  
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests 
with a Bonferroni correction; *p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 4 
FURTHER CHARACTERIZATION OF THE TMX2-28 BREAST CANCER 
CELL LINE 
Introduction 
 Human breast tumor cell lines are needed for multidisciplinary research in breast 
cancer.  Cell lines that have been thoroughly characterized are the most useful for 
research.  The TMX2-28 cell line has been used as a model for breast cancer in a number 
of studies including the research in this dissertation.  As mentioned in prior chapters, 
Fasco and colleagues first characterized these cells following selection of 28 clones 
resulting from prolonged exposure of MCF-7 cells to the anti-estrogen Tamoxifen (69).  
While the majority of the clones expressed varying ratios of wildtype ERα and its splice 
variant ER∆3, one clone, later termed TMX2-28, had completely lost expression of ERα 
mRNA and protein.  It was noted that these cells grew faster than MCF-7 under standard 
culture conditions, had the ability to form foci independently of estradiol or Tamoxifen, 
and thus must rely on ER-independent genes and signaling pathways for cell growth (69). 
Studies in the Arcaro laboratory continued characterizing these cells by studying 
differentially expressed genes resulting from a cDNA microarray comparing TMX2-28 
with their parent cell line MCF-7 (68).  One thousand four hundred and two transcripts 
were found to be differentially expressed greater than two fold in TMX2-28 cells (200 
upregulated, 1202 downregulated).  Results from this array not only confirmed ERα 
down regulation, but also determined that TMX2-28 cells retained expression of luminal 
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cytokeratins 8, 18, 19, and 20, and gained expression of basal cytokeratins 5, 14, and 17 
(68), giving them a mixed basal/luminal cytokeratin profile.   
 Studies for this dissertation research further revealed that TMX2-28 cells fall into 
the triple-negative designation (Chapter 2) in that they not only lack ERα expression, but 
also lack expression of PR and HER2.  Continued investigation revealed that TMX2-28 
cells display an altered cell cycle with nearly twice the percentage of cells in the S and 
G2/M phases of the cell cycle than the G0/G1 phase, as compared to MCF-7 (68).  
Additionally, TMX2-28 cells were found to be highly invasive, as compared to MCF-7, 
demonstrated by their ability to invade through Matrigel similar to the highly invasive 
MDA-MB-231(67).   
An in depth study of specific proteins upregulated in TMX2-28 cells have 
identified a number of potential biomarkers (PLD1, PALM) and therapeutic targets 
(MIG2, SKP2, RhoA) for ERα-negative and triple-negative breast cancers (Chapter 2 & 
3; Ref (67, 68, 101).  Alongside the main research described in this dissertation, a number 
of genes involved in cell cycle, cell proliferation, anti-hormone resistance, cell migration 
and invasion, or are tumor subtype markers were also assessed in TMX2-28 cells.  
Expression of cytokeratins (CK) reflects the epithelial cell type, state of tissue 
growth, differentiation, and functional status of tissue (149).  In normal breast epithelium, 
the luminal and myoepithelial (basal) cells express different cytokeratin profiles. Luminal 
cells express CKs 7, 8, 18, and 19, while basal cells express CKs 5, 14, and 17 (150-152).  
Thus CK 5, 14, and 17 are used to define breast cancer with basal cell origins and tumors 
with acquired basal cell characteristics.   
96 
Epidermal growth factor receptor (EGFR) is a member of the epidermal growth 
factor receptor superfamily, which promotes tumor cell proliferation and survival in a 
variety of cancer types including lung, prostate, head and neck, stomach, kidney, brain, 
pancreatic, and breast (153-160).  Recent studies have brought EGFR into the forefront of 
cancer research due to its high association with poor patient prognosis and its 
overexpression in triple-negative, basal-like tumors, making it a standard marker for 
basal cell origin (161-166).   
C-myc is a proto-oncogene with the ability to transform cells (167). C-myc 
encodes a transcription factor that regulates cell proliferation through targeting cyclin/ 
cyclin dependent kinase (CDK) complexes (168-171) and can drive cells through G1/S 
transition in the absence of growth factors (172).  Studies have also shown that C-myc 
activation can induce apoptosis (167, 173). 
The insulin-like growth factor 1 receptor (IGF1R) is a member of the tyrosine 
kinase receptor superfamily (174).  IGF1R is known to control cell proliferation, ERα 
expression, and it is suggested to be involved with cell motility/adhesion and anti-
hormone resistance in breast cancer (175-180).  Interference with activation, expression, 
or signaling of IGF1R results in inhibition of growth and induction of apoptosis in breast 
cancer cells (181). 
The cell cycle is based on two key families of proteins, CDKs and cyclins.  CDKs 
activate downstream signaling through phosphorylation of their target genes; cyclins bind 
to CDKs and control their ability to phosphorylate target proteins (182-185).  CDK4 is 
expressed and has actions in the G1 of the cell cycle.  Progression though G1 depends 
upon the ability of CDK4 to bind and be activated by Cyclin D (186). 
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FoxM1 is a member of the forkhead box family of transcription factors and 
promotes cell cycle progression into the M phase of the cell cycle (187, 188).  FoxM1 
controls transcription of a number of cell cycle, mitosis and genes responsible for 
chromosome segregation including Cyclin B1, Cyclin D1, NEK2, CDC25B, Aurora B 
Kinase, and Surviven (187-190).  In breast cancer, FoxM1 is known to be elevated and 
also to both regulate ERα expression, and to be regulated by ERα (191, 192). 
Rac1 and CDC42 are members of the Rho GTPase family.  Rac1 induces actin 
rich surface protrusions (lamellipodia) and cell ruffling, while CDC42 promotes the 
formation of actin-rich membrane extensions (filopodia) (193-196).  CDC42 also controls 
cell directionality during mesenchymal cell movement through polarizing microtubules 
(49).  p21 activated kinase (PAK) is a downstream target of both Rac1 and CDC42 (197-
199).  PAK then targets substrates involved in a number of cellular processes including 
cell proliferation, survival, motility, angiogenesis, EMT, anchorage independent growth, 
and metabolism (199-205). 
E-cadherin is a calcium regulated cell-cell adhesion molecule expressed primarily 
in epithelial cells (206, 207).  Studies have shown that expression of E-cadherin in breast 
cancer rescues progression and invasiveness of tumors, and formation of metastases 
(208).  Inactivation of E-cadherin is characteristic of invasive breast cancer and has been 
suggested as a useful prognostic factor for classifying subgroups of triple-negative and 
basal-like breast cancers (209-214).   
The importance of estrogen signaling in breast cancer progression is well 
described (215-218).  Estrogens are steroid hormones that regulate growth, differentiation 
and function in various tissues throughout the body.  Until the discovery of ERβ in 1996, 
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it was thought that all biological effects of estrogen were mediated through one receptor, 
ERα (215, 216, 219).  Human mammary tissue expresses both ER subtypes (219-221).  
ERβ is highly homologus to ERα, having 96% amino acid homology at the N-terminus, 
and 58% amino acid homology at the C-terminus (219).  ERβ can bind estradiol with an 
affinity similar to that of ERα and can stimulate transcriptional activation through 
estrogen response elements (222). A number of studies have found that ERα-negative 
breast cancers with ERβ immunoreactivity respond favorably to adjuvant Tamoxifen 
treatment (223-227).  Conversely, a number of studies have shown that ERβ can mediate 
opposite effects than those of ERα and suppress proliferation (228-230).  
The forkhead transcription factor, FoxP3 regulates the development and function 
of T regulatory cells (231, 232).  Until recently, FoxP3 expression was thought to be 
confined to the T cell lineage (231, 233), however studies have since shown that FoxP3 is 
expressed in cancer, including breast cancer, melanoma, and cell lines derived from solid 
tumors (234-237).  Studies from Zuo et. al. have demonstrated that FoxP3 may also act as 
a master regulator controlling the expression of the breast cancer oncogenes, SKP2 and 
HER2 through transcriptional repression (237, 238).  Zuo also noted that FoxP3 
heterozygous mice show an increase rate of spontaneous mammary cancer (238).  Lastly, 
expression of FoxP3 in breast cancer has also been associated with poor patient survival 
(239).  
Materials and Methods 
Cell Culture:  TMX2-28 and MCF-7 cells were maintained in T-75 culture flasks 
at 37°C and 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with calf serum (5%), insulin (10 µg/ml), non-essential amino acids (100X), penicillin-
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streptomycin (10,000 µg/ml), and L-glutamine (200 mM). MDA-MB-231 cells were 
maintained in Leibovitz-15 (L-15) medium supplemented with 10% FBS at 37°C and 0% 
CO2.  Jurkat cells were maintained in RPMI medium supplemented with 10% FBS at 
37°C and 5% CO2.  All cells were passaged when near 80% confluence.   
 
RNA Isolation:  Total RNA (n=3 biological samples) was isolated with Tri-
Reagent (Molecular Research Center, Cincinnati, OH) according to manufacturer’s 
suggestions and protocols as previously described (67, 68, 101).  RNA was then treated 
with Turbo DNA-Free (Ambion, Austin, TX) to remove any DNA contamination.  The 
quality of the RNA was assessed by 260/280 nm spectrophotometer readings (Nanodrop 
8000; Thermo Scientific, Wilmington, DE).  
 
Quantitative Real Time Reverse Transcriptase PCR (qRT-PCR): RNA samples  
(n=3 biological samples) were reverse transcribed and amplified using the One Step RT-
PCR kit (Qiagen, Valencia, CA) in the Roche LightCycler (Roche, Indianapolis, IN) as 
previously described. Gene specific primers, designed using Primer3 software 
(http://frodo.wi.mit.edu/), and purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA), were used for CK 5, CK 14, CK17, EGFR, C-myc, IGF1R, CDK4, 
FoxM1, CDC42, Rac1, PAK, E-Cadherin, ERβ; primers for FoxP3 were purchased from 
SABiosciences (Valencia, CA; Table 4.1).   
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Results 
Gene expression of markers of basal cells, proliferation, migration/invasion and 
hormone signaling in TMX2-28 
Using qRT-PCR to determine the gene expression of basal markers, it was 
revealed that TMX2-28 cells have significantly higher relative expression of CKs 5, 14, 
and 17 than luminal MCF-7 cells and similar levels as basal MDA-MB-231 cells (Table 
4.2).  Contrary to our prediction, TMX2-28 cells had significantly lower expression of 
EGFR than MDA-MB-231 cells.  The proliferation markers C-myc, IGF1R, CDK4, and 
FoxM1 were also examined for mRNA expression in TMX2-28 cells.  No significant 
difference in expression of C-myc or FoxM1 was found, however there was a significant 
decrease in IGF1R expression compared to MCF-7 and a significant increase in 
expression of CDK4 compared to MDA-MB-231 cells (Table 4.2). 
I also examined the expression of four genes involved in cell migration, adhesion 
and invasion (Rac1, CDC42, PAK, and E-Cadherin).  It was determined that TMX2-28 
cells express significantly higher levels of Rac1 mRNA than do MCF-7, and similar 
levels as those of MDA-MB-231 cells.  TMX2-28 also had significantly less PAK 
expression than MCF-7 cells, and although not significant, they have higher expression of 
PAK than MDA-MB-231 cells.  These cells were also found to have significantly less 
expression of CDC42 than MDA-MB-231 cells (Table 4.2). Lastly, TMX2-28 cells were 
found to express significantly less E-cadherin mRNA than MCF-7 cells, not significantly 
different from MDA-MB-231 (Table 4.2; Figure 4.1).  
Further gene expression studies revealed that TMX2-28 cells have little to no 
expression of ERβ, similar to MCF-7, and significantly less than MDA-MB-231 cells, 
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which are considered ERβ-positive (Table 4.2).  Figure 4.2 shows that compared to 
expression of ERβ in human tissues (prostate and testis), TMX2-28 cells lack ERβ 
expression.  Lastly, relative FoxP3 expression was also determined.  FoxP3 was found to 
be significantly less expressed in TMX2-28 cells when compared to MCF-7 and Jurkat T 
lymphocyte cells, both of which are known to be FoxP3 expressing cells (Table 4.2; 
Figure 4.3).  
Discussion 
A great advantage to cancer research has been the development of the ability to 
culture tumor cell lines in an in vitro setting.  With this technology, researchers have been 
able to examine the effects of manipulating the levels of oncogenes, proto-oncogenes, 
and suppressor genes on behavioral properties.  They can then compare in vitro properties 
with those in human cancer tissue, and investigate the mechanisms that differ between 
them to determine which cell line best mimics the cancer of interest.  In this chapter, gene 
expression of basal cell markers, genes associated with cell proliferation, hormone 
signaling, migration, adhesion, and invasion were examined in TMX2-28 cells in order to 
further characterize this cell line as a model for triple-negative and basal-like breast 
cancers.   
It was discovered that TMX2-28 cells express a number of basal cell markers, CK 
5, 14, and 17, and the proliferation marker CDK4. Expression of one gene associated 
with invasion, CDC42, was found to have low expression in TMX2-8 cells.  This was not 
surprising as CDC42 is known to play an important role in protease-dependent, 
mesenchymal invasion and as I have shown in Chapter 3, TMX2-28 utilizes a protease-
independent, amoeboid invasion mechanism.  The mRNA expression of the adhesion 
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protein E-Cadherin was also determined to be at low expression levels in TMX2-28 cells.  
Gene expression assays also revealed that TMX2-28 cells do not express ERβ, suggesting 
that they truly rely on ER independent growth mechanisms.  Lastly, TMX2-28 cells do 
not express the transcription factor FoxP3, suggesting that FoxP3 regulates neither SKP2 
nor HER2 expression in TMX2-28 cells.  The gene expression profiling in this chapter 
has revealed a number of unique expression patterns in the TMX2-28 breast cancer cells 
line.  These patterns help explain the hormone-independent and Tamoxifen insensitive, 
uncontrolled aggressive growth phenotype associated with ERα-negative, triple-negative, 
and basal-like breast cancers.   
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Table 4.1 
Primers used to detect relative mRNA expression of genes 
Gene RefSeq 
Number 
Forward 
Sequence (5'-3') 
Reverse Sequence 
(5'-3') 
CK 5 NM_000424.3 CAACCCACTAG
TGCCTGGTT 
ATAGCCACCCA
CTCCACAAG 
CK 14 NM_000526.4 TTCTGAACGAG
ATGCGTGAC 
GCAGCTCAATC
TCCAGGTTC 
CK 17 NM_000422.2 GCTGCTACAGC
TTTGGGCTCT 
TCACCTCCAGC
TCAGTGTTG 
EGFR NM_005228.3 TTCCCGTAATTA
TGTGGTGACAG
ATC 
ACCCCTAAATG
CCACCGGC 
C-myc NM_002467.4 TTCGGGTAGTG
GAAAACCAG 
CAGCAGCTCGA
ATTTCTTCC 
IGF1R NM_000875.3 TCATCCGCAAC
GGCAGCCAG 
TGGCGCCCTTT
AGTCCCCGT 
CDK4 NM_000075.3 TTTCCGCGCGCC
TCTTTGGC 
GACGTCCATCA
GCCGGACAACA 
FoxM1 NM_202002.2 GGAGGAAATGC
CACACTTAGCG 
TAGGACTTCTT
GGGTCTTGGGG
TG 
CDC42 NM_00103980
2.1 
CCAACGCCCCG
GTGGAGAAG 
TCAGGCACCCA
CTTTTCTTTCAC
G 
Rac1 NM_018890.3 GTGGTGGGAGA
CGGAGCTGTA 
TGAGTGCGAAG
GCTCCACCG 
PAK2 NM_002577.4 TGCACTGGGAC
AGGAGGTTGCT 
GCGTTTGCTCT
GCTCAGGGGT 
E-
Cadherin 
NM_004360.3 CGCCCCATCAG
GCCTCCGTT 
CAGCCTCCCAC
GCTGGGGTA 
ERβ NM_001437 ACCTTCCTTTTC
AGTGTCTCTC 
CCATCGCCAGT
TATCACATCT 
FoxP3 NM_014009.3 SABiosciences Cat# PPH00029B 
(Start position lies in exon 12) 
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Table 4.2 
Relative mRNA expression of epithelial to mesenchymal genes in cell lines 
Target Function TMX2-28 MCF-7 
MDA-MB-
231 
Jurkat 
CK 5 
Basal Cell 
Markers 
1.259 ± 0.438
†
 0.002 ± 0.001 0.142 ± 0.047 
N/A 
 
CK 14 5.431 ± 0.982
a 
0.045 ± 0.033 6.906 ± 2.456 
CK 17 2.262 ± 0.527
††, *
 0.007 ± 0.004 0.581 ± 0.157 
EGFR 0.017 ± 0.008
*** 
0.007 ± 0.001 0.101 ± 0.011 
C-myc 
Proliferation 
0.523 ± 0.226 0.056 ± 0.013 0.189 ± 0.058 
N/A 
IGF1R 0.024 ± 0.013
†††
 0.256 ± 0.026 0.014 ± 0.003 
CDK4 0.175 ± 0.011
*
 0.171 ± 0.002 0.078 ± 0.027 
FoxM1 4.871 ± 1.600 1.736 ± 0.831 2.373 ± 1.054 
CDC42 
Migration, 
Adhesion, 
Invasion 
0.217 ± 0.010
***
 0.228 ± 0.019 0.708 ± 0.066 
N/A 
Rac1 0.968 ± 0.251
† 
0.105 ± 0.029 0.953 ± 0.188 
PAK2 
0.002 ± 4.607 x 
10
-4 † 
0.004 ± 4.01 x 
10
-4 
8.89 x 10
-6  
± 
2.759 x 10
-6 
E-
Cadherin 
0.006 ± 0.003
††
 0.098 ± 0.019 
7.68 x 10
-6  
± 
3.045 x 10
-6 
ERβ 
Estrogen 
Signaling 
1.051 x 10
-5 
± 
1.871 x 10
-6 *** 
1.989 x 10
-5  
± 
1.596 x 10
-6 
5.096 x 10
-5 
± 
4.877 x 10
-6 N/A 
FoxP3 
Regulation 
of SKP2 
and HER2 
0.009 ± 0.006
†††, 
¶
 
0.604 ± 0.030 N/A 
0.238 ± 
0.029 
Data were analyzed using one-way ANOVAs and t-tests with Bonferroni corrections; for 
comparisons between TMX2-28 cells and MDA-MB-231 cells *p<0.05, **p<0.01, 
***p<0.001; for comparisons between TMX2-28 and MCF-7 cells †p<0.05, ††p<0.01, 
†††p<0.001; for comparisons between TMX2-28 and Jurkat cells ¶p<0.001; §only one 
biological sample was available for assaying; 
a 
Significant ANOVA (p<0.05) but not 
significant with post hoc t-tests. . 
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Figure 4.1 E-Cadherin is downregulated in TMX2-28 cells.  Relative mRNA expression 
of E-Cadherin was determined by qRT-PCR and normalized to the housekeeping gene 
HPRT.  Differences among cell lines were analyzed with one-way ANOVA and post hoc 
t-tests with a Bonferroni correction; **p<0.01. 
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Figure 4.2 ERβ is downregulated in TMX2-28 cells.  Relative mRNA expression of ERβ 
was determined by qRT-PCR and normalized to the housekeeping gene HPRT.  
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests 
with a Bonferroni correction; NS= not significant. ***p<0.001.   
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Figure 4.3 FoxP3 is downregulated in TMX2-28 cells.  Relative mRNA expression of 
FoxP3 was determined by qRT-PCR and normalized to the housekeeping gene HPRT.  
Differences among cell lines were analyzed with one-way ANOVA and post hoc t-tests 
with a Bonferroni correction; ***p<0.001. 
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CHAPTER 5 
TUMORIGENICITY AND METASTATIC POTENTIAL OF TMX2-28 CELLS 
Introduction 
Previous studies have validated that MCF-7 cells respond to estrogen (17β 
estradiol; E2) in vivo in xenograft model systems in mice by inducing tumor growth (240, 
241).  Thus, I established a collaboration with the laboratory of Dr. Sallie Smith-
Schneider to test TMX2-28 and SKP2 knockdown TMX2-28 cells for their in vivo 
tumorigenicity and metastasis potential in mouse xenograft models.  Based on the highly 
proliferative and invasive nature of TMX2-28 cells, and the data we have showing that 
suppressing SKP2 alters their cell cycle and thus decreases proliferative potential, it is 
predicted that TMX2-28 and TMX2-28-NC (negative control) cells will establish tumors 
of larger size and volume than MCF-7 and TMX2-28-S2 (SKP2 knockout cells). 
Materials and Methods 
 
Xenograft assays for tumorigenicity:  For the first set of xenograft studies, two 
groups of 10, 5-week-old) athymic nude mice (Jackson Laboratories, Bar Harbor, ME) 
received subcutaneous inoculations of cells without E2 supplementation.  For group 1, 
inoculations consisted of 2 x 10
6
 TMX2-28 or MCF-7 cells in 100 µL of Hank’s balanced 
salt solution, injected into the right and left flank, respectively.  For group 2, each 
inoculation consisted of 2 x 10
6
 TMX2-28-NC or TMX2-28-S2 cells in 100 µL of Hank’s 
balanced salt solution, injected into the right and left flank, respectively.  During this 
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twenty-four day assay, mice were manually palpated beginning at day 3 post injection 
and every 3-4 days after.   
For the second set of xenograft studies, a group of 10, 6-week-old non-obese 
diabetic background severe combined immune deficient (NOD-SCID) mice (Jackson 
Laboratories, Bar Harbor, ME) received subcutaneous inoculations of cells without 
estrogen supplementation.  Each inoculation consisted of 2 x 10
6
 TMX2-28-NC or 
TMX2-28-S2 cells in 100 µL of Hank’s balanced salt solution, injected into the right and 
left flank, respectively.  During this sixty-two day assay, mice were manually palpated 
beginning at day 3 post injection and every 3-4 days after.  IACUC approval was 
obtained for all work with animals.  
Results 
TMX2-28 cells were unable to sustain palpable tumors in xenograft models 
 
Xenograft studies for tumorigenicity revealed that TMX2-28 cells, regardless of 
SKP2 expression levels, were unable to sustain appreciable tumor growth.  The first set 
of xenograft studies involved evaluation of tumorigenesis potential of TMX2-28 versus 
MCF-7 cells (Group 1) and the potential of TMX2-28-NC versus TMX2-28-S2 cells 
(Group 2) in the absence of E2 in athymic nude mice.  Following the twenty-four day 
study, growth size at the sight of injection steadily decreased from all 20 mice with 
possible tumors 4 days post injection to 10 (day 12), 5 (day 15), 1 (day 18), and finally 
zero by day 21.  Although none of the mice produced sustainable palpable tumors, upon 
surgical evaluation, seven mice had small growths at the site of injection, four of which 
were injected with TMX2-28 cells, and the remaining three were injected with TMX2-
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28-S2 cells.  These seven growths were collected, fixed and embedded in paraffin along 
with the lungs and livers of all twenty mice, and are available for further study. 
The second set of xenograft studies only involved evaluation of tumorigenesis 
potential of TMX2-28-NC versus TMX2-28-S2 cells in the absence of E2 in NOD-SCID 
mice.  During this 62-day study, “possible” tumors were manually detected in 8 of the 10 
mice by 6 days post injection.  This number increased to 9 mice by day 9, however 
steadily it decreased to 5 (day 13), 3 (day 16), 1 (day 20), and finally 0 mice by day 24. 
The majority of mice began to develop tumors even though they were not sustainable.  
Upon surgical evaluation, three mice had small growths at the site of injection, two 
injected with TMX2-28-S2 and one injected with TMX2-28-NC cells. One of the mice 
with the TMX2-28-S2 injection site growth also had an abdominal growth present.  For 
this study a number of organs that are frequent sites of breast cancer metastasis (brain, 
liver, and lungs) were collected along with the four growths; the tissue at the injection 
site, and the surrounding mammary glands (lower glands).  These tissues have been fixed, 
embedded in paraffin and are available for further study. 
Discussion 
Xenograft studies for tumorigenicity revealed that TMX2-28 cells, regardless of 
SKP2 expression levels, were unable to sustain appreciable tumor growth following 
subcutaneous flank injections into xenograft mouse models.  During both studies, 
possible tumors were manually detected in mice by 6 days post injection, but ultimately 
all mice lost them by day 24. 
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Knowing that TMX2-28 cells are triple-negative, have a mixed basal/luminal CK 
expression profile, and are highly proliferative and invasive when cultured in vitro, we 
would expect this cell line to establish sustainable tumors in a xenograft mouse model.  
Surprisingly, they did not.  One other study has also evaluated the in vivo tumorigenicity 
of TMX2-28 cells.  Spink and colleagues inoculated the mammary glands of 6- and 8-
week-old SCID mice, with and without E2 supplementation.  They too observed that 
TMX2-28 cells grew poorly as mammary gland xenografts regardless of E2 
supplementation (242).   
Given that TMX2-28 cells are highly proliferative and invasive in vitro, that the 
majority of mice began to develop tumors even though they were not sustainable, and 
that both studies had a few mice with small growths upon surgical evaluation, it is 
reasonable to suggest that these cells may not have formed substantial tumors at the 
injection site for two reasons:  1. The cells had already left the “primary” tumor site to 
establish metastatic niches throughout the body or 2. The cells lack expression of genes 
that are critical to the process of growth in the in vivo setting.   
To address the first hypothesis, a number of tissues were collected after both 
xenograft assays and were fixed in formalin and embedded in paraffin. With these tissues 
we can exploit the fact that the shRNA construct used to stably transfect TMX2-28 cells 
also contains a GFP gene, which results in GFP expression in the control and SKP2-
silenced cell lines (TMX2-28-NC andTMX2-28-S2).  Anti-GFP antibodies could be used 
to evaluate the presence or absence of TMX2-28 cells in the various organs collected.  
Observations that these cells were able to establish metastatic growths would fit with the 
112 
aggressive and highly metastatic nature of triple-negative and basal-like tumors seen in 
breast cancer patients. 
It is equally possible that TMX2-28 cells grew poorly in xenograft models simply 
because they were unable to successfully establish in an in vivo setting.  If this were the 
case then deciphering why they are unable to grow would be instrumental in designing 
targetable therapy to combat tumor growth and metastasis.  It is known that MCF-7 cells 
(TMX2-28’s parent cell line) are typically non-invasive but will form tumors in vivo in 
the presence of E2 (242-244), so what is lacking in TMX2-28 cells that made them loose 
this ability?  To address this hypothesis, further studies comparing MCF-7 and TMX2-28 
cells are needed.  Our lab has both cDNA and methylation array data that compare the 
parent and derivative cell lines.  Looking for genes that are related to growth and 
metastasis and that are downregulated and/or promoter-methylated in TMX2-28 as 
opposed to MCF-7 would be the first place to start.   
Additionally, it may be advantageous to compare these cells with another triple-
negative cell line that is known to form xenograft (i.e. MDA-MB-231).  Another 
direction would be to study other Tamoxifen-selected lines such as  the TMX2-11 and 
TMX2-4 cell lines, which were created alongside TMX2-28, or to look at cells during the 
process of Tamoxifen selection.  These cells could shed light on the pathway genes that 
were altered and are preventing TMX2-28 cells from growing in vivo.  If we can 
determine why these cells do not form primary tumors in vivo, we will have a greater 
understanding of how to target aggressive types of cancers in patients. 
113 
CHAPTER 6 
DISCUSSION AND FUTURE DIRECTIONS 
Introduction 
Breast cancer is a heterogeneous disease that varies in its biology and response to 
therapy.  Homeostasis of non-cancerous cells requires a delicate balance between 
proliferation, cell cycle arrest and apoptosis; this equilibrium is disrupted during cancer 
progression.  Historically, estrogen receptor (ERα), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER2) are the most important prognostic 
factors in breast cancer, dictating a patient’s therapeutic options.  Currently, breast 
tumors are further classified into subtypes based on their gene expression patterns (7, 11).  
One tumor subtype lacks expression of ERα, PR, and HER2 and is referred to as triple-
negative.  The basal-like tumor subtype is associated with positive basal cytokeratin (CK) 
expression and is often triple-negative (7, 16, 78-80). Patients with these subtypes face 
poor prognosis, as these cancers are typically aggressive in their growth, highly 
metastatic and often unresponsive to anti-estrogen and anti-HER2 therapies (17, 18).  The 
data presented here was designed to answer questions specifically related to growth and 
invasion in triple-negative and basal-like breast cancers, with the objective of furthering 
our understanding of the molecular mechanisms underlying these processes.   
In this study, we use the Tamoxifen-selected, MCF-7 derivative, TMX2-28 breast 
cancer cell line.  TMX2-28 cells have lost expression of ERα and have acquired a mixed 
basal/luminal cytokeratin profile, suggestive of a more basal-like phenotype (32-34).  
Morphologically, TMX2-28 cells retained an epithelial cell shape similar to MCF-7.  
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Behaviorally, TMX2-28 cells are highly proliferative and invasive (32, 33). It is these 
characteristics that make TMX2-28 cells an interesting and relevant model for studying 
increased growth and invasive behavior in triple-negative and basal-like breast cancers. 
It was also discovered that TMX2-28 cells express a number of basal cell 
markers, CK 5, 14, and 17, and the proliferation marker CDK4.  Additionally, low 
expression (mRNA) of one gene associated with invasion, CDC42, and the adhesion 
protein E-Cadherin also was found in TMX2-28 cells.  Gene expression assays also 
revealed that TMX2-28 cells do not express ERβ, suggesting that they truly rely on ER-
independent growth mechanisms.  Lastly, TMX2-28 cells do not express the transcription 
factor FoxP3, suggesting that SKP2 and HER2 expression is not regulated by FoxP3 in 
TMX2-28 cells.   
SKP2 Mediates Proliferation In Vitro and is Associated With Aggressive Breast 
Cancer Subtypes 
S-phase kinase-associated protein 2 (SKP2) plays an important role in cell cycle 
regulation by targeting p27 for degradation (21, 28, 35, 36).  During the transition from 
G1 to S phase, p27 undergoes phosphorylation modifications at three major sites, Serine 
10 (Ser10), Threonine 187 (Thr187) and Threonine 198 (Thr198) (29).  Phosphorylation 
at Ser10 stabilized p27 in quiescent cells, however, this phosphorylation event has been 
shown to promote cell proliferation (29-32).  Thr198 phosphorylation is catalyzed by 
ROCK 1 kinase, only when Ser10 is already phosphorylated, and results in the 
inactivation of both free and CDK bound p27 (33, 34).  Lastly, phosphorylation of 
Thr187 is catalyzed by SKP2 and promotes the ubiquitin ligase-mediated degradation of 
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p27 (21, 28, 35-39).  The cyclin-dependent kinase (CDK) inhibitor p27 regulates G1/S 
transition by binding cyclin/CDK complexes and abrogating its activity (21, 35, 36).   
Overexpression of SKP2 has been associated with poor prognosis on its own (94) and in 
combination with high Cyclin E expression (92) as well as other unfavorable prognostic 
factors including increased tumor grade, lack of expression of ERα and PR, and HER2 
overexpression (95, 96).  
The primary objective of the present study was to provide insight into the 
oncogenic role of SKP2 in triple-negative and basal-like breast cancers.  To accomplish 
this, we first evaluated SKP2 expression in a triple-negative, basal-like breast cancer cell 
line TMX2-28 (Chapter 2).  We found significantly higher SKP2 levels in TMX2-28 
cells, and that these cells overexpress a number of SKP2 pathway proteins including p27, 
CDK2, and Cyclin E, but did not overexpress an alternative cell cycle pathway protein 
Cyclin D1.  We also discovered that partially blocking SKP2 expression in TMX2-28 
cells using RNAi results in altering their cell cycle pattern by decreasing the percentage 
of cells in the S phase and increasing the percentage of cells in the G1/G0 phase of the cell 
cycle.    
Another way we could establish that SKP2 overexpression is resulting in the 
increase of G1/S transition in TMX2-28 cells is to examine the activity of CDK2.  CDK2, 
in complex with Cyclin E is responsible for G1/S transition through the phosphorylation 
of a number of proteins including the retinoblastoma (Rb) (245).  In order for 
CDK2/Cyclin E to have its kinase actions on Rb, CDK2 must first be activated though 
phosphorylation of Thr160.  Cyclin E binding to CDK2 results in conformational changes 
that reduced steric hindrance around Thr160 allowing the residue to be available for 
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phosphorylation by Cyclin Activating Kinase (246-250) Thus to show activation of 
CDK2, protein expressions of activated CDK2 (Thr160 phosphorylated CDK2) and 
phosphorylated Rb could be examined.   
Additionally, we assessed mRNA and protein expression of SKP2, and its 
associated proteins, in human breast and breast cancer tissues.  SKP2 mRNA was found 
to be more frequently expressed in ERα-negative, basal cytokeratin expressing, and 
basal-like breast cancers.  Using IHC and TMA methods, we also evaluated the 
relationships between SKP2 and its pathway genes as well as the relationship between 
SKP2 and several clinicopathological features.  High levels of SKP2 did not always result 
in low levels of p27.  In our study 11% of tumors expressed high SKP2/low p27, 
however, 32% of tumors with high SKP2 also had high p27.  Furthermore, low levels of 
SKP2 were associated with low p27 in 20% of the tumors.  While we found no 
significant relationship (neither positive nor inverse) between SKP2 and p27 expression, 
a significant positive relationship was discovered between SKP2 and the phosphorylated 
form of p27 (pSer10p27), a form of p27 associated with increased proliferation rates (30, 
38).   
Taken together with the work from other groups, these findings strongly suggest 
that SKP2 could play a vital role in the progression of triple-negative and basal-like 
breast cancers.  The next step in this study would be the evaluation of p27 
phosphorylation in TMX2-28 cells and human breast tissues.  The relationships between 
SKP2 overexpression and pThr187p27, pSer10p27/pThr187p27 double phosphorylation, 
and pSer10p27/pThr198p27 double phosphorylation needs to be determined.   
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In vitro studies would involve immunoprecipitation of pSer10p27 using the same 
anti-pSer10p27 monoclonal antibody used for IHC studies in Chapter 2 (ab62364; 
Abcam, Cambridge, MA).  The resulting protein can then be run out on a Western 
immunoblotting gel and probed for either pThr187p27 or pThr198p27.  For this assay I 
would suggest using Abcam’s anti-pThr187p27 (ab118644) and anti-pThr198p27 
antibodies (ab64949; Abcam, Cambridge, MA). Although Abcam’s antibody is not 
backed by literature yet, I was unable to optimize the antibody for pThr187p27 that is 
seen in literature (sc-16324, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for either 
Western blotting or IHC (251-253).   
It would also be advantageous to evaluate the expression of these pThr187p27 and 
pThr198p27 in breast and breast cancer tissues (as performed in Chapter 2) and see if its 
expression correlates with age, tumor type, tumor grade, ERα and triple-negative status, 
and SKP2 expression using the same antibodies as above and consecutive slices of tissue 
samples.  Alternatively, sequential antibody staining of tissue could be performed in 
order to visualize multiple proteins (Ser10, Thr187, Thr198, and SKP2) within the same 
tissue slide.  This could be done using secondary antibodies with different fluorophores 
attached to them.  Potential problems with this approach include cross contamination, and 
limitations on the antibodies that are available for the phosphorylated forms of p27.   
SKP2 overexpression could modulate the malignant phenotype of triple-negative 
and basal-like breast cancers through direct and indirect regulation of p27 
phosphorylation.  SKP2 is known to directly regulated p27 through SCF/E3 ligase 
activity (resulting in pThr187p27), however SKP2 may be indirectly regulating the p27 
inactivation thorough its ability to stimulate RhoA transcription.  Increased RhoA leads 
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to increased activation of its downstream effectors ROCK 1/2 and mDia, which in turn, 
not only activates SKP2 transcription but ROCK 1 also catalyzes the phosphorylation of 
pSer10p27 at Thr198 resulting in the inactivation of p27.  
The results from these additional studies would help elucidate the extent to which 
combined high levels of SKP2 and pSer10p27 alone, in combination with pThr187p27 
and/or pThr198p27 may be a good indicator of whether inhibiting SKP2 will result in 
slowing cell cycle and proliferation. Knowledge of these relationships may further 
delineate SKP2 as a suitable and favorable target for the development of specific 
therapeutic intervention; providing a molecular signature that would predict which 
patients will benefit from SKP2-targeted therapy. 
RhoA is Vital to the Invasion Mechanism of TMX2-28 Cells 
A foremost threat to patients is tumor invasion and metastasis, with the greatest 
risk to patients diagnosed with triple-negative and basal-like breast cancers.  To manifest 
their malignant potential, tumor cells must have the ability to invade the extracellular 
matrix (ECM), enter the blood or lymphatic system, travel to and invade distant tissues, 
and establish new tumor sites (41-43).  Two distinct morphological/functional 
mechanisms are known for single cell migration in tissues: fibroblast-type mesenchymal 
invasion, and leucocyte-type amoeboid invasion.  Mesenchymal movement is 
characterized by an elongated cellular shape, and involves the use of proteases that cause 
cellular lysis in tissues, thereby creating a path through which cells can invade (44-47). 
Amoeboid migrating cells have a rounded morphology and their movement is protease–
independent; instead, cells find paths through the ECM by pushing and squeezing 
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through regions of adequate size (43, 44, 47, 51, 52).  Proteins that control cell-cell and 
ECM interactions also are thought to play a role in invasion and metastasis in a 
proteolytic-independent way, by controlling cell morphology, motility, and interactions 
with the tumor microenvironment (41, 44).   
The primary objective of the present study was to better define the molecular 
aspects underlying invasion, in TMX2-28 cells as a model of triple-negative, basal-like 
breast cancer.  Despite their aggressive phenotype, TMX2-28 retains morphology similar 
to non-aggressive MCF-7 cells, suggesting that their invasion may be proteolytic-
independent. We determined that TMX2-28 lack MMP-1 mRNA, and MMP-2/MMP-9 
protein expression; each of which are important in protease-dependent invasion. It is 
important to note, however, that the activity of other MMPs (i.e. collagenases, 
stromelysins, membrane type, and others), as well as other proteases (i.e. serine/threonine 
proteases), have not yet been examined in TMX2-28. 
TMX2-28 cells have low expression of other genes key to protease-dependent 
invasion such as Slug, Zeb 1, Zeb 2, Vimentin, Fibronectin and N-cadherin. Conversely, 
these cells have high expression of protease-independent invasion genes such as Rho, 
ROCK 1, ROCK 2, and E-cadherin. Finally, treating TMX2-28 cells with a RhoA 
pathway inhibitor or shRNA targeting RhoA, significantly reduces their invasiveness.  
These data suggest that TMX2-28 cells use a RhoA dependent, proteolytic-
independent invasion mechanism.  However, additional studies are still needed to 
definitively state that TMX2-28 cells move in an amoeboid fashion.  One such study 
would involve live cell microscopy.  Live cell microscopy would allow us to observe 
TMX2-28 cell movement in a 3D matrix and thus determine if movement is characteristic 
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of amoeboid or mesenchymal invasion mechanisms.  For these studies, collaborations 
were established first with Dr. Dominique Alfandari.  However, we were unable to 
complete these studies because we were unable to replicate optimal culture conditions 
while cells were at the microscope thus we were unable to keep the cells alive long 
enough to observe movement.   
A new collaboration was established with Dr. Sallie Smith Schneider at the 
Pioneer Valley Life Sciences Institute to use their microscope that included a heated 
microscope stage and the ability to regulate CO2 levels.  Working with Nicholas 
Panzarino, we have begun the process of optimizing the conditions for live microscopy 
(Matrigel thickness, concentration of cells, length of recording time, etc.).  
Following microscopy studies, there are a number of directions in which this 
research can go.  If microscopy does not confirm amoeboid movement, then the next step 
would be to determine whether these cells undergo epithelial-to-mesenchymal transition 
(EMT) when in a 3D environment.  This could be done by examining MMP and protease 
expression and activation, as well as expression of genes known to change during EMT 
in TMX2-28 cells cultured in a 3D matrix.  However, this would still leave us with the 
initial problem that targeting mesenchymal movement is insufficient because cells can 
switch to amoeboid movement when challenged with protease inhibitors (47).   
If microscopy confirms amoeboid movement then we would need to further 
define the possible interacting proteins involved in this invasion mechanism in order to 
design effective targets.  For example, RhoC is another member of the Rho superfamily 
that has 95% homology to RhoA and a higher affinity and specificity to RhoA’s main 
target genes, ROCK 1 and ROCK 2 (254-256).  The activation of the ROCKs by RhoC 
121 
has been shown to lead to the disruption of adherens junctions and increased cell motility 
and enhanced F-actin assembly (255).  Overexpression of RhoC has been observed in 
bladder, ovarian, head and neck, pancreatic, hepatocellular, esophageal, and breast cancer 
(257-262).  Given that RhoC plays a role in cell motility, at least partially through the 
same downstream effectors (ROCK 1 & 2) as RhoA, it is possible that RhoC may also be 
involved in the amoeboid invasion mechanism.   
Another example is RhoE.  RhoE was the first member of the Rho kinase family 
to be identified (129).  Unlike the other family members, RhoE does not act as a classic 
GTPase switch, as it does not hydrolyze GTP (129-131).  RhoE functions by binding to 
and inhibiting the RhoA effector ROCK 1 (but not ROCK 2).  This interaction also 
results in the phosphorylation of RhoE by ROCK 1, which increases RhoE’s stability and 
activity (73, 132).  In addition, RhoE binds to p190RhoGAP and increases its activity 
toward RhoA, thus promoting the formation of inactive GDP-bound RhoA (133).   
RhoC appears to work in concert with RhoA to promote cell motility, while RhoE 
seems to be a negative regulator of motility via inhibition of RhoA.  With this 
knowledge, we can design inhibiting molecules that mimic the actions of RhoE and target 
RhoA/C resulting in down regulation and abrogation of invasive behaviors.  Then we 
could engineer breast cells that have the ability to grow in an in vivo setting, to express 
varying levels of the target gene and evaluate the efficacy of the designed inhibitors on 
these cells.  Targeting the Rho pathway may provide therapeutic strategies that could be 
used individually or in combination with protease inhibitors in patients with increased 
risk of metastasis.   
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SKP2 and RhoA Work Jointly to Produce the Aggressive Phenotype of Triple-
Negative and Basal-Like Breast Cancers 
The research outlined in this dissertation suggests individual and critical roles of 
SKP2 and RhoA on proliferation and invasion (respectively) of triple-negative and basal-
like breast cancers.  One point of study that must also be considered and evaluated is that 
SKP2 and RhoA have been shown to regulate the transcription of each other (263, 264).  
A number of studies between 1993 and 2001 observed that Rho family proteins were vital 
for progression through the G1 phase of the cell cycle.  RhoA was reported to down-
regulate both p21 and p27 and stimulate Cyclin D1 accumulation (265-269).  The 
downstream effectors causing these affects were unknown until studies by Mammato and 
colleagues deciphered that RhoA, through its target genes ROCK 1 & 2 and mDia, were 
stimulating the transcription of SKP2 in late G1 phase and thus mediating cell growth 
(263).  Another study by Chan et. al. in 2010 demonstrated that SKP2 cooperated with C-
myc to induce transcription of RhoA independently of the SCF
SKP2
/E3 ligase activity 
(264).  SKP2 and C-myc were found to induce transcription of RhoA through recruitment 
of the transcriptional co-regulators, Miz1 and p300 to the RhoA promoter (264).  Data 
from Mammoto and Chan suggest that SKP2 and RhoA work in concert to regulate cell 
growth and invasive potential. 
In our triple-negative, basal-like breast cancer cell model TMX2-28 both SKP2 
and RhoA are overexpressed.  Given that SKP2 can induce the transcription of RhoA and 
vice versa, it is not unreasonable to suggest that there is a positive feedback loop 
occurring that is driving the overexpression of both genes in this cell line (Figure 6.1).  
Two questions that need to be evaluated are, when SKP2 is suppressed in TMX2-28 cells, 
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what happens to the expression of RhoA, and what is the effect on invasion potential 
(using TMX2-28-S2 and TMX2-28-MC cells)?  If this positive feedback loop were in 
play, than we would expect that knocking down SKP2 would also have resulted in 
decreased expression of RhoA and inhibition of invasion.  Evaluation of the interactions 
of SKP2 with C-myc, p300, Miz1, and/or the RhoA promoter could be performed in the 
SKP2 knockdown cells by immunoprecipitation and CHIP analysis.  Our studies also 
indicate that SKP2 overexpression is correlated with triple-negative breast cancers, thus it 
would be advantageous to see if the relationship between SKP2 and RhoA translates to 
human samples.   
Recently Yamamura et. al. discovered that microRNA-34a could suppress the 
assembly and function of SKP2/C-myc/Miz1 complex (270, 271).  Likewise, microRNA-
31 has been shown to suppress breast cancer metastasis partially through down regulation 
of RhoA (272).  Studies of the expression and activity of these microRNAs would add to 
the knowledge of how growth and metastasis is regulated in triple-negative and basal-like 
breast cancers.  
Lastly, findings by Mohanty and colleagues indicated that the potency at which 
p27 inactivates CDK2 is controlled through C-terminal phosphorylation (Thr197/8) by 
ROCK but only when p27 was phosphorylated at Ser10 in advance.  When p27 was 
doubly phosphorylated (Ser10 and Thr197/8) it could no longer inactivate CDK2 and 
thus promoted S phase transition of the cell cycle (253).  Our studies elucidated that 
TMX2-28 cells overexpress ROCK 1 & 2, that suppression of SKP2 in these cells 
completely abolished pSer10p27 and that there was a positive correlation between SKP2 
and pSer10p27 in human triple-negative tumors.  Our data, together with Mohanty’s 
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evokes the question of the role of ROCK phosphorylation of p27 in these breast cancer 
subsets.  ROCK’s involvement in the process of p27 degradation would add to our 
finding that regulation of p27 is vital to the proliferative nature of triple-negative and 
basal-like breast cancers. 
The results of these studies could provide additional important information about 
patients with aggressive breast cancer subsets.  Collectively, the data presented here 
demonstrate the roles of SKP2 and RhoA in triple-negative and basal-like breast cancers 
and that both genes make desirable therapeutic targets.  However, additional studies are 
needed to provide a full understanding of the mechanisms behind cell growth and 
metastases, and how the proteins involved in these processes interact and regulate each 
other.   
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Figure 6.1 Model of how SKP2 and RhoA work in concert to regulate cell growth and 
invasive potential.  SKP2, independent of its SCF/E3 ligase activity, can complex with C-
myc and Miz1 to activate the transcription of RhoA.  RhoA’s downstream effectors, 
Rock1/2 and mDia can stimulate the transcription of SKP2.  This positive feedback loop 
could drive the overexpression of both SKP2 and RhoA and subsequent dysregulation of 
proliferation and invasion.   
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APPENDIX A 
DIFFERENCES IN SCORING IMMUNOREACTIVITY OF SKP2 AND p27 IN 
BREAST CANCER 
Differences in scoring immunoreactivity of SKP2 and p27 in breast cancer  
Author Year 
Scoring for 
SKP2 
(Intensity; 
Distribution) 
Scoring for 
p27 
(Intensity; 
Distribution) 
N 
SKP2 & p27 Relationship 
Significance 
!! ! !" ! "! ! "" !
Signoretti 
2002 
Hi/Lo; 
 >/<10% 
Hi/Lo; 
 >/< 50% 
83 1(4%) 21(25%) 30(36%) 32(35%)     Inverse 
High SKP2 in ERα-negative 12/18 (67%), Low in ERα-positive 7/47 (15%) 
Zheng 2005 
Hi/Lo; 
>/<50% 
Hi/Lo;  
>/< 50% 
 82 8(10%) 45(55%) 23(28%) 6(7%) Inverse 
Slotky 2005 
Hi/Lo; 
>/<10% 
Hi/Lo;  
>/< 50% 
 43 3(7%) 15(35%) 22(51%) 3(7%) Inverse 
Traub 
2006 
Pos/Neg; 
>/<5% 
Pos/Neg; 
>/<50% 
338 63(19%) 116(34%) 45(55%) 114(34%) None  
No significant association seen with ERα status 
Sonoda 2006 Hi/Lo N/A 137 14(10%) 52(38%) 38(28%) 33(24%) No stats 
Voduc 2008 Hi/Lo N/A N/A N/A N/A N/A N/A None  
Davidovich 2008 Hi/Lo N/A  40 10(25%) 7(17.5%) 22(55%) 1(2.5%) Inverse 
Ravaioli 
2008 Hi/normal/low Normal/low 1598 N/A 208(13%) N/A N/A Inverse 
ERα-negative N/A N/A N/A 119(80%) N/A N/A N/A 
ERα-Positive N/A N/A N/A 87(54%) N/A N/A N/A 
Fagan-Solis 
2012 
Hi/Lo; 
>/<50% 
Hi/Lo; 
>/<50% 
159 51(32%) 18(11%) 58(36%) 32(20%) None  
2012 
Pos/Neg; 
>/<50% 
Pos/Neg; 
>/<50% 
159 92(58%) 6(4%) 54(34%) 7(4%) None  
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APPENDIX B 
H-1152 INHIBITOR DOSE RESPONSE MIGRATION ASSAYS 
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Notes:  HeLa and TMX2-28 cells were treated with H-1152 at noted concentrations for 
48 hours without media change.  
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APPENDIX C 
ZYMOGRAPHY PROTOCOL 
Precast gelatin gels-BioRad (Cat# 161-1167) 
 
Buffers: 
 
1.  Running Buffer (10x Stock) 
 
Tris Base  15g 
Glycine  72g 
SDS   5g 
Ultra Pure H2O ~500ml 
 
(pH should be around 8.3) 
 
2.  Sample Buffer- From BioRad (Cat# 161-0764) 
3.  Renaturing Buffer- From BioRad (Cat# 161-0765) 
4.  Developing Buffer- From BioRad (Cat# 161-0766) 
6.  Staining Buffer- 40% Methanol, 10% Acetic Acid, 0.5% Coomassie Blue, 49.5% 
Ultra Pure H2O. 
7.  Destaining Buffer- 40% methnol, 10% Acetic Acid, 50% Ultra Pure H2O 
 
Protocol: 
 
1. Dilute 1 part sample with 1 part sample buffer. 
2. Incubate at room temperature for 10 min. 
3. Load samples into gel and run at 100V for 90 min (or until dye front reaches 
bottom of the gel. 
4. Place gels in renaturing buffer for 30 min at room temp. 
5. Transfer gel to developing buffer and incubate for 30 min at room temp. 
6. Transfer gel to fresh developing buffer and incubate at 37°C with gentle shaking 
overnight. 
7. Stain gel with staining buffer for 1 hour at room temp. 
8. Destain until clear bands appear against blue background (30-60 min.). 
a. Gel may shrink following detaining.  To rehydrate gel prior to 
photographing, incubate in Ultra Pure H2O until gel regains original size 
(~10min). 
130 
BIBLIOGRAPHY 
1. Understanding breast changes: A health guide for women [Internet].; 2011. Available 
from: http://www.cancer.gov/cancertopics/screening/understanding-breast-
changes/allpages#2. 
2. Wheeler JE, Enterline HT. Lobular carcinoma of the breast in situ and infiltrating. 
Pathol Annu. 1976;11:161-88. 
3. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular 
carcinoma in situ) of the breast. Cancer. 1978;42(2):737-69. 
4. American Cancer Society. Cancer facts & figures 2012. . 2012. 
5. American Cancer Society. Breast cancer facts & figures 2011-2012. . 2012. 
6. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, et al. Linking gene 
expression patterns to therapeutic groups in breast cancer. Cancer Res. 2000 Apr 
15;60(8):2232-8. 
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression 
patterns of breast carcinomas distinguish tumor subclasses with clinical implications. 
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. 
8. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-
expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 
19;347(25):1999-200. 
9. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated 
observation of breast tumor subtypes in independent gene expression data sets. Proc Natl 
Acad Sci U S A. 2003 Jul 8;100(14):8418-23. 
10. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast 
cancer classification and prognosis based on gene expression profiles from a population-
based study. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8. 
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular 
portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. 
12. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular 
forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 2005 Oct 
10;23(29):7350-6. 
 
131 
13. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. 
Gene expression profiling and histopathological characterization of triple-negative/basal-
like breast carcinomas. Breast Cancer Res. 2007;9(5):R65. 
14. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 
2009 Feb 19;360(8):790-80. 
15. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling 
to breast cancer classification, prognostication and prediction: A retrospective of the last 
decade. J Pathol. 2010 Jan;220(2):263-80. 
16. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 
2010 Nov 11;363(20):1938-4. 
17. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev. 1995 
Oct;16(5):559-8. 
18. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. 
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor 
clinical outcome. Am J Pathol. 2002 Dec;161(6):1991-6. 
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70. 
20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011 Mar 
4;144(5):646-74. 
21. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase 
activity, is related to p21. Cell. 1994 Jul 15;78(1):67-74. 
22. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant 
transformation. Semin Cancer Biol. 2003 Feb;13(1):41-7. 
23. Cheng T. Cell cycle inhibitors in normal and tumor stem cells. Oncogene. 2004 Sep 
20;23(43):7256-6. 
24. Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. 
Nat Rev Cancer. 2001 Dec;1(3):222-31. 
25. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-
TrCP: Tipping the scales of cancer. Nat Rev Cancer. 2008 Jun;8(6):438-49. 
26. Nakayama KI, Nakayama K. Ubiquitin ligases: Cell-cycle control and cancer. Nat 
Rev Cancer. 2006 May;6(5):369-81. 
27. Bashir T, Pagano M. Don't skip the G1 phase: How APC/CCdh1 keeps SCFSKP2 in 
check. Cell Cycle. 2004 Jul;3(7):850-2. 
132 
28. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-
mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999 Aug;1(4):193-9. 
29. Vervoorts J, Luscher B. Post-translational regulation of the tumor suppressor 
p27(KIP1). Cell Mol Life Sci. 2008 Oct;65(20):3255-64. 
30. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al. A 
growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell 
cycle progression. EMBO J. 2002 Jul 1;21(13):3390-401. 
31. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase 
inhibitor p27Kip1 is stabilized in G(0) by mirk/dyrk1B kinase. J Biol Chem. 2004 May 
21;279(21):22498-504. 
32. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell 
cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional 
and posttranscriptional levels. Cancer Res. 2008 Jul 1;68(13):5076-85. 
33. Arakawa-Takeuchi S, Kobayashi K, Park JH, Uranbileg B, Yamamoto H, Jinno S, et 
al. Mammalian target of rapamycin complex 1 signaling opposes the effects of anchorage 
loss, leading to activation of Cdk4 and Cdc6 stabilization. FEBS Lett. 2010 Jul 
2;584(13):2779-85. 
34. Park JH, Arakawa-Takeuchi S, Jinno S, Okayama H. Rho-associated kinase connects 
a cell cycle-controlling anchorage signal to the mammalian target of rapamycin pathway. 
J Biol Chem. 2011 Jul 1;286(26):23132-41. 
35. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential 
elements of the cyclin A-CDK2 S phase kinase. Cell. 1995 Sep 22;82(6):915-2. 
36. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, et al. 
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell 
Biol. 1999 Aug;1(4):207-14. 
37. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, et 
al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a 
prerequisite for its proteolysis. EMBO J. 2001 Dec 3;20(23):6672-8. 
38. Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation 
in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 
mutation. J Biol Chem. 2005 Jan 14;280(2):1095-102. 
39. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A 
pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and 
tumor suppression. Genes Dev. 2006 Jan 1;20(1):47-64. 
133 
40. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is 
oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001 Apr 
24;98(9):5043-8. 
41. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and 
metastasis: An integrated view. Curr Mol Med. 2003 Nov;3(7):659-71. 
42. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells 
in metastatic sites. Nat Rev Cancer. 2002 Aug;2(8):563-72. 
43. Friedl P, Wolf K. Proteolytic and non-proteolytic migration of tumour cells and 
leucocytes. Biochem Soc Symp. 2003;(70)(70):277-85. 
44. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of 
positive and negative regulation. Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-9. 
45. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape 
mechanisms. Nat Rev Cancer. 2003 May;3(5):362-74. 
46. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 2005 
Feb;15(1):87-96. 
47. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. 
Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid transition 
after blocking of pericellular proteolysis. J Cell Biol. 2003 Jan 20;160(2):267-7. 
48. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev 
Cancer. 2003 Dec;3(12):921-30. 
49. Etienne-Manneville S, Hall A. Integrin-mediated activation of Cdc42 controls cell 
polarity in migrating astrocytes through PKCzeta. Cell. 2001 Aug 24;106(4):489-98. 
50. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell 
migration: Integrating signals from front to back. Science. 2003 Dec 5;302(5651):1704-9. 
51. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct 
requirements for rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003 
Aug;5(8):711-9. 
52. Parri M, Chiarugi P. Rac and rho GTPases in cancer cell motility control. Cell 
Commun Signal. 2010 Sep 7;8:23. 
53. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK- and myosin-
dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. 
Curr Biol. 2006 Aug 8;16(15):1515-23. 
134 
54. Friedl P, Wolf K. Plasticity of cell migration: A multiscale tuning model. J Cell Biol. 
2010 Jan 11;188(1):11-9. 
55. Jaffe AB, Hall A. Rho GTPases: Biochemistry and biology. Annu Rev Cell Dev Biol. 
2005;21:247-69. 
56. Hanazaki M, Yokoyama M, Morita K, Kohjitani A, Sakai H, Chiba Y, et al. Rho-
kinase inhibitors augment the inhibitory effect of propofol on rat bronchial smooth 
muscle contraction. Anesth Analg. 2008 Jun;106(6):1765-71. 
57. Micuda S, Rosel D, Ryska A, Brabek J. ROCK inhibitors as emerging therapeutic 
candidates for sarcomas. Curr Cancer Drug Targets. 2010 Mar 1;10(2):127-34. 
58. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in 
transformation, metastasis and invasion. Cancer Metastasis Rev. 2009 Jun;28(1-2):65-76. 
59. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008 
Apr;20(2):242-8. 
60. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity 
of Rac1 and RhoA for tumor cell motility. Cancer Cell. 2003 Jul;4(1):67-79. 
61. Torka R, Thuma F, Herzog V, Kirfel G. ROCK signaling mediates the adoption of 
different modes of migration and invasion in human mammary epithelial tumor cells. Exp 
Cell Res. 2006 Nov 15;312(19):3857-71. 
62. Rosel D, Brabek J, Tolde O, Mierke CT, Zitterbart DP, Raupach C, et al. Up-
regulation of rho/ROCK signaling in sarcoma cells drives invasion and increased 
generation of protrusive forces. Mol Cancer Res. 2008 Sep;6(9):1410-2. 
63. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer 
Res. 2010 May;8(5):629-42. 
64. Bellizzi A, Mangia A, Chiriatti A, Petroni S, Quaranta M, Schittulli F, et al. RhoA 
protein expression in primary breast cancers and matched lymphocytes is associated with 
progression of the disease. Int J Mol Med. 2008 Jul;22(1):25-31. 
65. Faried A, Faried LS, Usman N, Kato H, Kuwano H. Clinical and prognostic 
significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. 
Ann Surg Oncol. 2007 Dec;14(12):3593-601. 
66. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, et al. Up-regulation of 
small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian 
carcinoma. Lab Invest. 2003 Jun;83(6):861-70. 
135 
67. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF. Use of an 
aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. 
Mol Cancer Res. 2006 Dec;4(12):905-13. 
68. Gozgit JM, Pentecost BT, Marconi SA, Ricketts-Loriaux RS, Otis CN, Arcaro KF. 
PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of 
phospho-akt-negative breast carcinomas. Br J Cancer. 2007 Sep 17;97(6):809-17. 
69. Fasco MJ, Amin A, Pentecost BT, Yang Y, Gierthy JF. Phenotypic changes in MCF-
7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol. 2003 Aug 
29;206(1-2):33-47. 
70. Defining molecular mechanisms of imatinib treatment in GIST [Internet].; 2009. 
Available from: 
http://www.liferaftgroup.org/gist_news/index.php?option=com_zine&view=article&id=2
26:defining-molecular-mechanisms-of-imatinib-treatment-in-gist. 
71. Magori S, Citovsky V. Hijacking of the host SCF ubiquitin ligase machinery by plant 
pathogens. Front Plant Sci. 2011;2:87. 
72. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev 
Cancer. 2003 Dec;3(12):921-30. 
73. Riento K, Ridley AJ. ROCKs: Multifunctional kinases in cell behaviour. Nature 
Reviews Molecular Cell Biology. 2003 06/01;4(6):446(11). 
74. Voth DE, Ballard JD. Clostridium difficile toxins: Mechanism of action and role in 
disease. Clin Microbiol Rev. 2005 Apr;18(2):247-63. 
75. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of 
eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer 
J Clin. 2011 Jul-Aug;61(4):212-36. 
76. Bast RC,Jr, Ravdin P, Hayes DF, Bates S, Fritsche H,Jr, Jessup JM, et al. 2000 update 
of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical 
practice guidelines of the american society of clinical oncology. J Clin Oncol. 2001 Mar 
15;19(6):1865-78. 
77. Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, et al. Molecular therapy 
of breast cancer: Progress and future directions. Nat Rev Endocrinol. 2010 Sep;6(9):485-
93. 
78. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like 
breast cancer defined by five biomarkers has superior prognostic value than triple-
negative phenotype. Clin Cancer Res. 2008 Mar 1;14(5):1368-76. 
136 
79. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, et al. 
Molecular profiling and characterization of luminal-like and basal-like in vivo breast 
cancer xenograft models. Mol Oncol. 2009 Dec;3(5-6):469-82. 
80. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et 
al. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. 
Clin Cancer Res. 2009 Apr 1;15(7):2302-10. 
81. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of 
the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 2002 Apr 
18;416(6882):703-9. 
82. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased 
proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in 
aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231-4. 
83. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM, et al. 
Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in 
colorectal carcinomas. Cancer. 2001 May 1;91(9):1745-51. 
84. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-
expression of p45(SKP2) in kaposi's sarcoma correlates with higher tumor stage and 
extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. 
Mod Pathol. 2002 Nov;15(11):1227-35. 
85. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, et al. 
Regulation of p27 by S-phase kinase-associated protein 2 is associated with 
aggressiveness in non-small-cell lung cancer. J Clin Oncol. 2004 Oct 15;22(20):4165-73. 
86. Katagiri Y, Hozumi Y, Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma 
cell growth in vitro and in vivo. J Dermatol Sci. 2006 Jun;42(3):215-24. 
87. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, et al. 
Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr 
Relat Cancer. 2007 Jun;14(2):405-20. 
88. Alvaro T, Lejeune M, Garcia JF, Salvado MT, Lopez C, Bosch R, et al. Tumor-
infiltrated immune response correlates with alterations in the apoptotic and cell cycle 
pathways in hodgkin and reed-sternberg cells. Clin Cancer Res. 2008 Feb 1;14(3):685-91. 
89. Fujita T, Liu W, Doihara H, Date H, Wan Y. Dissection of the APCCdh1-Skp2 
cascade in breast cancer. Clin Cancer Res. 2008 Apr 1;14(7):1966-75. 
90. Hulit J, Lee RJ, Li Z, Wang C, Katiyar S, Yang J, et al. p27Kip1 repression of ErbB2-
induced mammary tumor growth in transgenic mice involves Skp2 and wnt/beta-catenin 
signaling. Cancer Res. 2006 Sep 1;66(17):8529-41. 
137 
91. Sun L, Cai L, Yu Y, Meng Q, Cheng X, Zhao Y, et al. Knockdown of S-phase kinase-
associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic 
effects of epirubicin. Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):999-1007. 
92. Voduc D, Nielsen TO, Cheang MC, Foulkes WD. The combination of high cyclin E 
and Skp2 expression in breast cancer is associated with a poor prognosis and the basal 
phenotype. Hum Pathol. 2008 Oct;39(10):1431-7. 
93. Chan CH, Lee SW, Wang J, Lin HK. Regulation of Skp2 expression and activity and 
its role in cancer progression. ScientificWorldJournal. 2010 Jun 1;10:1001-15. 
94. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, et al. 
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 
2002 Sep;110(5):633-41. 
95. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. Over-expression 
of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in 
primary breast cancer. Breast Cancer Res. 2008;10(4):R63. 
96. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, et al. p27 
and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-
endocrine treatments in node-negative early breast cancer. Ann Oncol. 2008 
Apr;19(4):660-8. 
97. Zheng WQ, Zheng JM, Ma R, Meng FF, Ni CR. Relationship between levels of Skp2 
and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids. 
2005 Oct;70(11):770-4. 
98. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, et al. The 
expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer 
Res. 2005;7(5):R737-44. 
99. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. Significance of 
skp2 expression in primary breast cancer. Clin Cancer Res. 2006 Feb 15;12(4):1215-20. 
100. Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of 
Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006 Sep;99(2):185-91. 
101. Turk CM, Fagan-Solis KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi 
SA, et al. Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. 
Cancer Cell Int. 2012 May 10;12(1):17. 
102. Gozgit JM. USE OF AN AGGRESSIVE, ESTROGEN RECEPTOR-NEGATIVE 
MCF-7 CELL LINE VARIANT, TMX2-28, TO STUDY BREAST CANCER: 
EXPRESSION OF PLD1, MIG2, SKP2, AND PALM IN HUMAN BREAST 
CARCINOMAS [dissertation]. University of Massachusetts Amherst; 2007. 
138 
103. Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: 
Regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell 
Biol. 2011 Aug 23;12(9):605-20. 
104. Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, et al. 
Development of standard estrogen and progesterone receptor immunohistochemical 
assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol 
Morphol. 2007 Sep;15(3):325-31. 
105. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. 
American society of clinical oncology/college of american pathologists guideline 
recommendations for immunohistochemical testing of estrogen and progesterone 
receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 
Jul;134(7):e48-72. 
106. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate 
myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999 
Oct 1;18(19):5310-2. 
107. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. 
Direct induction of cyclin D2 by myc contributes to cell cycle progression and 
sequestration of p27. EMBO J. 1999 Oct 1;18(19):5321-33. 
108. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in 
cancer. J Cell Physiol. 2000;183(1):10-7. 
109. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. 
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung 
cancer. Cancer Res. 1997 Aug 15;57(16):3381-5. 
110. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, et al. 
p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell 
carcinomas. Cancer Res. 1998 Mar 1;58(5):1042-7. 
111. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. 
Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: 
A prognostic factor independent of ras. Cancer Res. 1999 Feb 1;59(3):684-8. 
112. Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. The mTOR inhibitor 
rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast 
cancer cells. Breast Cancer Res. 2006;8(4):R46. 
113. Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. 
Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 2012 Apr 
1;72(7):1836-43. 
139 
114. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, et al. 
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle 
arrest and activation of autophagy. Blood. 2008 May 1;111(9):4690-9. 
115. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. Chemical genetics approach 
to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate 
cancer cells. BMC Biol. 2010 Dec 23;8:153. 
116. Huang HC, Lin CL, Lin JK. 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, quercetin, 
curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells 
through downregulation of Skp2 protein. J Agric Food Chem. 2011 Jun 22;59(12):6765-
7. 
117. Huang HC, Way TD, Lin CL, Lin JK. EGCG stabilizes p27kip1 in E2-stimulated 
MCF-7 cells through down-regulation of the Skp2 protein. Endocrinology. 2008 
Dec;149(12):5972-83. 
118. Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D. Retinoic acid-mediated 
growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. J Biol 
Chem. 2001 Dec 7;276(49):45945-51. 
119. Curran S, Murray GI. Matrix metalloproteinases: Molecular aspects of their roles in 
tumour invasion and metastasis. Eur J Cancer. 2000 Aug;36(13 Spec No):1621-30. 
120. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of 
matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast 
carcinomas. Jpn J Cancer Res. 1996 Jun;87(6):602-11. 
121. Montcourrier P, Mangeat PH, Salazar G, Morisset M, Sahuquet A, Rochefort H. 
Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. 
Cancer Res. 1990 Sep 15;50(18):6045-54. 
122. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, et al. 
Immunochemical characterization of assay for carboxyterminal telopeptide of human 
type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone. 2000 
Apr;26(4):367-73. 
123. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: 
Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 
2000;2(4):252-7. 
124. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, 
and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999 
Oct;189(2):161-8. 
140 
125. Maquoi E, Noel A, Frankenne F, Angliker H, Murphy G, Foidart JM. Inhibition of 
matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin 
inhibitor. FEBS Lett. 1998 Mar 13;424(3):262-6. 
126. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast 
cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22(3):237-46. 
127. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma 
VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with 
a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004 
Nov 15;10(22):7621-8. 
128. Bartsch JE, Staren ED, Appert HE. Matrix metalloproteinase expression in breast 
cancer. J Surg Res. 2003 Apr;110(2):383-92. 
129. Foster R, Hu KQ, Lu Y, Nolan KM, Thissen J, Settleman J. Identification of a novel 
human rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. 
Mol Cell Biol. 1996 Jun;16(6):2689-9. 
130. Guasch RM, Scambler P, Jones GE, Ridley AJ. RhoE regulates actin cytoskeleton 
organization and cell migration. Mol Cell Biol. 1998 Aug;18(8):4761-7. 
131. Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P. A new member of 
the rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell 
adhesion. J Cell Biol. 1998 Apr 6;141(1):187-9. 
132. Riento K, Totty N, Villalonga P, Garg R, Guasch R, Ridley AJ. RhoE function is 
regulated by ROCK I-mediated phosphorylation. EMBO J. 2005 Mar 23;24(6):1170-8. 
133. Wennerberg K, Forget MA, Ellerbroek SM, Arthur WT, Burridge K, Settleman J, et 
al. Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol. 
2003 Jul 1;13(13):1106-15. 
134. Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, Sasaki Y. Inhibition of 
rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) 
phosphorylation in human neuronal cells by H-1152, a novel and specific rho-kinase 
inhibitor. J Neurochem. 2002 Apr;81(1):9-16. 
135. Sasaki Y, Suzuki M, Hidaka H. The novel and specific rho-kinase inhibitor (S)-(+)-
2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule 
for rho-kinase-involved pathway. Pharmacol Ther. 2002 Feb-Mar;93(2-3):225-32. 
136. Iwata H, Kobayashi S, Iwase H, Okada Y. The expression of MMPs and TIMPs in 
human breast cancer tissues and importance of their balance in cancer invasion and 
metastasis. Nihon Rinsho. 1995 Jul;53(7):1805-10. 
141 
137. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer. 2002 Jun;2(6):442-54. 
138. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Differential cadherin expression: 
Potential markers for epithelial to mesenchymal transformation during tumor progression. 
J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):127-33. 
139. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The 
transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour 
cells. Nat Cell Biol. 2000 Feb;2(2):84-9. 
140. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et 
al. The transcription factor snail controls epithelial-mesenchymal transitions by 
repressing E-cadherin expression. Nat Cell Biol. 2000 Feb;2(2):76-83. 
141. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-
cadherin in breast cancer. Cancer Res. 2002 Mar 15;62(6):1613-8. 
142. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. 
Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in 
vitro and in vivo. Cells Tissues Organs. 2007;185(1-3):191-203. 
143. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in 
EMT and cancer. Oncogene. 2008 Nov 24;27(55):6958-69. 
144. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and 
cancer: Trials and tribulations. Science. 2002 Mar 29;295(5564):2387-92. 
145. Tu Y, Wu S, Shi X, Chen K, Wu C. Migfilin and mig-2 link focal adhesions to 
filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003 Apr 
4;113(1):37-4. 
146. Shi X, Wu C. A suppressive role of mitogen inducible gene-2 in mesenchymal 
cancer cell invasion. Mol Cancer Res. 2008 May;6(5):715-24. 
147. Shi X, Ma YQ, Tu Y, Chen K, Wu S, Fukuda K, et al. The MIG-2/integrin 
interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem. 
2007 Jul 13;282(28):20455-66. 
148. Wu M, Wu Z, Rosenthal DT, Rhee EM, Merajver SD. Characterization of the roles 
of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in 
inflammatory and aggressive breast cancers. Cancer. 2010;116(S11):2768-82. 
149. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their 
neoplasms using monoclonal antibodies to keratins: Strategies, applications, and 
limitations. Lab Invest. 1985 Mar;52(3):243-56. 
142 
150. Taylor-Papadimitriou J, Stampfer M, Bartek J, Lewis A, Boshell M, Lane EB, et al. 
Keratin expression in human mammary epithelial cells cultured from normal and 
malignant tissue: Relation to in vivo phenotypes and influence of medium. J Cell Sci. 
1989 Nov;94 ( Pt 3)(Pt 3):403-1. 
151. Debus E, Weber K, Osborn M. Monoclonal cytokeratin antibodies that distinguish 
simple from stratified squamous epithelia: Characterization on human tissues. EMBO J. 
1982;1(12):1641-7. 
152. Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, et al. 
Characterization of breast carcinomas by two monoclonal antibodies distinguishing 
myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986 Jul;34(7):869-
81. 
153. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, et al. Expression of 
epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990 
May;43(5):385-9. 
154. Chrysogelos SA, Yarden RI, Lauber AH, Murphy JM. Mechanisms of EGF receptor 
regulation in breast cancer cells. Breast Cancer Res Treat. 1994;31(2-3):227-36. 
155. Gershtein ES, Ermilova VD, Kuz'mina ZV, Kuzlinskii NE, Letiagin VP. Expression 
of epidermal growth factor receptors and their ligands in malignant tumors of the breast. 
Vestn Ross Akad Med Nauk. 1996;(3)(3):15-9. 
156. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced 
nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-
receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000 Jul 
18;97(15):8542-7. 
157. Bolufer P, Lluch A, Molina R, Alberola V, Vazquez C, Padilla J, et al. Epidermal 
growth factor in human breast cancer, endometrial carcinoma and lung cancer. its 
relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. Clin 
Chim Acta. 1993 Apr 16;215(1):51-6. 
158. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in 
breast cancer. Oncogene. 2000 Dec 11;19(53):6102-14. 
159. Jardines L, Weiss M, Fowble B, Greene M. Neu(c-erbB-2/HER2) and the epidermal 
growth factor receptor (EGFR) in breast cancer. Pathobiology. 1993;61(5-6):268-82. 
160. Bates SE, Fojo T. Epidermal growth factor receptor inhibitors: A moving target? 
Clin Cancer Res. 2005 Oct 15;11(20):7203-5. 
 
143 
161. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of 
epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor 
status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002 Jan;71(1):67-
75. 
162. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. 
Immunohistochemical and clinical characterization of the basal-like subtype of invasive 
breast carcinoma. Clin Cancer Res. 2004 Aug 15;10(16):5367-74. 
163. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and 
the basal phenotype: From expression profiling to clinical practice. Adv Anat Pathol. 
2007 Nov;14(6):419-30. 
164. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. 
Oncology (Williston Park). 2008 Oct;22(11):1233,9; discussion 1239-40, 1243. 
165. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent 
the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007 
Feb;16(1):104-7. 
166. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging 
estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: A 
promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 
2006 Jul-Aug;12(4):360-2. 
167. Mateyak MK, Obaya AJ, Sedivy JM. C-myc regulates cyclin D-Cdk4 and -Cdk6 
activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 
1999 Jul;19(7):4672-83. 
168. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the 
cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-myc. EMBO J. 1996 Dec 
2;15(23):6595-604. 
169. Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, et al. 
Identification of a myc-dependent step during the formation of active G1 cyclin-cdk 
complexes. EMBO J. 1995 Oct 2;14(19):4814-26. 
170. Rudolph B, Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge W, et al. 
Activation of cyclin-dependent kinases by myc mediates induction of cyclin A, but not 
apoptosis. EMBO J. 1996 Jun 17;15(12):3065-76. 
171. Perez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/Cdk2 
kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) 
binding to newly formed complexes. Oncogene. 1997 May 22;14(20):2373-81. 
144 
172. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the 
alpha-prothymosin gene. EMBO J. 1991 Jan;10(1):133-41. 
173. Amati B, Littlewood TD, Evan GI, Land H. The c-myc protein induces cell cycle 
progression and apoptosis through dimerization with max. EMBO J. 1993 Dec 
15;12(13):5083-7. 
174. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-
like growth factor I receptor primary structure: Comparison with insulin receptor 
suggests structural determinants that define functional specificity. EMBO J. 1986 
Oct;5(10):2503-12. 
175. Lai A, Sarcevic B, Prall OWJ, Sutherland RL. Insulin/insulin-like growth factor-I 
and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression 
in MCF-7 breast cancer cells through differential regulation of cyclin E and 
p21WAF1/Cip1. Journal of Biological Chemistry. 2001 July 13;276(28):25823-3. 
176. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB. Role of insulin-like growth 
factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem. 2000 
Jan;76(4):605-14. 
177. Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB. Regulation of 
estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol. 2000 
May;165(2):371-8. 
178. Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth 
requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in 
human breast cancer cells. Exp Cell Res. 1997 Feb 25;231(1):149-62. 
179. Bracke ME, Vyncke BM, Bruyneel EA, Vermeulen SJ, De Bruyne GK, Van 
Larebeke NA, et al. Insulin-like growth factor I activates the invasion suppressor function 
of E-cadherin in MCF-7 human mammary carcinoma cells in vitro. Br J Cancer. 1993 
Aug;68(2):282-9. 
180. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W. Estrogen signals via an extra-
nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast 
cancer cells. Steroids. 2009 Jul;74(7):586-94. 
181. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like 
growth factor receptor function in breast cancer. Breast Cancer Res Treat. 1998 
Feb;47(3):255-67. 
182. Morgan DO. Principles of CDK regulation. Nature. 1995 Mar 9;374(6518):131-4. 
183. Sherr CJ. The pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 2000 Jul 
15;60(14):3689-95. 
145 
184. Pines J. Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J. 
1995 Jun 15;308 ( Pt 3)(Pt 3):697-711. 
185. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. Cyclin: A protein specified 
by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 
1983 Jun;33(2):389-96. 
186. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian 
fibroblasts. Science. 1993 Mar 26;259(5103):1908-12. 
187. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, et al. Over-
expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001 Oct 
19;507(1):59-66. 
188. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. 
FoxM1 is required for execution of the mitotic programme and chromosome stability. 
Nat Cell Biol. 2005 Feb;7(2):126-3. 
189. Wang I, Chen Y, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box 
M1 regulates the transcriptional network of genes essential for mitotic progression and 
genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005 December 
15;25(24):10875-94. 
190. Wang X, Hung NJ, Costa RH. Earlier expression of the transcription factor HFH-
11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte 
entry into S-phase following carbon tetrachloride liver injury. Hepatology. 2001 
Jun;33(6):1404-1. 
191. Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, et 
al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer 
endocrine sensitivity and resistance. Oncogene. 2010 May 20;29(20):2983-95. 
192. Madureira PA, Varshochi R. The forkhead box M1 protein regulates the 
transcription of the estrogen receptor alpha in breast cancer cells. . 2006 Sep 
1;281(35):25167-76. 
193. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding 
protein rac regulates growth factor-induced membrane ruffling. Cell. 1992 Aug 
7;70(3):401-10. 
194. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of 
focal adhesions and actin stress fibers in response to growth factors. Cell. 1992 Aug 
7;70(3):389-9. 
195. Nobes CD, Hall A. Rho, rac and cdc42 GTPases: Regulators of actin structures, cell 
adhesion and motility. Biochem Soc Trans. 1995 Aug;23(3):456-9. 
146 
196. Kozma R, Ahmed S, Best A, Lim L. The ras-related protein Cdc42Hs and 
bradykinin promote formation of peripheral actin microspikes and filopodia in swiss 3T3 
fibroblasts. Mol Cell Biol. 1995 Apr;15(4):1942-5. 
197. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein 
kinase activated by Cdc42 and Rac1. Nature. 1994 Jan 6;367(6458):40-6. 
198. Tahara SM, Traugh JA. Cyclic nucleotide-independent protein kinases from rabbit 
reticulocytes. identification and characterization of a protein kinase activated by 
proteolysis. J Biol Chem. 1981 Nov 25;256(22):11558-64. 
199. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in 
cancer. Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63. 
200. Kiosses WB, Daniels RH, Otey C, Bokoch GM, Schwartz MA. A role for p21-
activated kinase in endothelial cell migration. J Cell Biol. 1999 Nov 15;147(4):831-44. 
201. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 
phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, 
modulates snail's subcellular localization and functions. Cancer Res. 2005 Apr 
15;65(8):3179-84. 
202. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, et al. 
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. 
J Biol Chem. 2002 Jan 4;277(1):550-8. 
203. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, et al. 
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent 
growth and abnormal organization of mitotic spindles in human epithelial breast cancer 
cells. J Biol Chem. 2000 Nov 17;275(46):36238-44. 
204. Shalom-Barak T, Knaus UG. A p21-activated kinase-controlled metabolic switch 
up-regulates phagocyte NADPH oxidase. J Biol Chem. 2002 Oct 25;277(43):40659-65. 
205. Gururaj A, Barnes CJ, Vadlamudi RK, Kumar R. Regulation of 
phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene. 
2004 Oct 21;23(49):8118-27. 
206. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and ig-CAMs 
in cancer. Nat Rev Cancer. 2004 Feb;4(2):118-32. 
207. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat 
Rev Mol Cell Biol. 2005 Aug;6(8):622-34. 
208. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of 
the breast and its distant metastases. Breast Cancer Res. 2003;5(6):R217-22. 
147 
209. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. Role of morphogenetic 
factors in metastasis of mammary carcinoma cells. Oncogene. 1998 Jan 8;16(1):9-20. 
210. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-
cadherin expression is associated with invasiveness and unfavorable prognosis in breast 
cancer. Am J Clin Pathol. 1996 Apr;105(4):394-402. 
211. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R, et al. Reduced E-
cadherin immunohistochemical expression in node-negative breast carcinomas correlates 
with 10-year survival. Am J Clin Pathol. 1998 Apr;109(4):431-8. 
212. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: 
What to expect and when to expect it. J Clin Oncol. 2000 Feb;18(3):591-9. 
213. Mohammadizadeh F, Ghasemibasir H, Rajabi P, Naimi A, Eftekhari A, Mesbah A. 
Correlation of E-cadherin expression and routine immunohistochemistry panel in breast 
invasive ductal carcinoma. Cancer Biomark. 2009;5(1):1-8. 
214. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, et al. 
Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010 
Jul 13;103(2):249-55. 
215. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. 
Mechanisms of estrogen action. Physiol Rev. 2001 Oct;81(4):1535-6. 
216. McGuire WL. Endocrine therapy of breast cancer. Annu Rev Med. 1975;26:353-6. 
217. Colditz GA. Relationship between estrogen levels, use of hormone replacement 
therapy, and breast cancer. J Natl Cancer Inst. 1998 Jun 3;90(11):814-23. 
218. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 
26;339(22):1609-18. 
219. Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of 
a novel human estrogen receptor. FEBS Lett. 1996 Aug 19;392(1):49-53. 
220. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, et al. Estrogen 
and progesterone receptors in the normal female breast. Cancer Res. 1991 Apr 
1;51(7):1817-22. 
221. Markopoulos C, Berger U, Wilson P, Gazet JC, Coombes RC. Oestrogen receptor 
content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br 
Med J (Clin Res Ed). 1988 May 14;296(6633):1349-51. 
148 
222. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. 
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. 
Endocrinology. 1998 Oct;139(10):4252-63. 
223. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, et al. Estrogen 
receptor beta expression in invasive breast cancer. Hum Pathol. 2001 Jan;32(1):113-8. 
224. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance 
of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant 
tamoxifen therapy. J Clin Oncol. 2008 Aug 1;26(22):3727-34. 
225. Cappelletti V, Veneroni S, Coradini D, Oriana S, Tomasic G, Younes M, et al. Re: 
Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of 
estrogen receptor status. J Natl Cancer Inst. 2003 Apr 16;95(8):629-30. 
226. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner 
M, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to 
predict tamoxifen resistance in breast cancer. Clin Cancer Res. 2004 Sep 1;10(17):5769-
76. 
227. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, et al. 
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-
negative breast carcinoma. Clin Cancer Res. 2007 Apr 1;13(7):1987-94. 
228. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, et al. Ligand-, cell-
, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) 
promoter elements. J Biol Chem. 2000 Feb 25;275(8):5379-87. 
229. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. 
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. 
Science. 1997 Sep 5;277(5331):1508-10. 
230. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing 
action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 
2002 Jul 5;277(27):24353-60. 
231. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. 
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. 
Immunity. 2005 Mar;22(3):329-41. 
232. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol. 2006;24:209-26. 
233. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of 
regulatory T cells. Curr Opin Immunol. 2007 Apr;19(2):176-85. 
149 
234. Liu Y, Zheng P. FOXP3 and breast cancer: Implications for therapy and diagnosis. 
Pharmacogenomics. 2007 Nov;8(11):1485-7. 
235. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, et al. 
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion 
in cancer. Cancer Res. 2007 Sep 1;67(17):8344-50. 
236. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, et al. 
Foxp3 expression in human cancer cells. J Transl Med. 2008 Apr 22;6:19. 
237. Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, et al. FOXP3 is a novel 
transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007 
Dec;117(12):3765-73. 
238. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked 
breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. 
Cell. 2007 Jun 29;129(7):1275-86. 
239. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, et al. 
FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009 Apr 
10;27(11):1746-52. 
240. Gierthy JF, Lincoln DW,2nd, Roth KE, Bowser SS, Bennett JA, Bradley L, et al. 
Estrogen-stimulation of postconfluent cell accumulation and foci formation of human 
MCF-7 breast cancer cells. J Cell Biochem. 1991 Feb;45(2):177-8. 
241. Bennett JA, Zhu S, Pagano-Mirarchi A, Kellom TA, Jacobson HI. Alpha-fetoprotein 
derived from a human hepatoma prevents growth of estrogen-dependent human breast 
cancer xenografts. Clin Cancer Res. 1998 Nov;4(11):2877-84. 
242. Spink BC, Bennett JA, Lostritto N, Cole JR, Spink DC. Expression of the aryl 
hydrocarbon receptor is not required for the proliferation, migration, invasion, or 
estrogen-dependent tumorigenesis of MCF-7 breast cancer cells. Mol Carcinog. 2012 
Mar 2. 
243. Clarke R. Human breast cancer cell line xenografts as models of breast cancer. the 
immunobiologies of recipient mice and the characteristics of several tumorigenic cell 
lines. Breast Cancer Res Treat. 1996;39(1):69-86. 
244. Morton CL, Houghton PJ. Establishment of human tumor xenografts in 
immunodeficient mice. Nat Protoc. 2007;2(2):247-50. 
245. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The 
retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 
1991 Dec;10(13):4279-90. 
150 
246. Solomon MJ, Lee T, Kirschner MW. Role of phosphorylation in p34cdc2 activation: 
Identification of an activating kinase. Mol Biol Cell. 1992 Jan;3(1):13-27. 
247. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by 
phosphorylation of Thr160 and Tyr15. EMBO J. 1992 Nov;11(11):3995-400. 
248. Kato JY, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent 
kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol. 1994 Apr;14(4):2713-21. 
249. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, et al. Mechanism 
of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 
Jul 27;376(6538):313-20. 
250. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase 
activation by phosphorylation. Nat Struct Biol. 1996 Aug;3(8):696-700. 
251. Wigle JT, Chowdhury K, Gruss P, Oliver G. Prox1 function is crucial for mouse 
lens-fibre elongation. Nat Genet. 1999 Mar;21(3):318-22. 
252. Troncone G, Martinez JC, Iaccarino A, Zeppa P, Caleo A, Russo M, et al. p27Kip1 
is expressed in proliferating cells in its form phosphorylated on threonine 187. BMC Clin 
Pathol. 2005 Feb 23;5(1):3. 
253. Mohanty AR, Kan Q, Srivastava S, Uranbileg B, Arakawa-Takeuchi S, Fujita N, et 
al. Successive phosphorylation of p27KIP1 protein at serine-10 and C terminus crucially 
controls its potency to inactivate Cdk2. J Biol Chem. 2012 Jun 22;287(26):21757-64. 
254. Madaule P, Furuyashiki T, Reid T, Ishizaki T, Watanabe G, Morii N, et al. A novel 
partner for the GTP-bound forms of rho and rac. FEBS Lett. 1995 Dec 18;377(2):243-8. 
255. Sahai E, Marshall CJ. ROCK and dia have opposing effects on adherens junctions 
downstream of rho. Nat Cell Biol. 2002 Jun;4(6):408-15. 
256. Wheeler AP, Ridley AJ. Why three rho proteins? RhoA, RhoB, RhoC, and cell 
motility. Exp Cell Res. 2004 Nov 15;301(1):43-9. 
257. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, et al. 
Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of 
the pancreas. Br J Cancer. 1998;77(1):147-52. 
258. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. 
Characterization of RhoC expression in benign and malignant breast disease: A potential 
new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002 
Feb;160(2):579-84. 
151 
259. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, et al. Significant association 
of rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 
2003 Jul;9(7):2632-41. 
260. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, et al. Genomic 
analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor 
prognosis. Br J Cancer. 2004 Jun 14;90(12):2349-55. 
261. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, et al. RhoC-
GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of 
the breast. Breast Cancer Res Treat. 2005 Sep;93(2):101-10. 
262. Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q, et al. RhoC GTPase 
expression as a potential marker of lymph node metastasis in squamous cell carcinomas 
of the head and neck. Clin Cancer Res. 2006 Aug 1;12(15):4485-90. 
263. Mammoto A, Huang S, Moore K, Oh P, Ingber DE. Role of RhoA, mDia, and 
ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S 
transition. J Biol Chem. 2004 Jun 18;279(25):26323-30. 
264. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the 
transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell 
Biol. 2010 May;12(5):457-6. 
265. Yamamoto M, Marui N, Sakai T, Morii N, Kozaki S, Ikai K, et al. ADP-ribosylation 
of the rhoA gene product by botulinum C3 exoenzyme causes swiss 3T3 cells to 
accumulate in the G1 phase of the cell cycle. Oncogene. 1993 Jun;8(6):1449-55. 
266. Olson MF, Ashworth A, Hall A. An essential role for rho, rac, and Cdc42 GTPases 
in cell cycle progression through G1. Science. 1995 Sep 1;269(5228):1270-2. 
267. Welsh CF, Assoian RK. A growing role for rho family GTPases as intermediaries in 
growth factor- and adhesion-dependent cell cycle progression. Biochim Biophys Acta. 
2000 Jul 31;1471(1):M21-9. 
268. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of 
cyclin D1 expression within G1 phase is controlled by rho. Nat Cell Biol. 2001 
Nov;3(11):950-7. 
269. Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, et al. 
Integrin-specific activation of rac controls progression through the G(1) phase of the cell 
cycle. Mol Cell. 2001 Jul;8(1):115-27. 
270. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. MicroRNA-34a 
modulates c-myc transcriptional complexes to suppress malignancy in human prostate 
cancer cells. PLoS One. 2012;7(1):e29722. 
152 
271. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Chang I, et al. MicroRNA-34a 
suppresses malignant transformation by targeting c-myc transcriptional complexes in 
human renal cell carcinoma. Carcinogenesis. 2012 Feb;33(2):294-300. 
272. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, et al. A 
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009 
Jun 12;137(6):1032-46. 
 
